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Abstract 
Hair plays an important role in human social and sexual communication. The 
androgen-stimulated, patterned loss of hair in cases of androgenetic 
alopecia (or common baldness) in genetically pre-disposed individuals, is 
associated with ageing and can cause marked phychological distress. 
However, it is poorly controlled. To investigate the effectiveness of daily 
topical application of a Chinese medicine-derived herbal mixture, Xiantene, 
on balding progression, two double-blind, placebo-controlled studies (3 and 
12 months) were carried out on balding men using the trichogram approach. 
Xiantene significantly increased both the total number of hairs and those in 
anagen, improving the ratio of anagen:telogen hairs. This suggests that 
topical Xiantene increased the length of the anagen phase and may promote 
a cessation, or partial reversal, of the progression of androgenetic alopecia 
in men. 
 
Canities, loss of scalp hair colour, is another mark of ageing. To investigate 
whether early greying may protect follicles from androgenetic alopecia, the 
extent of alopecia, assessed using the Hamilton scale, was compared 
between men who first became grey before, or after, 30. Both alopecia and 
greying increased with age in 843 men (217 European, 626 Thai) whenever 
they first started greying. However, men who showed greying before 30 
were significantly less bald, though more grey, in both groups. Hair follicle 
melanocytes synthesise the pigment melanin, producing reactive oxygen 
species (ROS) and oxidative stress; losing melanocyte pigmentary activity, 
and therefore these toxic factors, appears to enable hair follicles to maintain 
their full size for longer, despite the androgen drive to miniaturisation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Fair tresses man’s imperial race ensnare  
                     and beauty draws us with a single hair.”  
 
Alexander Pope (1688-1744) 
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1. Introduction 
 
1.1 Hair growth 
1.1.1 Hair growth overview  
Hair is the important distinguishing feature of the mammals (Chase, 1954), 
although some insects (bees, spiders, etc.) have a complex sensory system 
of tactile thread-like structures, which give the insect knowledge of its 
surroundings and its own body position. Mammalian hair fibres produced by 
the keratinisation of cortical cells extrude from the hair follicles to form the 
coat or ‘pelage’, the unique feature of the mammals (Dry, 1929).  Many 
vertebrates have developed a variety of glands and pigmented structures, 
derivatives of their epidermis (scales, claws, quills, nails, horns, feathers and 
hairs), as adaptations to changing environments. The epidermis thickens to 
give a topological epithelial appendage or structure (Whiting, 2004) with 
specialised functions: protection, insulation, hunting, flight, communication 
and so on.  However, it is only in the mammals where ‘endothermy’ occurs; 
the maintenance of a relatively constant body temperature (Stenn & Paus, 
2001) independent of that of the surrounding environment allowing a high 
level of activity over prolonged periods, independent of ambient temperature 
changes.  This single ability has given the mammals their huge evolutionary 
success. 
 
The overriding importance of the mammalian coat is to insulate the warm 
blooded mammals against heat loss (Stenn & Paus, 2001), i.e. to give them 
the ability to control their own environment; however, the ‘pelage’ has 
 2
important secondary functions.  It maintains sensory support with tactile hairs 
and whiskers on the animal’s body, allowing sensory positioning and 
protection and it provides sexual and social communication, the coloration 
and pattern of the pelage indicating camouflage or self-advertisement 
(Goodhart, 1960). The pelage has regenerative properties and ‘determinate’ 
growth occurs in most mammals, i.e. the coat is renewed by a periodic 
‘moult’ (Dry, 1926).  A synchronised telogen effluvium occurs and a majority 
of the hair follicles in specific areas of the pelage enter the non-growing 
phase and the hairs are shed.  The new anagen hair, which may vary in 
colour and texture from the preceding hair fibre, forms the new pelage, the 
pattern of moulting varying from species to species and within successive 
cycles in the same species (Ling, 1970).  In many mammals the moult 
proceeds in a ‘wave’ across the body in a seasonal regeneration controlled 
by the photoperiod – the duration of daylight – and the sexual cycle (Chase & 
Eaton, 1959; Ebling & Harvey, 1964).  Moulting provides replacement of 
‘wear and tear’ and the ability to allow colour and density changes to adapt to 
seasonal and climatic changes.  The thick white winter coat of some arctic 
animals, for example turns to a shorter, brown coat in the summer (Flux, 
1970).  In man, the hair growth is non-synchronous, or ‘indeterminate’ and 
proceeds on a continuous basis (Chase, 1954), although seasonal variations 
in human beings are present (Courtois et al, 1996).  Human scalp hair was 
shown to exhibit an annual cycle with 90% of hairs in the anagen growing 
phase in the spring and early summer, falling to 80% at the end of the 
summer (Randall & Ebling, 1991), confirming an environmental influence on 
follicular activity.   In this mosaic pattern of moulting the activity of each hair 
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follicle is largely independent of that of its neighbour (Chase, 1954), and any 
connection between the sexual cycle and the hair cycle has been lost. 
In some mammals the hair coat is reduced; it is almost completely missing 
on the naked skin of whales, it grows sparsely on the skin of elephants and 
naked skin appears on the buttocks of some monkeys.  In man, hair, 
although covering almost the entire body, is drastically reduced in thickness 
and length and full hair growth effectively remains only on the scalp, beard, 
axillae and pubic areas. Small fine unpigmented vellus hairs cover the whole 
body except the palms, soles, lips and mucous areas; thicker, longer, 
pigmented terminal hairs are seen in the areas considered to be hairy, and in 
man hair now serves two remaining key functions; protection and 
communication (Randall, 2007). The head and scalp are protected from solar 
radiation by scalp hair (Tobin & Paus, 2001); the eyelashes protect the eyes 
and nasal hairs filter the inhaled air. However the roles of scalp and body 
hair in social and sexual communication have become paramount (Randal, 
2007), and hair is a key secondary sexual characteristic differentiating male 
from female, adult from child and old from young. The colour, styling and 
presentation of scalp hair help to create the image and perception we wish to 
project and are crucial for social communication (Randall, 2007). The pattern 
of hair growth varies with age (Shah, 1957) and differs between the sexes 
with marked changes in hair growth, in both sexes at puberty (Marshall & 
Tanner, 1969; Marshall & Tanner, 1970). Loss of human scalp hair and hair 
colour will affect this social communication and premature hair loss, in both 
sexes can cause considerable psychological stress (van der Donk et al, 
1991; Cash, 1992; Girman et al, 1998).   
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Human scalp hair is commonly lost through genetically controlled patterned 
androgenetic alopecia, or common baldness (Hamilton, 1951), and less 
commonly in cases of alopecia areata, due to an autoimmune response 
(Randall, 2001) or through a disturbance to the systemic hormone balance, 
or in response to medical or external trauma. Excess body hair may also 
cause considerable psychological distress (Rabinowitz et al, 1983); 
hirsutism, excess female body hair in the male pattern is an androgen 
dependent condition (Randall et al, 2007); hypertrichosis is a generalised 
excess hairiness in both men and women (Barth et al, 1988) caused usually 
by an underlying systemic condition. Excess hair, whilst distressing is 
relatively easily controlled by depilation, epilation, or laser treatment 
(Elghblawi, 2008). Hair loss however is poorly controlled due to relatively 
little understanding of the biology and precise mechanisms of normal and 
abnormal hair growth and there is a need for better treatments to control hair 
loss conditions.  
 
1.1.2 Hair growth cycle 
Hair consists of long keratin fibres, twisted in a rope-like structure with a 
central, rigid medulla and an outer protective cuticle or coating of hardened, 
keratinised cells giving a structure of considerable tensile strength (Wolfram 
& Lindeman, 1971; Steinert, 1993). The hair is produced from the hair follicle, 
an oblique downward indentation of the epidermis which protrudes into the 
dermis and encloses at its lower end the dermal papilla, a dome shaped 
mesenchyme derived cluster of a small number of specific cells which 
regulate the behaviour of the epithelial cells or keratinocytes (Oliver, 1967; 
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Jahoda et al, 1984; Reynolds & Jahoda, 2004), see Figure 1.1. The layer of 
cells immediately around the enclosed papilla constitutes the matrix from 
which a cone of cells differentiates, moving upward to form the hair shaft, or 
growing fibre structure which becomes keratinised and hardened to form the 
final hair structure, extruding from the skin or the scalp.  The hair fibre at this 
point is dead tissue and it is only the growing or germinating root of the hair 
where the living keratinocytes are to be found.  The rate of cell proliferation 
or mitosis, during the active phase of the hair cycle to produce the hair shaft 
structure, is extremely high and is comparable with that of malignant tumour 
growth (Stenn & Paus, 2001).  
These highly active hair follicles cover the whole of the human body, except 
for the palms of the hands, soles of the feet, and the mucous areas; the 
number of hair follicles not normally increasing postnatal.  The body cannot 
normally grow or produce new hair follicles, although this may occur after 
wounding or trauma (Ito et al, 2007). Follicular loss can occur in some 
dermal tumours and cicatricial alopecias (Dalziel & Marks, 1986) and on pre-
determined scalp areas with the progression of androgenetic alopecia and 
senescent alopecia (Whiting, 2001). Hair growth proceeds on a cyclical basis 
through a repeated cycle of active follicular growth and rest phases (Chase, 
1954; Kligman, 1959), orchestrated by the dermal papilla, which produces 
the required proliferative or inhibitory stimuli for hair growth regulation, see 
Figure 1.2 (Oliver, 1967; Jahoda et al, 1984; Reynolds & Jahoda, 2004). The 
length of each phase is determined by age, sex, genetic profile and follicular 
body site, and can be further influenced by systemic and external factors 
(Ebling & Harvey, 1964; Randall, 1994).    
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Figure 1.1  
Hair bulb 
The hair bulb surrounds the dermal papilla. Hair matrix cells divide, 
differentiate, ascend and are elongated and compacted into hard keratin.  
The diagram shows the outer root sheath, and the 3 layers of the inner root 
sheath; Henle’s layer, Huxley’s layer and the cuticle of the inner root sheath. 
(Randall, 1994) 
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Figure 1.2  
Hair growth cycle 
Showing 3 main stages, anagen, catagen and telogen (Randall, 2000). 
Reproduced with kind permission. 
 
 
 
 
 
 
 
 
 
 
 
 
           Anagen                                                   New Anagen  
Catagen 
Telogen 
The old hair is shed 
(Exogen) due to 
enzymatic release 
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The length of the anagen (growing) phase determines hair length and in 
human scalp hairs, anagen lasts from 2 to 5 years or on average 1,000 days 
(Chase, 1954), although some Asian women may have an extended anagen 
cycle for scalp hair of 7 or 8 years (personal observation), see Figure 1.3.  
Conversely, the hair growth cycle on the finger may be 1½-3 months (Saitoh 
& Sakamoto, 1970).  Anagen commences with the downward growth of the 
follicle, enclosing the dermal papilla and accompanied by a dramatic 
increase in mitotic activity of the germinal cells at the base of the follicle, 
recreating the original morphogenesis of the follicle in fetal skin (Botchkarev 
& Paus, 2003).  The follicle extends to its maximum length, melanin is 
synthesised by the melanocytes, and the new hair shaft is formed, 
keratinising just below the level of the sebaceous gland.   
The previous resting telogen ‘club’ hair is ejected from the follicle and the 
new hair emerges at the skin surface. Anagen proceeds until the onset of the 
catagen (regression) phase when mitosis at the germinating matrix ceases, 
and the catagen phase begins (Parakkal, 1970), lasting only a few days.  
The dermal papilla moves upward as the hair follicle shortens and the lower 
section of the hair shaft becomes fully keratinised, club shaped, lacks 
pigment and is only partially connected to the epithelial cells as the hair 
follicle enters the telogen (resting) phase. The non-growing hair shaft is held 
in the upper section of the hair follicle in the scalp of man for approximately 
100 days, hence a normal anagen/telogen of 10:1, i.e. approximately 90% 
(Braun-Falco & Heilgemeir, 1985), and morphogenesis of the new anagen 
phase is recommenced at the end of telogen. 
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Figure 1.3  
Extended anagen (growing) phase 
An Asian woman (Thailand native) exhibiting extended anagen growth 
phase, estimated at 7 – 8 years, assuming an average growth rate of 
approximately 0.37 mm/day (Munro, 1966) 
Photo, author 
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The co-existence of the new anagen hair and the previous telogen hairs 
ensures that an animal is never naked and it has recently been suggested 
that the process of active hair shedding may constitute a separate distinct 
phase in the follicular cycle, for which the term “exogen” has been proposed 
(Stenn et al, 1996; Stenn & Paus, 2001; Van Neste et al, 2007). 
Anagen has been divided into 6 sub phases anagen I – VI (Chase, 1954) see 
Figure 1.4. Phases I to V are mainly of the same length for all human hair 
follicles, independent of body site, however phase VI varies and determines 
the length of both the anagen phase and that of the hair shaft itself (Saitoh & 
Sakamoto, 1970). During early anagen the secondary hair germ, an 
epidermal cluster of hair cells descends with the encased dermal papilla to a 
pre-determined depth in the dermis at which point the growth direction 
reverses and proliferation and differentiation of the hair matrix cells form the 
upward moving hair shaft and inner root sheath structures.  
The bulge area of the isthmus provides the source of quiescent, multipotent 
stem cells required for this very rapid proliferation and tissue generation 
(Cotsarelis, 1998, Cotsarelis et al, 1999; Nishimura et al, 2005). The 
inductive signal for initiation of anagen may arise from the dermal papilla 
(Stenn & Paus, 2001) which triggers proliferation of stem cells and transient 
amplifying cells from the bulge region, or by a signal from the secondary hair 
germ which is in intimate contact with the dermal papilla (Panteleyev et al, 
2001). The dermal papilla size varies according to body site (Itami et al, 
1990, Randall et al, 1992) and dictates the size of the bulb, and hence the 
size and character of the hair produced (Ibrahim & Wright, 1982).  
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Figure 1.4  
Hair growth cycle (anagen I – IV) 
Hair growth cycle showing telogen and anagen stages I – IV (Whiting, 2004). 
Reproduced with permission 
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The dermal papilla also changes in size during follicle life to accommodate 
changes in size of hair produced e.g. in response to androgens (Messenger 
et al, 1991). The dermal papilla sends and receives mesenchyme-epithelial 
signals by intimate contact with the hair matrix epithelium via its extracellular 
matrix (Link et al, 1990). 
Anagen papilla cells, isolated and placed in non-hair bearing skin can induce 
epithelial hair follicle formation (Reynolds & Jahoda, 1991) and if a papilla is 
separated experimentally from the growing hair follicle, follicle growth ceases 
(Link et al, 1990) and hair follicle destruction and alopecia ensues 
(Pantaleyev et al, 1998). Signalling in the reverse direction also occurs and 
hair follicle keratinocytes produce specific growth factors which stimulate the 
growth of human scalp dermal cells (Warren & Wong, 1994) and epithelial-
mesenchyme interactions are central to hair growth control (Hardy, 1992, 
Stenn & Paus, 2001). 
A number of the molecular markers present in early anagen have been 
identified (Botchkarev & Paus, 2003); high levels of lymphoid enhancer 
factor-1 (LEF-1) are present (Zhou et al, 1995) and early anagen is 
associated with proteolytic enzyme production, to digest the dermis and 
allow the downward growth of the hair follicle (Paus et al, 1994). The growth 
factors  epidermal growth factor (EGF) and transforming growth factor α 
(TGF-α) are implicated in the release of these metalloproteinases (MMP) 
which are expressed in the bulb and outer root sheath (ORS), but not in the 
dermal papilla (Weinberg et al, 1990). 
Trauma or wounding will induce anagen in the area of the trauma (Li et al, 
1999) and there are also a number of chemical agents which will increase 
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anagen, e.g. minoxidil (Burton & Marshall, 1979) and cyclosporin (Gebhart et 
al, 1986), or inhibit anagen e.g. glucocorticoids (Chedid et al, 1994); however 
oestradiol (Thornton et al, 2003; Thornton et al, 2006) and androgens 
(Randall, 2007) can have both inhibitory and stimulatory roles. Downward 
growth of the follicle, during anagen stage III (Stenn & Paus, 2001) bears 
similarities with the invasive downward growth of basal or squamous 
carcinomas, and the gene expression and mechanism may be similar 
(Kahari & Saarialho-Kere, 1997). During anagen stages IV and V (Figure 1.4) 
hair shaft and inner root sheath (IRS) construction commences, the follicle 
with the encased papilla having descended to its lowermost point. The ORS, 
which separates the hair shaft unit from the surrounding dermis partially 
maintains itself, independent of the bulbar matrix, by basal cell growth 
(Reynolds & Jahoda, 1991) and is not completely reformed with each cycle. 
The ORS supports the IRS and hair shaft, but is not quiescent and may play 
a role in hair cycle control with the ORS producing catagen inducing growth 
factors; Fibroblast Growth Factor (FGF) and neurotrophins (Botchkarev et al, 
1998), modulating the hair cycle. The hair shaft and IRS form a 
complementary core of ascending hardened tissue of nearly circular cross 
section (Priestley, 1967). A number of molecules are expressed in the IRS 
during anagen, Fibroblast Growth Factor-1 (FGF-1), Transforming Growth 
Factor-α (TGF-α), Sonic Hedgehog (SHh), tissue inhibitors of 
metalloproteinases (TIMP), β-catenin (Millar et al, 1995; Millar, 2002) and 
their profusion and differing or contradictory functions have not been fully 
elucidated. At approximately the level of the sebaceous gland, the IRS 
“dissolves” or dissociates possibly at a signal from the sebaceous gland 
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(Philpott et al, 1996), and sebum production is necessary for the emergence 
of the distal end of the hair shaft from the surface of the epidermis (Zheng et 
al, 1999). 
By the onset of anagen stage IV the lower portion of the hair follicle is fully 
reformed and full pigmented hair growth is established. Molecular control of 
hair follicle epidermal cells during hair growth may be effected using the 
Notch-pathway (Artavanis-Tsakonas et al, 1995; Schouwey & Beermann, 
2008); the Notch gene family encode for transmembrane proteins and the 
Notch signalling pathway is a major determinant of cell fate specification (Lin 
et al, 2000). Notch-1 is expressed in bulb cells of neonatal mice, although not 
in the cells adjacent to the papilla. The Notch-receptor is expressed in 
differentiating cells and Notch signalling may play a part in controlling 
epithelial cell differentiation during hair shaft growth, maintaining the required 
column of keratinocytes (Kopan & Weintraub, 1993, Kimble & Simpson, 
1997, Powell et al, 1998). 
Anagen ends after a pre-determined period of hair growth dependent on 
body site and follicle physiology, when a signal of unknown origin 
precipitates a massive and rapid coordinated cell differentiation and 
apoptosis (Lindner et al, 1997, Foitzik et al, 2000, Botchkarev et al, 2000). 
Cell growth and pigmentation cease, the dermal papilla shrinks and is 
released from the bulb (Deweert et al, 1982) and the lower portion of the 
follicle regresses leaving an epithelial strand. The volume of the hair bulb 
decreases (Kligman, 1959) and the condensed papilla moves distally 
attached by a vascular stalk to the regressing epithelial column above to a 
position approximately level with the sebaceous gland. Some specialised 
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follicles e.g. vibrissae do not show the normal pattern of cyclical shortening 
and regression, but undergo a cyclical change in diameter (Young, 1980). 
Initiation of catagen may be triggered by the finite number of remaining 
transient amplifying cells (Cotsarelis et al, 1990) or by an accumulation of 
paracrine apoptotic factors (Paus et al, 1999) or by a combination of these 
and other unidentified signals. The onset of catagen is predetermined, but 
catagen can also be induced artificially by severe trauma (Kligman, 1959), 
chemotherapy and chemical trauma or by hormone treatment (Uenalan et al, 
2000). There is an increase in FGF-5 expression in late anagen and in the 
absence of FGF-5 in mice, catagen is delayed resulting in the angora (long 
hair) phenotype (Herbert et al, 1994). The anagen-catagen transformation 
coincides with an increase in the number of deeply situated follicle mast cells 
(Maurer et al, 1997) which may modulate catagen progression or coordinate 
apoptosis of lower follicle cells (Majno & Joris, 1995).  This initiating signal 
for synchronous programmed cell death is unidentified, but is thought to be 
transmitted to the epithelial cells via an intracellular route involving mainly 
caspase enzyme activation (Enari et al, 1998, Evan & Littlewood, 1998). 
The signal may involve turning off the IGF-1 receptor, essential for follicle 
growth (Philpott et al, 1994) or the expression of Hepatocyte Growth Factor 
(HGF) or Transforming Growth Factor β1 (TGF- β1), both catagen promoting 
agents (Lindner et al, 2000, Foitzik et al, 2000). The apoptotic signal may 
therefore be positive i.e. activation of a death receptor and subsequent organ 
collapse or a negative inhibitor signal via modulation of apoptosis inhibitors 
which block or modulate cell death during anagen. The BCL-2 proteins are 
known anti-apoptotic agents (Hockenberg et al, 1993) containing apoptotic 
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antagonists that complex with caspases or their co-factors inhibiting cell 
death (Adams & Cory, 1998, Korsmeyer, 1999). During morphogenesis BCL-
2 is expressed in the epithelium and the mesenchyme from the earliest 
stages in fetal tissue (LeBrun et al, 1993) and in the adult follicle during 
anagen the bulb, IRS & ORS are BCL-2 positive. In contrast the dermal 
papilla continuously expresses BCL-2 throughout the complete murine hair 
cycle (Lindner et al, 1997), even during chemically induced apoptosis using 
cyclophosphamide (Tobin et al, 1998). There is a progressive decline of 
BCL-2 expression in the epithelium at the approach to catagen (Lindner et al, 
1997) and it is assumed BCL-2 protects the cells from programmed cell 
death. However it is unlikely that a simple control system precipitates entry 
into catagen and a complex multipathway is probable (Clem & Duckett, 1997; 
Stenn & Paus, 2001; Thompson, 1998; Alonso & Rosenfield, 2003). 
Transgenic BCL-2 knock-out mice exhibit largely normal hair growth, 
although the hair turns grey on the second coat (Veis et al, 1993).  
As the follicle enters catagen the bulb keratinocytes adjacent to the dermal 
papilla are the first to exhibit transformation with the appearance of apoptotic 
clusters of groups of cells (Lindner et al, 1997) and as catagen progresses, 
apoptotic cells are found in all regions of the hair follicle. The lower follicle 
atrophies and the papilla remnants which are attached by a vascular stalk 
ascend to the upper follicle. The papilla may be pushed or squeezed up by 
contraction of the surrounding connective tissue sheath (CTS) assisted by 
secreted enzymes (Chase, 1954, Ito & Sato, 1990) or it may simply be pulled 
up by the contraction and disintegration of cells undergoing apoptosis, which 
exerts an upward pull as adjacent cells move to fill the gap. Catagen is a 
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very short and effective organ contraction period following which the upper 
follicle enters the telogen resting phase although there is evidence that 
telogen may not simply be a quiescent period and increases in enzymes 
(proteases) levels (Koch et al, 1998) suggest telogen may be an anagen-
inhibition phase (Chase, 1954). 
The reduced telogen follicle extends only into the upper dermis. At the 
bottom of the follicle lies a group of epithelial cells or “hair germ” which 
although essentially quiescent with no keratin production, carry out limited 
protein synthesis (Bowden et al, 1998). The papilla forms a tight cluster of 
fibroblasts below the telogen follicle, reduced in size, but believed to contain 
essentially the same cells as the corresponding anagen papilla (Wessels & 
Roessner, 1965, Reynolds et al, 1999). Toward the end of telogen the cells 
of the hair germ swell and grow downwards again, encasing the dermal 
papilla, and the hair follicle re-enters the anagen phase (Chase, 1954, 
Műller-Rőver et al, 2001). The hair germ cells in late telogen express FGF-5, 
a regulator of the hair growth cycle (Herbert et al, 1994, Rosenquist & Martin, 
1996) and oestrogen receptor expression, also a hair cycle regulator, has 
been found in telogen papilla cells (Oh & Smart, 1996).  
The previous telogen club hair has a “shaving brush” like base attached to 
the remaining ORS immediately above the hair germ. The degenerated IRS 
remnants form a collar round the telogen shaft base (Pinkus et al, 1981), and 
the trichilemmal keratinous mass, anchors the shaft at a point just below the 
duct of the sebaceous gland prior to final ejection of the club hair, during 
exogen (Stenn et al, 1996). Often telogen hairs from previous growth cycles 
have not been shed in rodents and it is possible for there to be 2 or 3 hairs in 
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the same follicle with only one of the hairs actively growing (Chase & Eaton, 
1959). Telogen and exogen are therefore not precisely linked and can occur 
independently and probably therefore have their own control systems; a 
proteolytic pathway has been suggested in the formation and shedding of 
club hairs (Ekholm et al, 1998, Lavker et al, 1998).  
Anagen and telogen hairs have been shown to be firmly anchored in the hair 
follicle, but exogen hairs are only passively held in the hair follicle and may 
be distinguished by measurement of the differing cohesion forces (Van Neste 
et al, 2007). Telogen hairs retain cell-cell attachment to the outer root sheath, 
whereas exogen hairs do not and the exogen phase has been demonstrated 
in the murine (Milner et al, 2002) and human (Van Neste et al, 2007) hair 
cycles.  
The exogen phase can be altered; in cases of trichostatis spinulosa, the 
infundibulum of the hair follicle becomes dilated and hair shafts are retained, 
i.e. exogen is delayed (Young et al, 1985). In cases of androgenetic alopecia 
the hair shaft can be shed before anagen commences i.e. there is a latent 
period with no shaft (Whiting, 2001), which may indicate premature exogen 
or an extended telogen (Courtois et al, 1996). The process of exogen 
completes the growth cycle of the hair shaft with the hair follicle itself 
continuing to cycle throughout the life of the animal unless the follicle is lost 
by organ deletion as in cases of androgenetic alopecia (Whiting, 2001), or 
the sequence of cycling is dislocated by systemic or physiological 
disturbances e.g. alopecia areata (Randall, 2007). It has been shown 
recently that new hair follicles can be constructed after wounding in adult 
mice (Ito et al, 2007). The new follicles were shown to form from epithelial 
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cells which assumed a hair follicle stem cell phenotype following trauma. The 
resultant hair follicles produced hair and cycled in the normal way.    
 
1.1.3 Hair shaft structure 
The mesenchyme derived dermal papilla, containing fibroblast-like cells, 
initiates cell division, keratinisation and hair shaft formation (Oliver, 1967; 
Jahoda et al, 1984 & Jahoda, 2002), see Figure 1.1, the size of the papilla 
and surrounding bulb being directly related to the size of hair shaft produced 
(Panteleyev et al, 2001).   The inner root sheath (IRS) and outer root sheath 
(ORS) provide the funnel shaped mould through which the hair shaft 
emerges and determine the final shape of the hair shaft.  This hair shaft 
shape is genetically determined and may vary from almost circular 
(Caucasian) to oval or flat (Negroid) with the hair produced varying from 
cylindrical to a twisted “ribbon” pattern and a number of specific shaft 
defects: monilithrix, pilli torti, pilli annulati, etc., are known (Davies & Olsen, 
1996).  Epidermal cells proliferate, differentiate and elongate, moving upward 
into the hair shaft, and human hair growth has been shown to be 
approximately 0.37 mm/day (Munro, 1966).  Electron microscope studies 
(Birkbeck & Mercer, 1957) have confirmed keratinisation to be complete 
approximately 1 mm from the germinating root area, and to be relatively 
rapid, with approximately 2½ days to completion (Forslind & Swanbeck, 
1966).  Programmed cell death (apoptosis) occurs as the hair cells move 
upward; they are compacted and elongated, lose moisture and protein 
synthesis ceases with the eventual loss of the cell nucleus, and keratinisation 
is complete (Forslind et al, 1986).   
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The filament structure of the hair shaft has been reviewed (Steinert, 1993).  
The central medulla, a tube-like structure, which may be partially filled with 
melanin, spongy cellular matter and air spaces, is surrounded by ‘whorl-like’ 
cortical structures of straight protein filaments or macrofibrils aligned along 
the hair shaft axis in a twisted, helical, rope-like structure of high tensile 
strength and elasticity (Steinert, 1993) held together by a matrix of 
intercellular cement which is also composed of twisted polypeptide chains 
very rich in the amino acid cysteine (Johnson & Sikorski, 1965).  The outer 
cells of the cutex, 6-10 layers deep, are flattened, plate-like and overlap to 
form the protective cuticle structure with an outer lipid coating, see Figure 
1.1. 
The chemical composition of hair is highly complex with the insolubility of the 
keratinous protein accounting for the very stable hair structure; and hair 
55,000 years old has been identified (Dr. A. Cooper – personal 
communication, Oxford Hair Foundation seminar, London, 2003).   The main 
component of hair is the protein, keratin, approximately 65-95% by weight 
(Ogawa & Yoshike, 1984) with water, lipids, pigment, trace elements 
(Passwater & Cranton, 1983) and DNA (Leanza et al, 2007) also present.  
Keratin contains abnormally high levels of sulphur and human hair contains 
approximately 5% sulphur (Forslind et al, 1986).  The component amino acid 
units of the protein are chemically bound together by peptide linkages to form 
long chain polypeptides, which in keratin are arranged in an alpha-helix 
configuration, like a coiled spring, with three or four amino acids in each turn 
of the helix.  
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In the zone of keratinisation the polypeptide chains become connected by 
cross linkages between the coils of the chain and between adjacent coils. 
The strong S-S disulphide bond (or cystine linkage) between coils gives 
keratin its ladder-like molecular structure and considerable tensile strength 
with the weaker ionic bonds and hydrogen bonds between the coils 
contributing to the integrity of the structure whilst allowing elasticity of the 
hair (Steinert, 1993). The extruded hair shaft initially retains its integrity but 
may subsequently be damaged by chemical treatment or weathering 
(Dawber, 1977), with fragilitis crinium (split ends) common at the distal end 
as the cortical structure collapses.  The outer cuticle layer breaks down or is 
lost to expose the inner cortical structure, which unravels and breaks down, 
losing the shaft integrity (Rushton et al, 1990).  
 
1.1.4 Hair follicle morphogenesis   
During embryogenesis, skin appendages, including the hair follicle, develop 
from a common origin, a thickening of the epidermis which invaginates 
downward into the dermis or protrudes outward to form the specialised skin 
structure (Mikkola, 2007) see Figure 1.5 and changes to these structures can 
be induced from this common genesis (Choung & Noveen, 1999). In human 
embryos, at approx 50 days gestation, the single cell layer of overlaying 
ectoderm, separated by a basement membrane from the mesenchyme, 
forms a placode (see Figure 1.5) a thickening of the epidermis, which 
descends into the mesenchyme following an initiating signal from the dermis 
itself (Oro & Scott, 1998, Botchkarev et al, 1999, Paus et al, 1999; Mou et al, 
2006).  
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Figure 1.5  
Embryology of hair follicle development 
A thickening of the epidermis invaginates downwards into the dermis, 
enclosing the dermal papilla cells following which hair growth commences. 
(Whiting, 2004). Reproduced with permission 
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The precise identity of the initiating signal is not known, but combination of 
dermal cells and non-hair bearing epidermis which can be induced to 
subsequently form hair follicles have shown that the dermis is the key 
activator and determines size and type of hair produced (Hardy, 1992; 
Reynolds et al, 1999; Alonso & Rosenfield, 2003). At least 3 key signalling 
pathways initiate and control placode development (Alonso & Rosenfield, 
2003; Botchkarev & Paus, 2003). These are the Wnt/β-catenin / lymphoid 
enhancer-binding factor (Wnt/β-catenin/LEF-1) system, the Ectodysplasin 
(Eda)/Ectodysplasin receptor (Edar) and Transforming growth factor β2 / 
Transforming growth factor β-receptor II (TGF- β-2/TGF- β-R II). A further 2 
signalling pathways inhibit hair follicle development (Botchkarev et al, 2002; 
Vassar & Fuchs, 1991); BMP-2/4 signalling and EGF signalling. Targeted 
deletion of β-catenin (Huelsken et al, 2001) or lymphoid enhancer-binding 
factor (LEF-1) (van Genderen et al, 1994), both Wnt effectors, results in 
sparse or absent placode development.  
Active foci of cells in the dermis, the dermal papilla are enclosed by the 
descending hair peg and play a central controlling role in morphogenesis and 
subsequent hair cycling (Oliver, 1967, Jahoda, 1992). These epithelial 
pockets protruding into the dermis become the embryonic hair follicles 
forming preferentially in certain body areas before developing across the 
fetus in a wave-like sequence (Hardy, 1992). 
The hair matrix cells at the base of the newly formed hair follicle are of 
ectodermal origin as are the cells of the inner and outer root sheath, although 
the cells of the dermal papilla and the fibroblastic cells in the connective 
tissue sheath are of mesodermal origin.  
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At 12 – 15 weeks gestational age, the hair follicle partially differentiates to 
form the sebaceous gland, the arrector pilli muscle and the bulge area, the 
site of subsequent stem cell formation (Cotsarelis et al, 1990; Waters et al, 
2007). The hair matrix cells overlying the top and sides of the dermal papilla 
ascend in the follicle and keratinise to form the three layers of the new hair 
shaft (medulla, cortex and cuticle), the three layers of the inner root sheath 
(IRS); the cuticle, the Huxley’s layer, the Henle’s layer, and the outer root 
sheath (ORS) which coats and supports the emerging hair shaft. The inner 
root sheath hardens and is keratinised before the hair fibre which it encases 
and thus determines the resultant hair shaft characteristics (Swift, 1997). The 
inner cuticle layer closest to the hair shaft is only a few cells deep, 
interlocking with the cells of the hair cuticle, and held in intimate contact. 
As the developing hair fibre ascends to the zone of keratinisation 
approximately at the mid-point of the follicle, intense protein synthesis occurs 
(Parakkal, 1969), the cells become elongated, the nucleus disintegrates and 
the final hair structure is formed at the completion of apoptosis. At the bulge 
area the inner root sheath layer desquamates and the outer root sheath 
keratinises to form the stratum corneum, indistinguishable from the 
surrounding epidermis (Sperling, 1991). At nineteen weeks the first laguno 
hair emerges (Holbrook & Minami, 1991) to be shed usually immediately 
before birth (Kligman, 1961). A second laguno synchronised shedding occurs 
during the first three or four months of life, following which the mosaic pattern 
of follicular cycling in human beings becomes established indistinguishable 
from follicular morphogenesis (Stenn et al, 1999). 
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1.1.5 Molecular controls  
It is important to note that a large part of the current understanding of the 
molecular control of hair follicle cycling and morphogenesis is derived from 
animal studies, particularly rodents, and the biochemistry in human beings is 
not therefore necessarily the same. This thesis deals with hair biology, 
particularly androgenetic alopecia and hair greying in men and this section 
on molecular controls is therefore of interest and supplementary to and 
supports the main research topic. 
As discussed earlier in section 1.1.2 (Hair cycling) and section 1.1.4 (Hair 
follicle morphogenesis) communication between epithelial and mesenchyme 
derived dermal cells is critical for hair follicle development and hair cycling 
(Stenn & Paus, 2001; Rendl et al, 2005) and therefore intercellular molecules 
signalling between these different cell types play key roles. The groups of 
signalling molecules, growth factors and molecular pathways which provide 
the switch–on and switch-off mechanisms to control morphogenesis and the 
hair cycle are a key area of research (Pittelkow, 1990; Hardy, 1992; Peus & 
Pittelkow, 1996; Cotsarelis, 1998, Oro & Scott, 1998; Stenn & Paus, 2001; 
Millar, 2002; Alonso & Rosenfield, 2003; Botchkarev & Paus, 2003; 
Mecklenberg et al, 2005). Results have been obtained from studying the 
expression patterns of candidate molecules or by experiments using 
transgenic or knock-out mice carrying a specific gene mutation or by analysis 
of results introducing candidate molecules through bead implantation into the 
skin. Although animal systems, particularly rodents, are not identical to 
human beings (e.g. the response to androgens is different), the basic 
regulating mechanisms are thought to be similar (Millar, 2002). Key peptide 
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regulators may have a stimulatory effect on cell proliferation and DNA 
synthesis or an inhibitory effect, using a network of positive and negative 
feedback loops. Regulatory molecules may be soluble growth factors, 
peptide hormones or other cytokines e.g. interleukins, and they exert their 
influence via specific cell surface receptors. Cell adhesion molecules (CAM), 
which are regulated in expression and activity by growth factors, also 
contribute to cellular communication and are membrane associated.  
The mode of activity of growth factors may be: autocrine, production and 
reception of growth factors by the same cell; paracrine, regulating signals 
transmitted to neighbouring cells within the same or adjacent tissues; 
juxtacrine: regulation and transmission of a signal from a growth factor 
tethered to a producer cell; or endocrine: activation at a distant site, the 
signalling factor being transported via the blood. To exert its effect the growth 
factor is required to bind to a surface cell specific receptor forming a ligand-
receptor complex. The growth factor receptor has 3 distinct spatial regions; 
the extracellular domain that binds the growth factor to the ligand, the 
transmembrane domain and the intracellular domain (Peus & Pittelkow, 
1996). Receptor activation requires the ligand to bind to two neighbouring 
receptors or sub units to induce a conformational change transmitting a 
signal to the intracellular domain of the receptor complex and a cascade or 
series of intracellular reactions are initiated (e.g. protein phosphorylation). 
DNA synthesis and replication provide the specific cellular response (Fantl et 
al, 1993; Lemmon & Schlessinger, 1994; Millar, 2002). 
Some of the growth factors are structurally or functionally similar and they 
will therefore be divided into main family groups. 
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(a) Epidermal Growth Factor Family  
Epidermal growth factor (EGF), as it’s name suggests, stimulates growth and 
differentiation of the epidermis (Cohen, 1965) and it is also a mitogen for 
many other cell types; it can also inhibit hair growth in both mice and In 
human beings when injected (Moore et al, 1981, Philpott et al, 1995), but 
may play an important role in the initiation of anagen in mice and act as 
biologic switch in the hair cycle (Mak & Chan, 2003). EGF is expressed in the 
intermediate layers of the epidermis prior to follicle initiation in sheep (Du 
Cross et al, 1992) but subsequently only in the ORS adjacent to the region of 
fibre keratinisation. EGF receptors in rats are localised in the ORS and in the 
epithelial cells at the base of the hair follicle (Green & Couchman, 1984; 
Nanney et al, 1984). EGF receptors play a central role in the differentiation of 
the hair follicle and normal hair development in mice (Hansen et al, 1997). 
Transforming growth factor-α (TGF-α), another family member, plays a major 
role in controlling follicular differentiation and keratinisation and is expressed 
in normal adult epidermis in human beings and mice (Coffey et al, 1987; 
Vassar & Fuchs, 1991). TGF-α, binds to EGF receptors to activate the 
tyrosine kinase pathway (Wong et al, 1989) and has a critical role in the 
development and differentiation of a number of tissues, including the skin 
and hair follicle (Derynck, 1988), stimulating keratinocyte growth, cell 
migration and angiogenesis (Schreiber et al, 1986); over expression of TGF-
α is found in hyperproliferative skin diseases such as psoriasis (Elder et al, 
1989). TGF-α is expressed in the IRS, ORS and keratogenous zone of the 
anagen follicle (Stenn et al, 1994). Targeted deletion of TGF-α or its 
receptors results in premature keratinisation of the IRS, hair follicle 
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abnormalities, and wavy hair in mice (Luetteke et al, 1993; Hansen et al, 
1997). 
(b) Fibroblast Growth Factor Family  
The fibroblast growth factor (FGF) family consists of at least nine members 
which have a wide range of biological activities; cell growth, morphogenesis, 
bone growth, angiogenesis and wound healing (Klagsbrun & Edelman, 1989; 
Mikkola, 2008). They bind to high affinity receptors (Fernig & Gallagher, 
1994) that signal via tyrosine kinase (Miyamoto et al, 1993) and to low affinity 
receptors. They are potent mitogens for human hair follicle keratinocytes and 
melanocytes (Pittelkow & Shipley, 1989) and they are key modulators of 
ovine follicular melanogenesis and cycling (Du Cross et al, 1993) and the 
proliferation of human dermal papilla cells (Katsouka et al, 1987). FGF-5 
initiates entry into catagen in mice in vivo (Suzuki et al, 2000) and may have 
a paracrine role in shortening anagen during androgenetic alopecia (Hamada 
& Randall, 2006). Transgenic knockout mice made null for the FGF-5 gene 
have a prolonged anagen phase, giving long hairs and an angora-like 
phenotype and the FGF-5 gene is found to be mutated in angora mice 
(Hebert et al, 1995). Conversely, other members of the FGF family (FGF-1) 
(Du Cross et al, 1993) stimulate entry into catagen in sheep and the FGF 
family appear to be key modulators of the anagen-catagen switch. 
Keratinocyte growth factor (KGF) also known as FGF-7 is a mitogen for 
specific keratinocytes and other epithelial cells, but not for endothelial cells 
(Finch et al, 1989, Finch et al, 1995). KGF is up regulated during human 
wound healing (Werner et al, 1992) and accelerates dermal regeneration 
(Pierce et al, 1994). In the hair follicle KGF is localised to the dermal papilla, 
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whereas the KGF-receptor is found throughout the epithelial compartment, 
indicating paracrine regulation and KGF is thought to be a key mediator of 
hair follicle growth. KGF has been shown to prolong anagen and to reduce 
hair loss in chemically induced alopecia (Danilenko et al, 1995). 
(c) Transforming Growth Factor-β Family 
Transforming growth factor-β (TGF-β) is critically involved in cell production 
and proliferation during embryogenesis in both rabbits and humans (Porras-
Reyes et al, 1993, Paus et al, 1997) and in wound healing (Massague, 1990; 
Atkins et al, 2006); TGF-β inhibits growth of normal human epithelial cells, 
including hair follicle keratinocytes (Philpott et al, 1990), but stimulates 
proliferation of human fibroblastic or mesenchymal cells (Pittelkow et al, 
1988). TGF-β expression is dependent on hair cycle phasing and it is 
expressed immediately before entry into catagen (Seilberg et al, 1995). TGF- 
β was shown to induce catagen in mouse (Soma et al, 2003) and human 
(Soma et al, 2002) hair cycles. TGF-β negatively controls proliferative activity 
of follicular epithelial cells and has key regulatory roles in murine and human 
hair growth (Blessing et al, 1993; Foitzik et al, 1999; Foitzik et al, 2000; 
Hibino & Nishiyama, 2004). TGF- β was found to be up regulated by 
androgens in human balding frontal dermal papilla cells, and transforming 
growth factor (TGF- β) is a strong candidate for inhibiting keratinocyte 
differentiation in androgenetic alopecia (Hibino & Nishiyama, 2004; Hamada 
& Randall, 2006). TGF-β was not similarly up regulated in human non-
balding dermal papilla cells (Inui et al, 2002). At least 3 isomers are known, 
TGF-β1, TGF-β2 and TGF-β3. 
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Bone morphogenic proteins (BMP) are members of the TGF-β superfamily 
and BMP 2 and BMP 4 are morphogenic regulatory factors, expressed 
during murine hair follicle morphogenesis (Lyons et al, 1990) and cycling 
(O’Shaughnessy et al, 2004). BMP 4 is transiently expressed in early murine 
mesenchymal condensation (Jones et al, 1991) preceding hair follicle 
formation and may modulate the dermal signal inducing germ formation. 
BMP 2 is expressed in the epidermal placode, and in mature follicles BMP 2 
expression coincides with the cessation of follicle cell proliferation (Wozney 
et al, 1988; Massague & Chen, 2000). 
(d) Insulin-Like Growth Factor (IGF) Family  
IGF-I & IGF-II, the primary members of the insulin-like growth factor family, 
both have a substantial amino acid homology to insulin and are probably the 
key regulators of human hair cell activity and hair follicle cycling (Philpott et 
al, 1994, Weger & Schlake, 2005). Both are synthesised in the body by a 
wide range of tissues. IGF-II is more prominently expressed in fetal tissue, 
whereas IGF-I persists at higher levels in adult tissue and, uniquely among 
growth factors, plasma contains substantial levels of IGF-I suggesting 
endocrine influence. Transgenic mice that over express IGF-1 are reported 
to have accelerated rates of whisker growth (Su et al, 1999). IGF-1 has a ten 
fold greater follicle growth potential than IGF-II, but both entities are powerful 
mitogens and important regulators of hair growth and may be major 
controlling influences on both the human and murine hair cycle (Philpott et al, 
1994; Su et al, 1999). IGF-I and IGF-II are potent suppressors of follicle entry 
into catagen. IGF-I stimulates replication of both mesenchymal and epithelial 
cells, increases human hair growth in vitro and in the absence of the IGF 
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signal, DNA synthesis and cell replication cease. IGF-I expression in the 
dermal papilla cells of human beard follicles is stimulated by androgens 
which may mediate their hair follicle activity via IGF (Itami et al, 1995). 
Interestingly IGF-I expression in human dermal papillae cells correlates with 
therapeutic efficacy of finasteride in androgenetic alopecia (Tang et al, 
2003). 
(e) Other important growth factors 
Nerve growth factor (NGF) is synthesised in developing skin (Davies et al, 
1987) and is expressed in both epithelial and mesenchymal compartments. 
NGF and brain-derived neurotrophic factor (BDNF) both members of the 
neurotrophin family, control morphogenesis of the follicular papilla 
(Botchkarev et al, 1999). NGF has neurotrophic and morphogenic properties; 
it exerts an inhibitory influence during murine anagen (Paus et al, 1994) but 
stimulates proliferation of keratinocytes in telogen. NGF-receptor levels are 
maximum during early murine anagen, in the bulge region, but expression 
declines in late anagen and catagen and hair cycling is dependent on NGF 
and NGF-receptor expression (Paus et al, 1994), and neurotrophins are key 
regulators of murine hair follicle morphogenesis and cycling (Peters et al, 
2002). 
Hepatocyte growth factor/Scatter factor (HGF/SF) acts as a mitogen or a 
morphogen, and also influences cell motility (Montesano et al, 1991).  
HGF/SF is secreted by mesenchyme derived cells and exerts a paracrine 
influence on neighbouring epithelial cells (Matsumoto & Nakamura, 1992) 
and has been shown to promote human hair growth in vitro (Jindo et al, 
1994, Shimaoka et al, 1995). The exact role of HGF/SF in the hair follicle is 
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unknown, but HGF/SF and its receptor have been shown to be key 
mediators of mesenchymal-epithelial interaction in murine hair follicle 
morphogenesis and cycling (Lindner et al, 2000). 
Vascular Endothelial Growth Factor (VEGF) is a highly specific mitogen for 
murine endothelial cells via specific cell surface receptors (Plate et al, 1992; 
Kim et al, 1993). However VEGF and VEGF receptors are localised to the 
dermal papilla cell during anagen with decreased expression during catagen 
and telogen (Lachgar et al, 1995). VEGF is an autocrine growth factor for 
dermal papilla cells (Lachgar et al, 1996). Platelet Derived Growth Factor 
(PDGF) is found in some endothelial cells and keratinocytes and binds to 
specific cell surface receptors. PDGF is implicated in many biological 
processes including morphogenesis and wound healing (Meyer-Ingold & 
Eichner, 1995). PDGF is present in the hair matrix and PDGF receptors are 
localised in the dermal papilla (Ponten et al, 1994). Its precise role is not 
known but it may activate and mediate proliferation of dermal papilla cells 
and possibly modulate the hair cycle and hair growth (Karlsson et al, 1999). 
Tumour Necrosis Factor-α (TNF-α) plays an inhibitory role in hair follicle 
cycling and has a role in catagen induction and human hair follicle 
degradation (Philpott et al, 1996).  
 
In summary over 100 growth factors or molecular entities have been 
identified as modulating morphogenesis or cycling of the pilosebaceous unit 
and the inductive focus, the dermal papilla, sends and receives its inductive 
signals using mesenchyme-epithelium reactions in a highly complex network 
(Stenn & Paus, 2001; Millar, 2002; Alonso & Rosenfield, 2003). 
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1.1.6 Stem cells 
Most mammalian organs and tissues essentially cannot self-renew and 
eventually undergo a terminal period of increased molecular disorder, 
senescence and death (Hayflick, 2007). However, some organs and tissues 
do retain the ability to renew and to affect repair after wounding or trauma 
and the source of this regenerative ability is a reservoir of undifferentiated, 
quiescent, multipotent specialised cells or stem cells. The capacity of stem 
cells to differentiate into a broad range of different types, and therefore the 
potential for the development of adult stem cell therapy has driven a very 
considerable amount of stem cell research (Miller et al, 1993; Morrison et al, 
1997; Cotsarelis et al, 1999; Blanpain et al, 2004; Nishimura et al, 2005; 
Hoffman, 2006; Waters et al, 2007; Fuchs, 2008). 
Embryonic stem cells function only during a very limited period of 
ontogenesis (Pera et al, 2000) but some mammalian systems retain their 
own lineages of stem cells; brain, liver (Morrison et al, 1997), muscles, 
cornea (Schermer et al, 1986) and some epithelial structures, like the 
epidermis or hair follicle, are good examples of self-renewing tissues.  Stem 
cells can also be re-programmed to produce different stem cells (Bjornson et 
al, 1999; Morrison, 2001) and murine hair follicle stem cells cultured in vitro 
have been shown to produce a full range of skin tissue; skin cells, follicle 
cells and sebaceous gland cells (Blanpain et al, 2004). Corneal stem cells 
can also be induced to proliferate and form hair follicles (Ferraris et al, 2000; 
Pearton et al, 2005). Hair follicle stem cells when grafted onto “nude” mice 
produce normal hair density (Blanpain et al, 2004). Additionally this 
 34
transdifferentiation and interconversion is modulated by the surrounding 
tissue (Fuchs & Segre, 2000; Seale & Rudniski, 2000; Ferraris et al, 2000).  
Hairs and epithelial cells are constantly shed and renewed and the 
proliferative pool of keratinocytes required is generated by epithelial stem 
cells (Cotsarelis et al, 1999; Tumbar et al, 2004), and also by hair follicle 
dermal stem cells after wounding (Jahoda & Reynolds, 2001; Gharzi et al, 
2003). Stem cells are undifferentiated, very slow cycling and form a latent 
reservoir with a high proliferative potential which in response to an inductive 
signal (i.e. post-trauma or the hair follicle entry into anagen) differentiate to 
form further stem cells and also transient amplifying cells which actively 
divide to replace keratinocytes lost during apoptosis. Each stem cell in the 
hair follicle provides a flow of cells and is described as an “epithelial 
proliferative unit” (Koloda et al, 1998; Cotsarelis et al, 1999; Fuchs, 2008).  
Most hair follicle stem cells reside in a reservoir located at approximately the 
bulge area or isthmus and this is thought to be the ultimate source of both 
epidermal and hair follicle keratinocytes (Cotsarelis et al, 1990; Kobayashi et 
al, 1993; Bickenbach & Chism, 1998; Akiyama et al, 2000; Waters et al, 
2007). These cells proliferate only briefly during early anagen; they are 
quiescent throughout the rest of the hair cycle (Lyle et al, 1998) and are 
thought to survive for the lifetime of the animal (Morris & Potten, 1999). 
Location of stem cells may differ between follicle types; pelage follicle stem 
cells are located at the bulge area whereas vibrissae (whisker) stem cells 
occur at the base of the follicle, although in both structures they effectively 
occur at the lowermost point of the permanent follicle. The bulge area is a 
prominent feature in human fetal skin, but is less easily identified in adults 
 35
and the arrector pilli attachment site is not necessarily an exact location 
(Wilson et al, 1994; Lyle et al, 1998). This slow cycling concentration of stem 
cells in the bulge area may also be the site of origin for some tumours. 
Genetic variations may accumulate preferentially in these cells and the hair 
follicle is a prime source of skin cancers (Miller et al, 1993; Jih et al, 1999). 
The bulge area of the ORS may also be the target for agents involved in 
various scarring and non-scarring alopecias; if the bulge area remains intact 
during alopecia, hair growth may re-commence, as in alopecia areata 
reversal or it may be permanently damaged and re-growth will not be 
possible i.e. systemic lupus erythematosus and pseudopelade. 
Stem cells are found to be biochemically different from the surrounding 
keratinocytes, and mesenchyme cells; they have a higher keratin content 
and they are rich in EGF-R and other receptors, with convoluted nuclei 
reflecting their proliferative potential (Cotsarelis et al, 1999). Keratin 
expression patterns correlate well with levels of cell differentiation and are 
used as a marker to define cells in the same state of differentiation (Lane et 
al, 1991; Schirren et al, 1997). Keratin 15 (K15) and keratin 19 (K19) are 
both markers for stem cells (Michel et al, 1996) and keratin expression 
patterns can be used to locate stem cell colonies in some species, although 
identification is less clear in human follicles. Many basal cell carcinomas and 
trichoepitheliomas arise in the bulge and are K15 positive, suggesting they 
originate from hair follicle stem cells (Jih et al, 1999). Loss of stem cell K15 
expression may be an early sign of transition from stem cell to transient 
amplifying cell (Michel et al, 1996). Using K19 expression patterns, two 
distinct populations of stem cells have been identified in the hair follicle, each 
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inductively independent; one population in the bulge area and a second 
population in the hair germ at the base of the hair follicle (Como et al, 2000). 
These two populations have unrelated cell lineages (Kamimura et al, 1997) 
and are of dual origin (Ghazizadeh & Taichman, 2001) and must therefore 
have multiple progenitor cells. It is suggested that the bulge stem cells are 
the source of the descending ORS structure whilst the hair germ stem cells 
are the source of keratinocytes to assemble the ascending hair shaft and IRS 
(Akiyama et al, 2000). During anagen III the bulge derived ORS pushes the 
hair follicle downward, simultaneously cell proliferation from the germ derived 
hair shaft and IRS pushes the assembled structure in an upward direction 
(Reyholds & Jahoda, 1991; Oshima et al, 2001). Transgenic “hairless” 
mouse skin in which the dermal papilla is stranded deep in the dermis and 
does not ascend shows a downward cellular string similar to an ORS, but 
does not exhibit an IRS or hair shaft (Panteleyev et al, 1998). The dermal 
papilla must ascend to the bulge and be aligned with it or the hair growth 
cycle will not recommence and a new hair will not be formed (Cotsarelis et al, 
1990). Labelling experiments show that bulge derived cells can migrate down 
the ORS to the lowermost part of the follicle in both vibrissae and pelage 
follicles (Oshima et al, 2001; Roh et al, 2005), and become the source of the 
epithelial proliferative unit (Taylor et al, 2000; Ghazizadeh & Taichman, 
2001). During mature anagen these virtually quiescent and bulge derived 
cells concentrate to form a “lateral disc”, at the base of the follicle, in intimate 
contact with the dermal papilla. 
This distinct group of apoptosis resistant epithelial cells at the base of the 
follicle can induce a new hair follicle without reference to the bulge region. 
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The murine hair follicle when transplanted maintains its original intrinsic 
rhythm over approximately the first hair cycle (Ebling & Harvey, 1964) and 
then acquires the features of the surrounding cycling follicles. The hair germ 
appears to initiate the entry into anagen signal via the dermal papilla, whilst 
in subsequent hair cycles the stem cells are modified by the surrounding 
tissue and adopt the neighbouring cycling sequence. It has been proposed 
therefore that there is a “pre-determination” of hair follicle genesis, which is 
conditioned by the preceding hair cycle (Panteleyev et al, 2001).  
 
In summary, the dual origin of the hair follicle stem cell lineages and the 
timing of recruitment of stem cells suggest that the ascending portion of the 
hair follicle (hair shaft and IRS) arises not from bulge located stem cells, but 
from stem cells in the secondary hair germ, the bulge stem cells contributing 
only to the descending ORS during anagen. The lower hair follicle 
disintegrates during catagen, but the lateral disc of cells survives apoptosis 
and is pulled upward with the dermal papilla to the bulge region, transforming 
into a secondary hair germ and reacquiring stem cell characteristics 
(Ferraris, 2000). The secondary hair germ initiates the primary signal to the 
dermal papilla and anagen is initiated stimulating the activity of bulge located 
stem cells and the cycle recommences (Waters et al, 2007). 
 
1.2. Hair pigmentation 
1.2.1 Description  
Hair colour in human beings ranges from white, yellow and red through to 
black, however most human beings have black hair (Eiberg et al, 2008). The 
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pigmentation serves no purpose and is purely decorative, but provides 
crucial sexual and social communication, although it is possible that there 
was an earlier evolutionary purpose (Bertazzo et al, 1996; Slominski et al, 
2004). In the furry mammals (canine, murine, feline etc.) pigmentation and 
patterning of the pelage provides communication and camouflage with the 
ability to adapt pelage pigmentation to seasonal changes (Flux, 1970). 
In some mammals e.g. Syrian golden hamster (Quevedo, 1961) the 
underlying epidermis is also pigmented, but in others it is unpigmented e.g. 
mouse, domestic animals, chimpanzees (Post et al, 1975). In human beings 
the epidermis is pigmented, the amount of pigmentation correlates 
approximately to latitude or racial origin i.e. the lower the degree of latitude 
the higher the level of pigmentation. Epidermal pigmentation is stimulated by, 
and provides protection from, UV exposure; the pigment melanin absorbs UV 
radiation, although too much melanin in the skin interferes with vitamin D3 
synthesis (Jablonski & Chaplin, 2000). Scalp hair colour does not correspond 
well with latitude nor does it necessarily correspond to skin colour. Several 
ethnic groups have black hair but white skin e.g. people of Chinese descent, 
other ethnic groups e.g. people of Thai or South Asian descent have black 
hair with brown skin, although the epidermis is less pigmented under the 
black scalp hair and the skin becomes pigmented when hair is lost as in male 
pattern alopecia (personal observation). Active melanocytes (melanin 
producing cells) are only present in the exposed areas (Post et al, 1975). 
People of African or Caribbean descent tend to have highly pigmented black 
hair and skin. In people of North European descent the hair is often blonde or 
not fully pigmented until puberty (Sunderland, 1956; Allende, 1972). The 
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unusually wide diversity of hair colour of Northern European people (brown, 
blonde and red) is pronounced and has been linked to polymorphism of the 
melanocortin 1 receptor  (MCI –R) gene (Rees, 2000). It has been suggested 
that an earlier genetic mutation affecting the OCA 2 gene, which codes for 
protein P, involved in the production of melanin, gave rise to reduced 
melanin synthesis and human beings with blue eyes, fair skin and blond hair 
(Eiberg et al, 2008). 
 
1.2.2. Melanin synthesis 
Epidermal and follicular pigmentation are provided by the pigment, melanin, 
the production of which is under complex genetic control (Hearing & 
Tsukamoto, 1991; Slominski et al, 2005). Tyrosine is the key precursor for 
melanogenesis and is converted by the copper containing enzyme tyrosinase 
to l–dihydrophenylalanine (DOPA) which is then oxidised to dopaquinone 
(Prota, 1995), a key intermediate in the production of the two main melanin 
types; pheomelanin and eumelanin. The synthesis of epidermal and follicular 
pigmentation is similar sharing identical chemical pathways, crucially 
however epidermal melanin can be in continuous production, stimulated 
further by UV exposure or trauma, whereas follicular melanin production is 
cyclical and is exactly linked to the hair cycle (Slominski et al, 2005). Hair is 
actively pigmented only in the anagen phase (Slominski & Paus, 1993; 
Slominski et al, 2005) and pigment synthesis is absent in catagen and 
telogen. During embryogenesis, after construction of the hair follicles, 
melanoblasts (potential melanin producing cells) migrate from the neural 
crest (Barsh & Cotsarelis, 2007) to all body regions specifically to the dermis 
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and into the epidermis from where some enter the maturing hair bulb to 
become active melanocytes. Mutations in the transcription factor FOXN 1 
which causes the nude phenotype in mice, characterised by a lack of visible 
hair, also contributes to hair colour by marking which cells are to receive 
pigment from the melanocytes (Weiner et al, 2007). The presence and 
densities of embryonic melanocytes has been determined (Holbrook, 1989) 
and melanogenic melanocytes have been shown to be present at all stages 
following the appearance of the hair germ (Peters et al, 2002). 
 
1.2.3 Melanin transfer 
Melanogenesis (the synthesis of the pigment melanin) in the hair occurs only 
in the hair bulb (Slominski et al, 2005), where highly specialised organelles, 
the melanosomes within the melanocytes produce pigment granules of 
melanin. Melanosome structure correlates with the type of melanin produced; 
eumelanosomes are elliptical and have a fibrillar matrix whereas 
pheomelanosomes are predominantly smaller and spherical and have a 
vesicular globular matrix (Slominski et al, 2005). The melanosomes locate to 
the dendritic tips of the melanocytes and when completely melanised (full of 
melanin) are transferred to the hair follicle keratinocytes. Melanosome 
transport may involve direct inoculation (Yamamoto & Bhawan, 1994), 
pinching off the inserted melanocyte dendrite tip; membrane fusion from 
melanocyte to keratinocyte or possibly the release of the melanosome into 
the intercellular space. Melanin granules are incorporated mainly into the 
cortex of the developing hair shaft (aligned parallel to the axis of the hair 
shaft itself) with a smaller number in the sponge like hair medulla, with very 
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few or none in the cuticle or inner root sheath. Hair colour in all mammals 
depends on the levels and types of melanins synthesised (Hearing & 
Tsukamoto, 1991) and also on the degree of effective melanin transfer to the 
hair shaft keratinocytes (Granholm et al, 1990, Vale, 2003). 
Melanosomes in the same cell can produce either type of melanin 
(pheomelanin or eumelanin) but not both simultaneously (Oyehaug et al, 
2002). Eumelanin is a black-brown pigment insoluble in all solvents produced 
by a multistep transformation from the common precursor dopaquinone. 
Pheomelanin is a red-brown alkali soluble pigment produced by the initial 
conversion of dopaquinone to cysteinyldopa and then by stages to 
pheomelanin, which is sulphur containing (Prota, 1995). Oxymelanins are 
similar to pheomelanins but contain no sulphur (Prota, 1988). Further types 
of melanins may be present by enzymatic oxidation of other agents 
(seratonin, melatonin) catalysed by tyrosinase (D’Ischia et al, 1991; Bertazzo 
et al, 1994). It has been proposed that the ratio and relative concentrations of 
the amino acids cysteine and glutathione are implicated in the regulatory 
switch between pheo and eumelanin synthesis (Jimbow et al, 1992). 
Cysteine transported through the melanosome membrane forms the 
intermediate cysteinyldopa producing pheomelanin (Potterf et al, 1999). High 
concentrations of glutathione lead to synthesis of eumelanin, whereas low 
concentration of glutathione produce pheomelanin (Slominski et al, 2005). 
The speed and specificity of melanin synthesis is controlled by a group of 
melanogenesis regulatory enzymes (MRE); however the availability and 
concentration of tyrosinase is the central component for the initiation and 
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regulation of melanogenesis (Pawalek & Korner, 1982, Schallreuter & Wood, 
1999, Westerhof, 2006).  
 
1.2.4 Melanocytes and melanin structure 
All melanins have a broadly similar organic C-C or C-N ring structure but 
they have different chemical and physical properties which allow melanin 
identification. Both exhibit chemiluminesence, but only eumelanin has a 
stable paramagnetic state giving a specific electron paramagnetic resonance 
(EPR) spectrum which allows identification of the melanin type (Seal et al, 
1982). 
Black and brown hair contains high levels of principally eumelanin pigment 
and these follicles have the largest number and density of melanocytes of 
any hair type. Red hair contains mainly pheomelanin pigment, deposited in 
irregular patches, whereas blonde hair contains smaller granules of mixed, 
poorly melanised eu & pheomelanins with often only the melanosomol matrix 
visible. Grey or white hair has little or no pigmentation with a reduced 
number of hair follicle melanocytes and decreased melanosome activity 
(Como et al, 2004). Melanocyte distribution in the hair bulb has been 
determined and hair follicle melanocytes have been cultured (Tobin et al, 
1995, Tobin and Bystryn, 1996). Two subtypes of functionally different 
melanocytes have been identified; pigmented dendritic melanocytes in the 
infundibulum and hair bulb and amelanotic non-dendritic melanocytes 
possibly transient in the outer root sheath and the middle and lower follicle 
(Narisawa et al, 1997). The amelanotic melanocytes are believed to be 
precursors for the dendritic ones (Nishimura et al, 2002; Nishimura et al, 
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2005). Hair bulb melanocytes are active only during anagen II-VI (Sugiyama 
et al, 1995) although tyrosinase synthesis occurs during early anagen 
(Slominski et al, 1991), accompanied by an increase in size and number of 
melanocytes. There is no tyrosinase synthesis during catagen and telogen 
and pigmented melanocytes lose their dendrites, become amelanotic and 
disappear from the hair bulb (Slominski and Paus, 1993). The fate of bulb 
melanocytes during catagen and telogen and the source of melanocytes as 
the new bulb invaginates downward into the dermis remains unclear (Tobin 
et al, 1999; Tobin & Paus, 2001). The melanocytes may survive in an 
undifferentiated form or they may undergo apoptosis during catagen and are 
lost (Lindner et al, 1997, Tobin et al, 1998) to be replenished in early anagen 
from a pool of undifferentiated melanocyte stem cells residing in the hair 
follicle bulge. These quiescent melanocyte stem cells residing in the bulge 
receive signals at entry into anagen to produce both transient amplifying cells 
which differentiate into active melanocytes and other dormant melanocyte 
stem cells which return to the niche (Nishimura et al, 2002). Recently it has 
been shown that there are 2 distinct melanocyte subpopulations in the hair 
follicle exhibiting differing patterns of apoptosis and survival during catagen 
(Sharov et al, 2005). The follicular melanocytes do not proliferate during 
catagen and melanocytes from the outer root sheath or dermal papilla; re-
populate the secondary hair germ in late catagen.  
 
1.2.5 Melanogenesis control systems 
Complex multi-layer molecular control systems regulate mammalian 
melanogenesis (Slominski et al, 2004), in a series of parallel control systems 
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with no simple linear control sequence. Extensive murine coat mutation 
experiments have shown that over 150 coat mutations can be engineered 
and some of the large numbers of genes involved in active pigmentation 
have been identified (Jackson 1994, Westbrook et al, 2001, Vale, 2003). 
Approximately 150 alleles spread over 90 loci have been determined 
(Nakamura et al, 2002) synthesising a multitude of protein products acting as 
enzymes, structural proteins, transcription regulators, transporters, receptors 
and growth factors with numerous functions and target cells (Hearing, 1999). 
Tyrosinase gene expression level appears similar across human racial 
groups (Fuller et al, 2001) and human melanogenic activity levels depends 
mainly on post-translational pathways, especially the effective processing of 
tyrosinase (Iozumi et al, 1993). 
Mutation in the c-kit gene results in piebaldism (Spritz, 1994) and in mice, 
inhibition or “knock out” of the c-kit gene results in the growth of unpigmented 
hair (Nishikawa et al, 1991) and the tyrosine kinosase receptor c-kit activated 
by stem cell factor (SCF) has a positive key role in murine melanocyte 
embryogenesis (Nishikawa et al, 1991, Hemesath et al, 1998), its presence 
is required for melanoblast proliferation and migration. Kit/SCF interaction is 
vital for melanocyte activity (Steel et al, 1992) and disruption of this pathway 
interferes with migration, differentiation and survival of melanocytes (Peters 
et al, 2002). Endothelin 3 and receptor B is another signalling pair essential 
for mammalian melanocyte development (Lahav et al, 1998; Alhaidari et al, 
1999). An array of enzymes mediate human and murine melanogenesis, 
principally tyrosinase, tyrosinase-related protein I (TRP I) and tyrosinase-
related protein II (TRP II) and the relative ratios may control the switch 
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between eumelanogenesis and pheomelanogenesis (Bentley et al, 1994 and 
Ganss et al, 1994). Other melanogenesis stimulating proteins have been 
identified; the peptide hormone, melanocyte stimulating hormone (MSH) has 
a regulatory role in melanogenesis and may also regulate the switch 
between production of eu and pheomelanin (Suzuki et al, 1999). Recently 
the synthetic alpha-MSH-related peptide, K(D)PT showed human hair re-
pigmentation stimulation, increasing the amount of melanin in the hair follicle 
after pre-treatment with Interferon type II (IFN-y) and demonstrating a 
possible anti-greying hair pathway (Meyer et al, 2008).  
Agouti signalling protein (ASP) is a key modifier and is an inhibitor of 
melanogenesis in animal, but not human hair, although it may modify 
intensity and end product of melanogenesis (Barsh et al, 2000), and the 
hormones serotonin (McEwan & Parsons, 1987) and melatonin (Valverde et 
al, 1995) have an anti-melanogenic effect in some mammals, possibly by 
interference in the regulation of apoptosis and proliferation of melanocytes 
(Slominski et al, 2003). Melatonin is known to be synthesised in the hair 
follicle and may have a functional role in hair cycle control (Fisher et al, 
2008). Melanin pigment itself may also modulate melanocyte behaviour 
(Donatien & Orlow, 1995). Intracellular signalling pathways have positive and 
negative roles with cAMP a critical positive factor in the regulation of 
melanogenesis (Pawalek, 1976, Pawalek, 1979). cAMP is activated by 
protein kinase A (PKA) and stimulates melanin proliferation and also 
melanocyte differentiation and proliferation (Korner & Pawalek, 1977, Park & 
Gilchrest, 1999). Abnormal pigmentation arises either from mutations in gene 
sequences or from defects in the subsequent melanogenic pathway. 
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Mutation in the tyrosinase gene gives rise to impaired or no tyrosinase 
activity and albinism results where hair, skin and eye pupils have no 
pigmentation. Lack of melanosomes or reduced melanosome size presents 
as vitiligo of the epidermis and whitening patches, piebaldism of the hair 
(Comings & Odland, 1966, Wankowitz-Kalinska, 2003) and in cases of 
alopecia areata spontaneous reversal of hair growth is not always 
accompanied by full pigmentation, indicating impaired melanogenesis (Paus 
et al, 1995, McDonagh & Messenger, 1996). 
 
1.2.6 Loss of scalp hair colour 
Melanocytes remain active for between 7 and 15 hair cycles (Peters et al, 
2002) until melanogenesis ceases or is seriously impaired and the gradual 
dilution of pigment with age leads to grey hair or canities. Hair greyness may 
be variable in degree and age of onset but correlates with age and is a prime 
marker of the ageing process (Bulpitt et al, 2001). Premature canities of the 
scalp hair may appear in the second or third decade, although the fourth 
decade would be normal for the onset of canities; it is proposed that 50% of 
caucasians are 50% grey by the age of 50 (Keogh & Walsh, 1965). It has 
been suggested that premature canities may be linked to low bone density 
(Morton et al, 2007), or to thyroid disease (Wright, 1986), or to pernicious 
anaemia (Dawber, 1970). All hair pigmentation is usually lost by the age of 
70 (Keogh & Walsh, 1965) and loss of hair pigmentation is usually 
permanent, although partial reversion has been reported (Tobin & Cargnello, 
1992; Shetty, 1995) 
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Greying or loss of scalp hair colour occurs in both sexes and in all races, 
usually starting in the parietal areas spreading gradually to the vertex and 
whole scalp, affecting the occipital area last (Boas & Michelson, 1932; 
Straile, 1964; Keogh & Walsh, 1965). The greying progress usually takes 
approximately 15 years to affect the full scalp (Burch et al, 1971). 
Melanocytes are lost through cell senescence (cellular ageing) or self-
destruction by apoptosis and the free radial theory of ageing, proposes that 
reactive oxygen species (ROS), generated by bulbar melanocytes in the 
synthesis of melanin induce “oxidative stress” (Tobin & Paus, 2001). 
Reactive oxygen species cause damage to the nuclear and mitochondrial 
DNA resulting in an accumulation of mutations. Hydrogen peroxide even in 
low doses can induce senescence in cultured fibroblasts (Hu et al, 1995) and 
the link between oxidative stress and longevity has been demonstrated in 
mice protected against oxidative stress which showed 30% longer life spans 
than unprotected controls (Migliacco et al, 1999). Melanocytes in grey hair 
are often highly vacuolated (Westerhof, 1997), a cellular response to 
increased oxidative stress, and may resemble apoptosis debris. These 
melanocytes contain fewer and smaller melanosomes, finally suffering 
degenerative changes and disappearing (Como et al, 2004; Nishimura et al, 
2005) and the melanocyte reservoir may experience genetically regulated 
exhaustion after the average grey free life span of 45 years. However it has 
been shown that some hair follicle melanocytes remain in senile white hair 
and these can be induced to pigment in culture (Tobin et al, 1995) raising the 
theoretical possibility of canities reversal. Additionally there may be 
dislocation of melanocyte–keratinocyte transfer and melanin granules may 
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be present in melanosomes, albeit reduced in number, but not incorporated 
into the keratinocytes (Tobin & Paus, 2001). 
BCL-2 is a human proto-oncogene which is a known apoptosis inhibitor 
(Veiss et al, 1993, Hockenberg et al, 1993). BCL-2 deficient mice turn grey 
with second coat hair growth (Nakayama et al, 1994) and BCL-2 appears 
necessary to prevent melanocyte stem cells undergoing uncontrolled 
apoptosis during entry into the dormant state (Veiss et al, 1993, Hockenberg 
et al, 1993). It has been shown using transgenic murine coat mutations that 
hair graying is probably due to incomplete maintenance of melanocyte stem 
cells in the bulge region (Steingrimsson et al, 2005), a process rapidly 
accelerated by BCL-2 deficiency (Nishimura et al, 2005), rather than loss of 
melanocytes from external cytotoxicity following melanin synthesis (Johnson 
and Jackson, 1992, Veiss et al, 1993). Hair colour may also be influenced by 
androgens (Slominski et al, 2004) which were shown to increase feather 
pigmentation in mallards (Hasse et al, 1995) and have been used as a 
treatment for generalised vitiligo of the skin (Muto et al, 1995). Conversely 
they were shown to reduce hair colour in androgenetic alopecia by inhibiting 
dermal papilla stem cell factor (SCF), disrupting melanocyte pigmentation in 
the hair bulb (Randall et al, 2008).  
 
1.3 Hormonal regulation of hair growth  
1.3.1 Androgens  
Androgens, the male sex steroid hormones, are the main regulators of 
human body hair growth and a connection between the testes and hair 
growth was noted by Aristotle. Androgens, in utero, determine the normal 
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male phenotype, and during childhood scalp hair, eyelashes and eyebrows 
grow normally with no androgens present. The appearance of male and 
female sex hormones at puberty determine libido, muscle mass, skeletal 
shape and induce the appearance of the secondary sexual characteristics. 
Androgens alter the body hair growth pattern in both sexes into well defined 
patterns (Marshall & Tanner, 1969; Marshall & Tanner, 1970) and the 
appearance of body hair in both sexes is a marker for the endocrine changes 
at puberty (Reynolds, 1951). 
In response to androgen stimulation, the vellus hairs of the axillae and pubis, 
which are fine, soft, poorly pigmented and with no central medulla, are 
replaced by thicker, medullated terminal hairs with greater pigmentation. The 
follicles of the male beard are changed from fine vellus hair production to 
terminal hair production (Reynolds, 1951), and in cases of androgenetic 
alopecia the reverse process occurs in defined areas of the scalp (Hamilton, 
1942; Hamilton, 1960). The growth of the eyelashes remains unchanged, 
beard growth is fully established at around 30 years of age (Raynolds, 1951), 
while ear canal hair growth is not established until 50 years of age (Hamilton, 
1946). The differing and contradictory hair growth responses to androgens 
present a paradox (Randall, 2007). Successive hairs from the same follicle 
are therefore able to change in length, diameter and colour as, for example, 
in case of androgenetic alopecia (Hamilton, 1951). It is probable that the 
same hair follicle is capable of producing laguno, vellus and terminal hairs, in 
successive hair cycles (Kligman, 1959) allowing these changes to occur.  
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1.3.2 Androgen synthesis 
Androgens are synthesised in the body by enzyme cleavage from 
pregnenolone, a 21 carbon substrate to give a C-19 complex with a C-17 
ketone, distal ring. This family of weak androgens, characterised by their 
affinity for androgen receptors, includes dehydroepiandrosterone (DHEA) 
which can be converted into testosterone, the key circulating androgen in 
man (see Figure 1.6), and a potent androgen with great affinity for the 
androgen receptor. Additionally, testosterone can be metabolised in many 
tissues, including the skin, into 5α-dihydrotesterone (DHT) by the enzyme 
5α-reductase. DHT is five times more potent than testosterone itself based 
on its affinity for androgen receptors (Fang et al, 1969; Mainwaring, 1969; 
Rosner et al, 1992) and it has been implicated in the pathogenesis of several 
disorders including benign prostatic hyperplasia, hirsutism and androgenetic 
alopecia. Enzymatic pathways in the skin can remove testosterone and DHT 
by conversion to weaker 17-ketosteroids or androstenedione and 
testosterone can be metabolised by other enzymes including aromatase to 
oestrogenic compounds including oestrone and 17β-oestradiol (Kaufman, 
1996).  
Systemic androgen levels in women are low, weaker androgens, such as 
DHEA and androstenedione acting as the precursors; however elevated 
androgen levels in women can produce hirsutism, excess hair growth in the 
male pattern, as found in cases of polycystic ovaries (Ferriman & Gallwey, 
1961; Conway et al, 1989). Hirsutism can also be idiopathic in nature with a 
case reported of hirsutism on one side of the body (Jenkins & Ash, 1973).  
 
 51
Figure 1.6 
Androgen metabolic pathways in the skin 
(Randall, 2000) Reproduced with kind permission.  
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Mutation of the 5α-reductase gene produces people with 5α-reductase 
deficiency having normal testosterone levels and greatly reduced DHT 
levels. The phenotype in men with this deficiency is partially feminised with 
body hair in the female pattern and no incidence of androgenetic alopecia or 
benign prostatic hyperplasia, whilst women are phenotypically normal 
(Imperato–McGinley et al, 1974; Walsh et al, 1974). Therefore, DHT rather 
than testosterone itself appears to mediate the progression of benign 
prostatic hyperplasia, beard and other male characteristic hair growth 
including androgenetic alopecia.  
Two isoforms of the enzyme 5α-reductase have been identified; type 1 and 
type 2 (Anderson & Russell, 1990; Anderson et al, 1991; Harris et al, 1992; 
Russell & Wilson, 1994) and these are differentially expressed in body 
tissues. Type 1 5α-reductase, which has an optimum pH of 7.5 for the 
reduction of testosterone to DHT, is the predominant form in the skin and 
sebaceous glands and is expressed normally in patients with 5α-reductase 
deficiency syndrome. Type 2 5α-reductase which has a lower optimum 
reduction pH of 5.0, is decreased or absent in patients with 5α-reductase 
deficiency, and is the predominant enzyme in genito-urinary tissues. Type 2 
tissue activity has been found in the beard, chest skin, liver, seminal 
vesicles, prostate, testes and foreskin. Men with 5α-reductase deficiency 
have not been reported to go bald and finasteride, a 5α-reductase type 2 
inhibitor, can stimulate hair to regrow in young men with androgenetic 
alopecia. Type 2 5α-reductase is also expressed in normal scalp skin briefly 
after birth, followed by an absence of expression of 5α-reductase until 
puberty, when type 2 expression appears and predominates through adult 
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life. The purpose of this brief role is unknown, but some form of imprinting of 
the immature hair follicles has been suggested (Thigpen et al, 1993). Type 2 
5α-reductase post puberty determines beard growth and the progression of 
androgenetic alopecia but it is not required for axillary and pubic hair growth 
(Randall, 2007; Randall, 2008). 
 
1.3.3 Androgen action at the hair follicle 
Androgens, in common with all steroid hormones, mainly exert their influence 
and physiological action by binding to unique intracellular receptors to form 
hormone-receptor complexes, which activate or modulate transcription and 
processing, stimulating production of specific proteins (Figure 1.7).  
The reaction is reversible and the circulating levels of free androgen are in 
equilibrium with androgens bound to the carrier proteins, principally sex 
hormone binding globulin. Androgens can also act independently of the 
intracellular androgen receptors by interaction with c-AMP providing a 
second messenger pathway (Nakhla et al, 1995; Rosner et al, 1992), though 
this is considered to be a very minor route. The current hypothesis (Randall, 
1994; Randall, 2007) for androgen action proposes that androgens in the 
blood stream enter the hair follicle via the capillaries in the dermal papilla and 
bind to specific androgen receptors inside the dermal papilla cells of 
androgen sensitive follicles, sometimes having first been converted to DHT 
which also binds to the appropriate receptors (see Figure 1.8). The hormone 
androgen receptor complex alters the gene expression of the dermal papilla 
cells, altering the production of paracrine factors resulting in changed activity 
of neighbouring keratinocyte and melanocyte cells.  
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Figure 1.7 
Androgen action at cell level 
Androgens inside the cell bind to specific androgen receptors and are 
metabolised to the more potent androgen 5α-dihydrotestosterone which 
binds more strongly to the androgen receptor (Randall, 1994). Reproduced 
with kind permission.  
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Figure 1.8 
Androgen action in the hair follicle 
Androgens in the blood enter the hair follicle via capillaries in the dermal 
papilla (Randall, 2007). Reproduced with kind permission. 
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In summary, androgens are not required for the production of terminal scalp 
hair or the other protective terminal hair seen in childhood e.g. eyelashes 
and eyebrows, but they are required for the expression of adult body hair. 
DHT is required for beard, chest and supra-pubic hair, but testosterone alone 
is sufficient for pubic and axillary hair in both sexes. DHT is required for the 
development of patterned hair loss in men. 
 
1.3.4 Oestrogens  
Oestrogens, the female sex hormones influence hair growth and also appear 
to be able to influence the hair cycle in rodents (Oh & Smart, 1996) and 
human beings (Moverare et al, 2002; Thornton et al, 2003). Growth of pubic 
hairs in male and female infants, aged 4 months to 2 years, was reported 
following the accidental application of a dermal cream containing oestrogen 
(Beas et al, 1969). However it it now know that oestrogens cannot promote 
sexual hair growth in the absence of functional androgen receptors (Thornton 
et al, 2002). 
Oestrogen, like testosterone, binds to a nuclear hormone receptor and 
oestrogen receptors are expressed in the hair follicle, localised in the dermal 
papilla and outer root sheath (Oh & Smart, 1996), it is now known that there 
are two separate oestrogen receptor types, alpha and beta, each of which is 
thought to play a specific role in hair follicle growth regulation (Couse et al, 
1997; Thornton et al, 2003; Thornton et al, 2006). The extended anagen 
phase during pregnancy followed by a diffuse telogen effluvium post partum 
is an established clinical phenomenon (Lynfield, 1960). The hormones of 
pregnancy appear to maintain anagen with oestrogen and prolactin the prime 
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candidates. Human hair follicles have receptors for both 17β-oestradiol 
(Thornton et al, 2006) and prolactin (Foitzik et al, 2006). However, 17β-
oestradiol has also been shown to inhibit hair growth and precipitate entry 
into catagen in rodents (Smart et al, 1999; Ohnemus et al, 2005), the 
opposite of the effect seen in pregnancy. Inhibitory and stimulatory effects 
have been demonstrated on non-balding scalp follicles (Conrad et al, 2004) 
and stimulatory effects on male frontal scalp follicles (Kondo et al, 1990). The 
enzyme aromatase may play a role as it can reversibly metabolise 
androgens (4-androstenedione and testosterone) into oestrogens (oestrone 
and oestradiol). Aromatase may lower the local levels of androgens by 
shunting the oestrogen pathway as hair follicle aromatase is expressed in the 
outer root sheath and at higher levels in non-balding than balding hair 
follicles; suggesting that conversion of androgen to oestrogen in occipital 
follicles may protect against androgen-derived hair loss (Sawaya & Price, 
1997). The role of oestrogens in hair growth has been reviewed (Ohnemus et 
al, 2006). 
 
1.3.5 Other hormonal regulators of hair growth 
The seasonal coat changes in many mammals are under photoperiod 
control, regulated by light and temperature (Lincoln & Richardson, 1998). 
These changes relate to serum prolactin levels (Gebbie et al, 1999; Hunt & 
Rose, 2002) and a ‘prolactin-pelage’ axis has been proposed (Alonso & 
Rosenfield, 2003) activated by the pituitary gland. Prolactin receptors have 
been located in the outer root sheath of the hair follicle and in the sebaceous 
gland and increased serum prolactin levels precipitate hair follicle entry into 
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catagen and a subsequent telogen shedding (Thompson et al, 1997; Nixon 
et al, 2002; Foitzik et al, 2006) mirroring the hair fall seen post partum in 
women. Targeted deletion of prolactin receptors in mice leads to a shorter 
anagen phase and an increased rate of hair cycling (Craven et al, 2001) and 
excess prolactin stimulation of adrenal androgen production may be a factor 
in hirsutism (Glickman et al, 1982). A number of other hormones are also 
known to cause changes to the normal hair cycle pattern when they are not 
present at optimum levels. Clinically the most common problems arise from 
the thyroid hormones which can affect hair growth, resulting in reversible 
alopecia and poor hair condition in cases of both hypothyroidism and hyper 
thyroidism (Credille et al, 2001). The thyroid hormone acts by binding to 
thyroid receptors (type α & β) which are found localised in the outer root 
sheath and dermal papilla (Ahsan et al, 1998). However targeted deletion of 
both thyroid receptors α and β in mice did not obviously affect hair growth 
(Aoki et al, 2000). 
In summary an array of hormones and hormone receptors are implicated in 
hair growth; however the androgens remain the key regulators of most 
human hair growth post-puberty. 
 
1.4. Androgenetic alopecia 
1.4.1 Description 
The replacement of pigmented terminal hairs by smaller pale vellus hairs in a 
progressive, distinctive pattern usually on the crown and frontal areas post 
puberty characterises androgenetic alopecia and produces a slow 
degenerative change in the hair growth of the scalp (Hamilton, 1951; 
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Rushton et al, 1983) (Figure 1.9).  This condition is referred to as common 
baldness, male pattern and female pattern alopecia or androgenetic 
alopecia.  
The scalp begins to show the characteristic bi-temporal recession and 
movement of the front hair line in men, with thinning of the frontal and crown 
areas, proceeding in pre-determined stages, leading ultimately to complete 
baldness in some cases.  The occipital and parietal areas do not usually 
exhibit hair loss (see Figure 1.9). Women have a different pattern of hair 
loss, the hairline is retained and diffuse thinning occurs behind the hairline on 
the frontal and crown areas, and the occipital areas may also be affected 
(Venning & Dawber, 1988). Complete baldness in women is unusual, 
although it is possible for some women to experience hair loss in the male 
pattern (Hamilton, 1951). The hair loss patterns are described as “Hamilton” 
for men, modified by Norwood, and “Ludwig” for women (Hamilton, 1951; 
Ludwig, 1977; Norwood, 1975). The length of the anagen phase of the hair 
cycle begins to decrease in the affected areas of the scalp, producing hairs 
of successively reduced length, colour and diameter, i.e. the length of the 
anagen phase is severely reduced. Miniaturisation continues until follicular 
activity ceases and atrophy of the hair follicle occurs.  
The incidence of androgenetic alopecia is high in male Caucasians 
approaching 100% (Hamilton, 1951), with wide genetic variations, as low as 
50% in Japanese and Afro-Caribbean men (Setty, 1970).  The incidence of 
androgenetic alopecia is lower in women, approximately 10% in pre-
menopausal women, where chronic telogen effluvium is more common, 
approximately 30% usually due to nutritional inbalance (Rushton, 2002). 
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Figure 1.9.A 
Pattern of androgenetic alopecia in men 
Androgens cause a gradual inhibition of hair growth in pre-disposed 
individuals. Bi-temporal recession spreads backwards joining thinning areas 
on the vertex to give a bald crown (after Hamilton, 1951). 
 
Figure 1.9.B 
Pattern of androgenetic alopecia in women 
Androgenetic alopecia is less common in women. The front hair line is 
normally retained and a general thinning on the vertex gradually becomes 
more pronounced until the vertex becomes bald (after Ludwig, 1977). 
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Post menopause the incidence of androgenetic alopecia is higher and 37% 
of women have a marked recession in the male pattern (Venning & Dawber, 
1988). In many cases hair loss and baldness in human beings can cause 
psychological stress particularly when this shift is premature (Cash, 1992). 
Some of the other primates also exhibit androgenetic alopecia: orang-utans, 
chimpanzees, gorillas and stump-tailed macaques (Rhodes et al, 1994), 
although both sexes are thought to pattern in the male form. The genetic 
influence in the progression of androgenetic alopecia has been confirmed 
(Hamilton, 1951; Setty, 1970); the pattern of inheritance may suggest an 
autosomal dominant trait with variable penetration (Kűster & Happle, 1984; 
Bergfeld, 1995; Ellis & Harrap, 2001; Birch & Messenger, 2001). 
Men with complete androgen insensitivity syndrome, i.e. without functional 
androgen receptors, do not exhibit androgenetic alopecia indicating that 
androgens and effective androgen receptors are a prerequisite for balding to 
occur (Imperato-McGinley et al, 1974).  The enzyme, 5α-reductase, appears 
to be involved in androgenetic alopecia; higher 5α-reductase activity has 
been found in plucked, balding scalp follicles, compared with non-balding 
follicles (Schweikert & Wilson, 1974), and men with 5α-reductase deficiency 
have not been reported to go bald (Wilson et al, 1993) although this may 
occur in women with this deficiency (Cousen & Messenger, 2010). Also 
finasteride, a 5α-reductase (type 2) inhibitor, has been used orally to halt 
progression or partially reverse androgenetic alopecia in stump-tailed 
macaques (Rhodes et al, 1994) and in human beings (Kaufman et al, 1998; 
Rushton et al, 2002). More recently dutasteride, a type 1 and type 2 5α-
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reductase inhibitor has also been found to be effective in the partial reversion 
of androgenetic alopecia (Olsen et al, 2006). 
Conversely, androgens stimulate increased hair growth in adult males of 
some animals, including the mane of the lion (West & Packer, 2002), and the 
deer (Randall et al, 1994) and the human beard (Randall et al, 1993). 
Changed hair growth in adult males would seem logical to distinguish a 
dominant breeding male particularly the oldest leading animal. A 
distinguishing feature could be useful to identify the leader, such as the silver 
(i.e. grey) back of the oldest male gorilla or the largest mane of the male deer 
and the bald crown of the older adult man in human beings would be an 
effective marker for an alpha male. The male lion with the largest darkest 
mane would be the preferred mate for a lioness (West & Packer, 2002), 
however recent research on lions has shown that the mane of some male 
lions is fullest and darkest when the lion is actually past his prime breeding 
age (approx. 4-5 years) and that lionesses would favour a mate with less 
hair; suggesting that hair and the absence of hair are useful sexual markers 
(Gnoske et al, 2006). 
 
1.4.2 Pathogenesis 
Androgenetic alopecia proceeds with a shortening of the anagen (growing) 
phase, and progressive follicular miniaturisation in the pre-determined areas 
of the scalp (Rushton et al, 1991; Kaufman et al, 2008). The normal telogen 
phase on the scalp remains unchanged lasting approximately three months 
(Kligman, 1959), and the anagen:telogen ratio change can be detected by 
unit area, trichogram measurement (Rushton et al, 1983). There may also be 
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a time lag following cessation of telogen (and shedding of the previous club 
hair) before anagen recommences when the follicle is without a developing 
hair (Guarrera & Rebora, 1996; Whiting, 2001) this ‘no-hair’ lag period may 
last up to 6 months and the term “kenogen” has been proposed (Rebora, 
2004). The rate of hair growth in successive anagen phases may also be 
reduced in androgenetic alopecia (Whiting, 2001) and the length of the lag 
phase may increase (Van Neste, 2008). 
Follicular miniaturisation and reversion of terminal to vellus hair follicles 
proceeds during androgenetic alopecia (Rushton et al, 1991) and ultra 
structural studies have shown that the early stages of androgenetic alopecia 
are accompanied by progressive fibrosis of the perifollicular sheath (Whiting, 
1990; Jaworsky et al, 1992; Whiting, 1993) with inflammation and fibroplasia 
present. It has been proposed that an immune system mechanism or related 
deficiency may initiate or modulate the progression of androgenetic alopecia 
(Jaworsky et al, 1992) and immunomodulatory therapy e.g. cyclosporin has 
been used in the treatment of androgenetic alopecia (Picascia & Roenick, 
1988). Inflammatory cells may infiltrate the region of the follicular bulge with 
possible cytotoxicity to the stem cell population, impairing normal follicular 
cycling and resulting in miniaturisation and eventual permanent hair loss 
(Jaworsky et al, 1992). Conversely reversible hair loss e.g. alopecia areata is 
found to be associated with lymphatic infiltration of the bulbar matrix, as 
opposed to inflammation around the infundibular epithelium, and the 
condition is reversible (McDonagh & Messenger, 1996). The gradual 
miniaturisation of the hair follicle in androgenetic alopecia produces smaller, 
less pigmented hair and the sebaceous gland (also an androgen dependent 
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tissue) becomes enlarged with the scalp having an oily and greasy 
appearance (Kligman, 1988).  The hairs produced are progressively shorter 
(Rushton et al, 1991), and miniaturisation of the follicle can be seen 
histologically (Whiting, 1993) as the process proceeds over several follicular 
cycles. The arrector pili muscle also reduces in size, but this reduction 
proceeds more slowly (Maguire & Kligman, 1963).  Electron microscopy 
studies of hair shaft structure in common baldness showed no abnormality 
(Puccinelli et al, 1968), and no abnormality in chemical composition of the 
hair shaft has been found (Salamon, 1971).  Miniaturisation continues until 
cessation of hair growth and the scalp area appears bald.  The miniaturised 
quiescent hair follicles lay dormant and the unsupported nerve network is 
coiled, twisted and truncated (Klemp et al, 1989). Whiting has proposed 
(Whiting, 2001) that the miniaturisation process may not be a smooth, 
lengthy transition but an abrupt, large-step process as a direct result of 
reduction in cell number and hence size of the dermal papilla. Other 
researchers (Van Neste, 2002) have found evidence that the transition to 
miniaturisation is a gradual process. It is suggested that the reduced length 
of the anagen phase represents the initial stages of androgenetic alopecia 
resulting in thick but shorter hairs and that miniaturisation and the production 
of thin hairs represents the final stages of the condition leading eventually to 
no visible hairs and baldness (Van Neste, 2006). 
The genetic influence on the progression of androgenetic alopecia is well 
established (Hamilton, 1942; Hamilton, 1951; Setty, 1970) and studies have 
been made to identify candidate genes. Using gene association studies 
comparing single nucleotide polymorphisms (SNP) between high incidence 
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and low incidence groups based on androgen related candidate genes (5α-
reductase genes [SRD5AI and SRD5A2], aromatase genes, IGF-I receptor 
genes, Y chromosome and androgen receptor genes) (Sinclair, 2006) a 
significant difference was found in the frequency of a single base change in 
the coding region of the AR gene between the 2 groups. Almost the entire 
young bald group had a particular variant of the AR gene indicating the 
importance of AR gene polymorphism in the development of androgenetic 
alopecia (Ellis et al, 2002; Hillmer et al, 2005). The location of the AR gene 
on the X chromosome supports maternal transmission of androgenetic 
alopecia (Sinclair, 2006). 
Recently a new gene-hunting technique GWA (genome wide association) 
has been used to search for gene variants linked to androgenetic alopecia 
(Hillmer et al, 2008; Richards et al, 2008). A highly significant association 
was shown for 5 SNPS (single neucleotide polymorphisms) on chromosome 
20, indicating therefore both paternal and maternal influence on the 
progression of AGA. No interaction was found with the already known X 
chromosome androgen receptor also implicated in AGA (maternal 
inheritance only) and this new locus on chromosome 20 may, surprisingly, 
indicate a new androgen independent pathway in the pathology of 
androgenetic alopecia, the mechanism for which is unknown.  
 
1.4.3 Role of androgens 
The central role of androgens in the progression of androgenetic alopecia 
has been known since earliest times when it was observed that eunuchs did 
not go bald and that the testes were associated with maleness.  The first 
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systematic correlation was made by Hamilton who showed that men 
castrated before puberty did not go bald and that eunuchs treated with 
testosterone therapy subsequently developed androgenetic alopecia, a 
process arrested when therapy was withheld (Hamilton, 1942).  More 
specifically, males born with androgen receptor deficiency exhibit no 
androgen effects post puberty and appear as phenotype women with no 
external testes and no axillary, pubic or body hair growth (Kutten et al, 1979), 
and no androgenetic alopecia (Quigley, 1998). In cases of androgenetic 
alopecia in men, circulating androgen levels are not elevated (Phillipou & 
Kirke, 1981), and normal androgen levels trigger the follicular regression in 
the genetically determined areas. In women, raised androgen levels do 
appear to be related to hair loss (Georgala et al, 1986) in women with an 
inherited pre-disposition. Androgens and androgen receptors mediate both 
positive signals to prolong anagen in beard, chest, nose and ear follicles etc. 
and negative signals to shorten anagen in androgenetic alopecia. Epithelial 
(ectoderm derived) and dermal (mesoderm derived) interactions control and 
coordinate the hair cycle (Millar, 2002; Rendl et al, 2005) and mesenchyme-
derived dermal papilla cells are found to have differing levels of androgen 
receptors dependent on body site. Dermal papilla cells from the beard, 
axillary and frontal scalp areas contain specific low capacity high affinity 
androgen receptors, whereas fewer androgen receptors were present in the 
cells from androgen independent occipital scalp hair follicles (Choudry et al, 
1992; Randall et al, 1992; Hibberts et al, 1998). Also beard dermal papilla 
cells have higher levels of 5α-reductase activity than occipital scalp, pubic or 
axillary cells in vitro (Itami et al, 1990; Thornton et al, 1993; Hamada et al, 
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1996) and this has been identified as type 2 5α-reductase. The expression of 
mRNA encoding for the androgen receptor in dermal papilla cells was found 
to be site specific and to be strongly expressed in the beard, frontal scalp 
and axillary areas (Asada et al, 2001). Also type 1 5α-reductase expression 
is found to be common for all dermal papilla types whereas type 2 5α-
reductase is limited to beard and frontal scalp dermal papillae. The 
progression of androgenetic alopecia appears to require the expression of 
type 2 5α-reductase, and for functional androgen receptors to be present in 
dermal papillae cells. Dermal papilla cells are the primary target cells for 
androgen activity and they mediate signals to follicular epithelial cells via a 
paracrine mechanism (Randall, 2007). Co-culture experiments using beard 
(and axillary) dermal papilla cells and outer root sheath cells showed that 
androgen significantly stimulated outer root sheath cells proliferation 
suggesting that dermal papilla cells produce androgen–dependent diffusible 
growth factors. IGF-I has been identified as a candidate diffusible growth 
factor (Itami et al, 1995) in promoting hair growth (see Figure 1.10).  
As discussed in section 1.1.5 IGF–I is a paracrine or autocrine growth factor 
present in many organs and tissues whose expression is usually limited to 
mesenchymal cells. IGF–I stimulates human hair growth in vitro and prevents 
premature entry of the follicle into catagen (Philpott et al, 1994). Conversely, 
co-culture experiments using dermal papilla cells from frontal scalp area with 
outer root sheath cells showed androgen induced inhibition of outer root 
sheath cells proliferation suggesting androgen–dependent soluble factors 
from dermal papilla cells are involved in hair growth suppression (Obana et 
al, 1997; Pan et al, 1999; Inui et al, 2003; Itami & Inui, 2005).  
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Figure 1.10 
Androgen action in human hair follicles 
Transforming growth factor-β1 (TGF- β1) is an androgen – dependent 
paracrine mediator for androgenetic alopecia (Randall, 2000). Reproduced 
with kind permission. 
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Similarly, factors secreted by balding dermal papilla cells have been shown 
to inhibit the growth of other dermal papilla cells and delay the onset of 
anagen in mice in vivo (Hamada & Randall, 2006). TGF–β1, a soluble growth 
factor, is known to inhibit hair growth and to induce catagen (Shipley et al, 
1986; Foitzik et al, 2000; Liu et al, 2001).  
TGF-β1 and TGF- β2 were found to be up-regulated by androgen in bald 
frontal dermal papilla cells but not in non-bald dermal papilla cells (Inui et al, 
2003). TGF–β1 may therefore mediate the signal from androgenetic alopecia 
dermal papilla cells for hair growth suppression. 
Differential gene sensitivity to androgens in dermal papilla cells from different 
follicles causing the production of different paracrine factors may partially 
explain the differing and converse response of body and scalp hair follicles to 
the same androgen stimulation. It suggests a possible therapeutic root for 
the treatment of androgenetic alopecia. 
 
1.4.4 Treatment 
The ideal treatment for androgenetic alopecia could be developed after 
isolation of the specific gene or set of genes responsible, but the high 
incidence has prevented this so far.  A number of drug therapies are 
available, but the genetic nature of the condition makes effective treatment 
very difficult, and a reduction of the rate of progression represents a realistic 
expectation.  
Anti-androgens, which block the binding of androgens to the androgen 
receptor, are not the first drug of choice as they would tend to block all 
systemic androgens with consequent loss of masculinity in men, and 
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possible feminisation of a male fetus in women. However, a number of these 
anti-androgens, e.g. spirolactone, cyproterone acetate, have been used for 
the treatment of female androgenetic alopecia and they may have some 
clinical effect on progression (Vexiau et al, 2002).   
 
There has also been some success with systemic and topical oestrogen 
treatment, although the use is restricted to women.  Oestrogens have an 
indirect anti-androgenic effect by increasing the production of sex hormone 
binding globulin (SHBG) and giving a decrease in bioactive testosterone, 
prolonging the anagen cycle, and inhibiting sebum secretion (Winkler, 1969; 
Moretti et al, 1977). The topical use of oestrogens in the treatment of female 
pattern alopecia has been found to be helpful (Conrad & Paus, 2004). 
Inhibition of 5α-reductase and hence inhibition of 5α-dihydrotestosterone 
synthesis offers a more elegant, selective and practical approach and a 
number of these blocking agents are known, a number of which occur 
naturally. The best researched drug for this application is finasteride 
(Kaufman et al, 1998; Rushton et al, 2002), a 5α-reductase type 2 inhibitor, 
used originally for the treatment for benign prostatic hyperplasia, and shown 
in clinical trials to have a hair growth effect. The conversion of testosterone 
to dihydrotestosterone is blocked, the anagen phase is extended, the lag 
phase may shorten and the miniaturisation of the hair follicle is delayes (Van 
Neste, 2006). Finasteride is used as a systemic treatment administered 
orally at a dose of 1mg per day, although used at 5mg per day for prostatic 
disorders.  Three double blind, placebo controlled trials totalling 1,879 men 
aged 18-41 years with mild to moderate androgenetic alopecia showed 
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reduced hair loss and increased scalp coverage, increasing the length and 
diameter of existing miniaturised hairs (Kaufman et al, 1998).  The beneficial 
effect is lost within twelve months if treatment is discontinued due to the 
underlying genetic pre-disposition with the androgen receptors and source of 
androgens still present.  It was not effective in the treatment of post-
menopausal women (Price et al, 2000) and it is contra-indicated in women of 
childbearing age due to possible birth defects of the male fetus.  Some side 
effects (less than 2%) have been reported in men, including reduced libido, 
erectile dysfunction and reduced ejaculate volume. 
More recently, it was shown that dutasteride, a dual type 1 and type 2 5α-
reductase inhibitor maybe effective in the treatment of male pattern hair loss 
(Olsen et al, 2006). In a study of 416 men, between the ages of 21 and 45 
years exhibiting androgenetic alopecia and treated with dutasteride, 
finasteride or placebo it was found that dutasteride significantly increased 
target area hair count compared with placebo and that dutasteride was 
superior to finasteride (Olsen et al, 2006).  Although the trial was limited to 
24 weeks, the results suggest that type 1 and type 2 5α-reductase may be 
important in the progression of androgenetic alopecia in men.  
A topical application, using a transdermal approach is probably the most 
useful to reduce potential side effects and to control the delivery point 
possibly using liposome technology allowing delayed release of actives into 
the hair bulb itself (Zulli & Suter, 1997; Vogt et al, 2006).  Minoxidil is the best 
known of the topical applications and was groundbreaking when discovered 
in the 1970s, the first time androgenetic alopecia had been shown to be 
partially reversible. Minoxidil is a vasodilator (Olsen et al, 1985) originally 
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used orally for the treatment of hypertension which had an unacceptable side 
effect of stimulating hypertrichosis.  A topical preparation was developed for 
the treatment of androgenetic alopecia and in some cases alopecia areata.  
Minoxidil was found to increase the length of the anagen phase of the hair 
cycle and was effective in partially reversing the miniaturisation process; the 
appearance of more terminal hairs gave a measurable cosmetic response 
(Olsen et al, 1985).  Approximately 25-30% of men in a study of 2,294 
balding men treated with minoxidil 2% or 3% had moderate re-growth (Olsen, 
1989) apparent after 4-6 months which plateaued after approximately one 
year.  Cessation of treatment resulted in loss of the re-grown hair within 3-4 
months.  The response to minoxidil treatment in cases of alopecia areata is 
controversial (Fielder, 1992; Epstein, 1991) especially as spontaneous 
reversal can be a feature of this condition.  Clinically minoxidil treatment for 
androgenetic alopecia was found to be useful, but not ideal. The re-growth 
was in most cases modest, and the new hair was lost when treatment 
ceased. The mechanism for minoxidil has been unclear for many years. 
Minoxidil is a vasodilator and the increased blood and nutrient supply to the 
dermal papilla would seem beneficial. Minoxidil is now known to be able to 
act as a potassium channel opener within the hair follicle itself (Davies et al, 
2005), independent of the vasodilator action (Shorter et al, 2007). Countless 
other remedies have been proposed for the treatment of androgenetic 
alopecia (Proctor, 1999), and probably cover most of the spectrum of the 
material world.  There is often a body of anecdotal supporting evidence but 
only limited clinical data, but an open mind is always essential when 
reviewing treatments.  The topical route is the preferred option to reduce 
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systemic effects, reduce dose and focus point of delivery at the hair follicle 
and particularly the dermal papilla and it has been shown recently (Hoffman, 
2002) that genes can be selectively targeted in hair matrix cells using a 
liposome carrier system and transdermal injection; suggesting a different 
therapeutic route. 
There are without doubt other agents available that could have a 
physiological effect and could be used to control, or partially reverse the 
progression of androgenetic alopecia; traditional Chinese medicine and 
Ayurvedic medicine are documented systems of health care that could 
provide such active agents. The ultimate treatment for androgenetic alopecia 
and certainly the most effective is the employment of a surgical procedure for 
the rearrangement of the hair follicles on the scalp.  The response to 
androgens is intrinsic to the individual hair follicle (Randall, 1994) and this 
site-specificity forms the basis of cosmetic hair transplant surgery. The 
dermis of the fronto-parietal region of the quail chick develops from the 
neural crest during embryogenesis, whereas the occipital-temporal areas of 
the scalp develop from the mesoderm (Ziller & Smith, 1982), if this is 
mirrored in the human body it may help to explain the differing response to 
androgens in cases of androgenetic alopecia. During human embryogenesis 
the mesoderm derived dorsal (occipital) covering is formed before the 
ectoderm derived ventral (fronto-partietal) area and their sensory nerve 
innervation differs. Sensory nerves can stimulate or inhibit target tissue 
activity by secreting differing neuropeptides (Paus et al, 1997) which may 
account for this differing response.  
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Recent advances in stem cell research have shown that hair follicle dermal 
papilla cells can be isolated and stimulated to produce cultured dermal 
papillae which can then be transplanted back into the donors scalp (Teumer 
& Cooley, 2005). The process is not yet available commercially, but could 
ultimately lead to the ‘holy grail’ of unlimited hair re-growth. 
 
1.5. Traditional Chinese Medicine (TCM) 
The Taoist hermits in their ancient search for the elusive elixir of life found 
that immortality was only spiritual, but their investigation of all animal, 
vegetable and mineral derivatives in their quest provided the therapeutic 
benefits on which traditional Chinese medicine is based (Weiyi Yang, 1998).  
This knowledge of herbs was recorded as early as 4th Century B.C. and the 
first Classic of Materia Medica containing details of 252 botanical extracts 
appeared around 220 AD.  The Imperial Medical School was founded in 624 
AD and their first pharmacopoeia (The newly revised Materia Medica) was 
published in 659AD containing references to 844 herbs.  Over 500 items are 
listed in The coloured atlas of Chinese materia medica (Dunmu & Jiangbo, 
1995), although only 300 or so are used in general practice and traditionally 
the whole plant or parts of it are used instead of a concentrated extract.  The 
plants are also used in combination for a maximum synergistic effect (Yanchi 
Liu & Zanwen, 1998), and the use of the whole or part of the plants and 
using them in combination provides particular difficulties for researchers and 
clinicians due to a technically uncertain and variable starting point for clinical 
research.  Additionally these products cannot usually be patented meaning 
that there is limited economic incentive to perform detailed clinical trials.  
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However, many herbal remedies contain powerful ingredients and their 
efficacy awaits further research. The “Herbalome Project” (De-An, 2008) at 
the Shanghai Institute of Materia Medica is probably the most ambitious 
project, attempting to identify active compounds and toxic contaminants in 
over 10,000 TCM herbs and animal tinctures. TCM is the treatment of choice 
and often the only recourse for many of the people in Asia. 
A herbal tea “Yin Zhi Huang” made from the plant, Artemisia capillaris, was 
proved in controlled experiments to be effective in the treatment of jaundice 
(Huang et al, 2004).  The active constituent, 6,7-dimethyl-esculetin, was 
identified and shown to stimulate the constitutive androstane receptors 
(CARs) on the surface of liver cells, key regulators in the control of jaundice.  
In 2004 the World Health Organisation symposium declared that the Chinese 
herb “Artemisia annua L” (or Qing Hao [Sweet Wormwood]) was now the 
number one drug of choice in the treatment of malaria.  Artemisia has been 
found to be highly effective against malaria parasites including multi-drug 
resistant ‘plasmodium falciparum’ and against chloroquine resistant malaria 
(Eckstein-Ludwig et al, 2003).  The unique anti-malarial properties of 
Artemisia annua L and related compounds are the focus of considerable 
current research. 
Recently it was shown that Cucubita ficifolia (Siam pumpkin or shark fin 
melon) fruit extract promoted regeneration of damaged pancreatic cells in 
diabetic rats (Xia & Wang, 2007), boosting levels of insulin–producing beta 
cells and insulin in the blood. The protective effect of Siam pumpkin is 
thought to be due to the presence of antioxidants and D-chiroinositol, a 
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mediator of insulin activity, offering a possible oral treatment to assist in the 
treatment of diabetes type 1. 
 
A number of plant extracts and mixtures have been used in traditional 
Chinese medicine in the treatment of androgenetic alopecia (Reid, 1995), 
and several proprietary “over the counter” products have been marketed.   
“Xiantene” is a complex mixture of traditional Chinese botanical derivatives, 
which experiments showed could stimulate normal human hair follicle growth 
in vitro (Dr. Z. Xia, personal communication). Xiantene is thus a good 
example of Chinese medicine to investigate for its potential action in vivo in 
the treatment of androgenetic alopecia. 
 
1.6. Aims 
The purpose of this study is to investigate two aspects in the understanding 
and treatment of androgenetic alopecia. 
A novel traditional Chinese medicine (TCM) topical mixture Xiantene will be 
tested in a preliminary (three months) and extended (12 months) consecutive 
double blind trials in subjects with androgenetic alopecia.  The trials will 
determine whether any naturally occurring factors in the herbal mixture 
Xiantene would have an effect on hair growth.  
Secondly, a possible relationship between two age related aspects of hair 
growth, canities (hair greyness) and androgenetic alopecia (patterned hair 
loss) will be investigated.  The purpose of this study will be to investigate 
whether the early onset of canities delays the progression of androgenetic 
alopecia in men.   
 77
2. Preliminary investigation into the effects of herbal mixture Xiantene 
on   hair growth in people with androgenetic alopecia 
 
2.1 Aim 
The purpose of this pilot study was to investigate whether naturally occurring 
hair growth factors in the herbal mixture Xiantene (based on eight herbs 
used in traditional Chinese medicine, see Sections 1.5 and 4.2) would have 
any effects on hair growth in cases of androgenetic alopecia when applied 
topically. Earlier work (Dr. Xia, Oxford, personal communication) had shown 
that Xiantene could stimulate normal human hair follicle growth in vitro. 
 
2.2 Experimental design 
A preliminary investigation of the effects of topical applications of the herbal 
mixture Xiantene on hair growth variables in people with androgenetic 
alopecia were investigated in a small group of men and women for three 
months. Half the subjects were given a control vehicle and half the Xiantene 
lotion. Neither the subjects nor the investigator were aware which subjects 
were given the Xiantene. Hair growth parameters were measured using the 
unit area trichogram method (Rushton et al, 1983) and a photographic record 
of each subject’s scalp was also made. The parameters to be measured 
were: total number of hairs, number of anagen hairs, anagen hair 
pigmentation (on a digitalised scale) and anagen hair shaft diameter.  
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2.3 Materials and methods 
2.3.1 Subjects 
A total of 35 subjects (31 men and 4 women) were invited to enter a three 
month trial of Xiantene (Xiantene I, see chapter 4) in the treatment of 
androgenetic alopecia, recruited at random by newspaper advertising. 
Subject ages ranged from 22 to 63 years. All subjects were examined by a 
qualified trichologist (the author) to confirm the presence and stage of 
androgenetic alopecia using the Hamilton grading scale for men (Hamilton, 
1951) or Ludwig scale for women (Ludwig, 1977) and to eliminate those with 
any underlying pre-condition.  Subjects were asked to sign a consent form 
and a disclaimer form and were verbally instructed and given a written 
standardised washing procedure (see Appendix I). The trial was conducted 
for a 3 month period, commercing in June and finishing in August.  
 
2.3.2 Application of Xiantene 
The experiment was conducted on a double-blind, vehicle-controlled basis 
with half the subjects using Xiantene and the remainder using a vehicle. The 
vehicle was prepared using 0.25% w/v caramel (Univar Ltd., Essex, UK), 
20% w/v denatured ethyl alcohol (Alcohols Ltd., London, UK) and made up to 
100% w/v with tap water. Neither researcher nor subject knew which 
treatment any participant received as this was identified by code number 
only. The test lotion was applied using a pump spray head provided with the 
30 ml plastic bottle of lotion (S. Murray & Co Ltd., Woking, UK), to the crown 
area only. Subjects were instructed to apply a single pump, approximately 
1ml, of the spray each night, and given a demonstration by the author before 
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commencing the trial. Subjects were seen by the same examiner (the author) 
throughout the trial and were required to present for examination each 
month. Each subject was thus expected to be seen four times during the 
three month study. 
 
2.3.3 Assessment of hair growth 
A photographic record was made at the beginning and end of the three 
month period.  Each subject’s crown area was photographed, using a tripod 
mounted Contax SLR camera with a 55 mm, 2.8 macro lens, fitted with a 
Sunpack ring flash attachment, at a distance of 30 cms (see Figure 2.1). 
Assessments of changes in the total number of hairs, the number of anagen 
hairs, anagen hair pigmentation and anagen hair diameter were made using 
the unit area trichogram method (Rushton et al, 1983).  A template was 
prepared from rigid plastic sheet, as per the Rushton method, with three 
circles of 8 mm diameter (area 50.7 mm²) precision cut in a triangular pattern 
(see Figure 2.2A). This was used to outline the areas of epilation on the 
crown approximately 20 mm below the centre point of the crown and 
approximately 10 mm right of the centre, delineated with an “Edding 1800 
Profipen (0.5)” indelible artist’s pen. Subjects with oily scalps had the crown 
area degreased with alcohol before the scalp was marked.   
All visible hairs in one of the circumscribed areas up to, and including, the 
outer pen marks were epilated using 10 cm surgical nasal forceps (Solingen, 
Germany) and an illuminated magnifying glass (magnification and 
manufacturer unknown). Validation of the methodology is given in Appendix 
II. 
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Figure 2.1  
Photographic equipment used to record subjects crown area. 
A photographic record was made using a Contax SLR 35 mm roll film 
camera fitted with a 55 mm 2.8 macro lens with a Sunpack ring flash 
attachment, at a distance of 30 cm. 
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Figure 2.2.A.  
Template used to define area of epilation. 
Template was prepared with 3 circles of 8 mm diameter (area 50.7 mm2) 
precision cut in a triangular pattern to outline the area of epilation on the 
crown.  
 
Figure 2.2.B.  
Plucked hairs mounted on microscope slide  
Hairs were epilated and mounted at the root end on a microscope slide using 
transparent adhesive tape (Sellotape), photo, (author) actual size  
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The hairs were mounted at the root end on a glass microscope slide using 
transparent adhesive tape (Sellotape) prior to measurements being made 
(see Figure 2.2B). After 3 months of treatment with Xiantene or vehicle, hair 
samples were collected in an identical manner in an adjacent area of the 
crown using the circle provided by the template. 
 
2.3.4 Hair measurements 
Hair samples were examined using a light microscope (Labor Lux S, Zeiss, 
Germany) and the numbers of hairs counted (magnification x40, i.e. x10 
eyepiece with x4 lens). Anagen and telogen hairs were distinguished by their 
typical morphology (Chase, 1954) (see Figures 2.3 and 2.4) and the images 
were collected by a video camera (800 x 600 pixels) connected to an IBM 
personal computer and analysed by image analysis software Optimas 5.2 
(Meyer Instruments, Texas USA). Hair diameter measurements were 
obtained from anagen hairs by taking the average of three diameter 
measurements between 0.2mm and 1mm above the hair root using the 
computer imaging cursor (Figure 2.5).  This was chosen as the area in which 
the final cross section and pigmentation of the emergent shaft were fully 
determined, but before any environmental or cosmetic damage to the shaft 
had occurred.  
The level of pigmentation of the shaft was assessed by computer imaging 
using the area morphometry macro and Optimas 5.2 (Meyer Instruments, 
Texas USA) software for analysis.  
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Figure 2.3  
Typical anagen and telogen hairs distinguished by their morphology. 
Anagen hairs exhibited soft, variably shaped, pigmented ends with tissue 
remnants and cellular matter. Telogen hairs exhibited a hard end with a 
rounded “shaving brush” appearance and loss of pigment. 
 
Typical hair in anagen phase (magnification x40) 
 
Typical hair in telogen phase (magnification x40) 
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Figure 2.4  
Non-typical anagen or telogen hairs. 
Hairs with non-typical morphology were re-examined by two independent 
assesors and classified by consenus. 
(A) Non-typical hair root morphology (magnification x40) 
Pigmented soft folded end with tissue remnant, classified as anagen 
 
(B) Non-typical hair root morphology (magnification x40) 
This is a broken hair suggesting that it was well anchored in the follicle and 
therefore classified as telogen 
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Figure 2.5  
Anagen hair shaft measurement (magnification x 25). 
Anagen hair shaft diameter measurements were obtained from the average 
of 3 diameter measurements between 0.2mm and 1mm from the hair root 
end. 
 
Anagen hair analysis 
Black arrows show 3 random points for diameter measurement. The red 
arrow and square show the area for pigmentation measurement.   
  .  
 86
A computer derived standard oblong template was constructed and 
superimposed on the hair fibre between 0.2 mm and 1mm above the hair 
root and the mean degree of pigmentation in the area covered was 
measured.  The level of pigmentation was digitalised and scored from 0-250, 
0 being white and 250 black.  The help of Dr. Zhidao Xia of the University of 
Oxford, in the measurement of hair parameters and in the compilation of the 
data, is gratefully acknowledged. The two sets of data, Xiantene and vehicle, 
were de-coded after data analysis, and all measurements were tabulated 
and expressed in graphical form. Mean values were calculated as mean ± 
standard error mean (SEM). Normal distribution was verified (Paul Bassett, 
personal communication) and paired Student’s t-tests were used for 
comparison between groups before and after treatment.  Results where 
p<0.05 were taken as significantly different. 
 
2.4 Results 
2.4.1. Subjects 
Thirty-five subjects commenced the experiment, half using Xiantene and half 
using the vehicle. Twenty six were re-examined at the end of the first month, 
19 at the end of the second month and 12 completed the full 3 month study. 
This included 6 subjects treated with Xiantene and 6 subjects using the 
vehicle. The methodology was validated (see Appendix II) and the coefficient 
of variation of the drawing of the circles on the scalps was found to be 
4.94%. 
Since no women completed the study, they were excluded from all the 
results including the pre treatment values. The high drop out rate was 
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unexpected, but importantly, equal numbers of treated and untreated 
subjects completed the trial.  
The age distribution of the 31 male participants who started and 12 who 
completed the trial are shown in graphical form (Figure 2.6). The mean age 
of all subjects commencing the study was 34.9 ± 1.6 years (mean ± SEM) 
and the mean age of subjects completing the study was higher at 39.0 ± 3.7 
years. The majority (68.0 %) of the younger group (20-40 years) failed to 
complete the trial; conversely most of the older group (66.7 %) (41-70 years) 
did manage to complete the trial.  
The extent of baldness as indicated by the Hamilton grading scale was also 
plotted (Figure 2.7). The Hamilton types ranged from 2 to 5 both before and 
after the study. The mean Hamilton type was 3.1 ± 0.2 for those who did not 
complete the trial and higher, at 3.7 ± 0.2 for subjects completing the trial, 
p=0.02. The subjects who completed the trial were significantly more bald 
than the subjects who did not finish the experiment.  
When the extent of baldness was related to age there was no significant 
difference between the commencement and completion of the study in the 
average age of the subjects at any particular extent of balding (Figure 2.8). 
Importantly the mean ages of the two study groups completing the trial did 
not vary significantly; mean age of the Xiantene group was 37.2 ± 4.9 years 
and the vehicle group 40.8 ± 6.0 years, p = 0.65, allowing a valid comparison 
of the effects of the Xiantene and vehicle treatments (see Figure 2.9).  
Similarly the extent of balding as measured on the Hamilton grading scale 
did not vary significantly between the two groups; Xiantene 3.8 ± 0.3 and 
vehicle 3.7 ± 0.3, p = 0.72, confirming the validity of the comparison.  
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Figure 2.6  
Age distribution of male subjects initially enrolled and completing the 
Xiantene pilot study. 
Subjects were invited to enter a 3 month trial of topical Xiantene in the 
treatment of androgenetic alopecia. Half of the subjects used Xiantene and 
half of the subjects used a vehicle.  
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Figure 2.7  
The extent of balding assessed using the Hamilton scale in subjects 
initially enrolled and completing the pilot study. 
Subjects were invited to enter a 3 month trial of Xiantene in the treatment of 
androgenetic alopecia. Half of the subjects used Xiantene and half of the 
subjects used a vehicle.  
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Figure 2.8  
Comparison of the mean age of subjects for each Hamilton stage of 
baldness between subjects initially enrolled and subjects completing 
the pilot study. 
Subjects were invited to enter a 3 month trial of Xiantene (n=35) in the 
treatment of androgenetic alopecia. Half of the subjects used Xiantene 
(n=18) and half of the subjects used a vehicle (n=17), values are mean ± 
SEM.  
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Figure 2.9  
There was no difference in the age or extent of balding at the beginning 
of the study in subjects completing the study treated with vehicle or 
Xiantene. 
Subjects were invited to enter a 3 month trial of Xiantene in the treatment of 
androgenetic alopecia. Half of the subjects used Xiantene and half of the 
subjects used a vehicle. Values are mean ± SEM for 6 men in each group. 
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2.4.2 Hair measurements before treatment 
The following measurements only refer to those who completed the study.  
The total number of hairs within the prescribed circle (50.7 mm²) and the 
number of hairs in anagen were recorded and plotted for each individual 
subject before, and after, treatment and the two groups, vehicle and 
Xiantene compared. Validation of methodology, see Appendix II.  
The mean total number of hairs per 50.7 sq mm before treatment did not 
differ significantly (p = 0.80) between the control 57.1 ± 8.2 and Xiantene 
treated 60.0 ± 7.1 groups (Figure 2.10A). There was also no significant 
difference (p = 0.76) between the mean number of anagen hairs per 50.7 sq 
mm before treatment between the control (39.8 ± 4.8) and Xiantene treated 
(42.2 ± 5.5) groups (Figure 2.10B). 
Further there was no significant difference in angen hair diameter pre-
treatment; vehicle group 73.8 ± 4.3 μm, Xiantene group 78.3 ± 6.4 μm, 
p=0.58 or in the level of hair pigmentation; vehicle group 175.9 ± 11.5 units, 
Xiantene group 167.2 ± 13.5 units, p=0.63. 
 
2.4.3 Hair measurements after treatment  
Each individual treated with Xiantene showed an increase in the total number 
of hairs epilated after treatment (Figure 2.11). This was in marked contrast to 
the control subjects where only 3 showed an increase i.e. subject numbers 
P4, P9 and P31, and 3 a decrease (see Figure 2.11). The vehicle group 
showed no significant difference (p = 0.98) when the mean number of hairs 
before (57.1 ± 8.2) and after treatment (57.0 ± 6.2) were compared. 
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Figure 2.10  
Comparison of the number of hairs and the number of anagen hairs, in 
the treated and control groups before and after treatment.  
Results are the mean ± SEM for men treated with vehicle (n=6) or Xiantene 
(n=6) for 3 months. Men with androgenetic alopecia used topical Xiantene (1 
ml) or a vehicle daily. All hairs were plucked from a circle of 50.7 mm2 area 
on the crown before and after 3 months treatment. Values are mean ± SEM. 
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Figure 2.11  
Total number of hairs before and after treatment in individual subjects 
using Xiantene or vehicle. 
Men with androgenetic alopecia used topical Xiantene (1ml) or a vehicle 
daily. All hairs were plucked from a circle of 50.7 mm2 area on the crown 
before and after 3 months treatment.   
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However, the Xiantene group showed a significant increase (p = 0.045) in 
the mean total number of hairs from 60.0 ± 7.1 before, increasing to 69.2 ± 
8.1 after treatment (see Figure 2.10.A.), an increase of 15.33%.  
The effect of Xiantene treatment on the number of anagen hairs was also 
investigated. Each subject treated with Xiantene also showed an increase in 
the number of anagen hairs epilated after treatment, whereas the control 
subjects only 3 showed an increase, i.e. subject numbers P4, P9 and P31 
and 3 showed a decrease (see Figure 2.12). There was no significant 
alteration in the mean number of anagen hairs over 3 months for the vehicle 
group from 39.8 ± 4.8 to 41.2 ± 3.6 (p = 0.84), but the Xiantene group 
showed a very highly significant increase in the mean number of anagen 
hairs from 42.2 ± 5.5 to 52.2 ± 6.1, p = 0.00033 (Figure 2.10B). Treatment 
with Xiantene had increased the number of anagen hairs in the six subjects 
by 23.71%. 
The number of telogen hairs before and after treatment were also counted. 
Neither the vehicle group with a mean number of telogen hairs of 17.3 ± 4.8 
before treatment and 15.8 ± 3.9 after treatment, (p = 0.36) nor the Xiantene 
group 17.8 ± 2.0 before treatment and 17.0 ± 3.0 after treatement (p = 0.81) 
showed any significant change in the numbers of telogen hairs. 
 
Hair diameter measurements 
Changes in anagen hair diameter were much more variable than the other 
parameters in both the control and treated groups (Figure 2.13).  
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Figure 2.12  
The number of anagen hairs before, and after, treatment in subjects 
using Xiantene or vehicle. 
Men with androgenetic alopecia used topical Xiantene (1ml) or a vehicle 
daily. All hairs were plucked from a circle of 50.7 mm2 area on the crown 
before, and after, 3 months treatment.   
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Figure 2.13  
Mean hair shaft diameters of anagen hairs before and after treatment in 
subjects using Xiantene or vehicle. 
Men with androgenetic alopecia used topical Xiantene (1ml) or a vehicle 
daily. All hairs were plucked from a circle of 50.7 mm2 area on the crown 
before and after 3 months treatment.   
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Hair diameter measurements of hairs in the anagen phase, before and after 
treatment, showed no significant change in mean hair shaft diameter for 
either the vehicle group (p = 0.78) or the Xiantene group (p = 0.51) after 3 
months, see Figure 2.13. 
Xiantene group mean diameters were 78.3 ± 6.4 μm before treatment and 
82.6 ± 4.3 μm after treatment; vehicle group 73.8 ± 4.3 μm before treatment 
and 75.3 ± 6.5 μm after treatment, (see Figure 2.14.A). The largest hair 
diameter recorded was 98.60 μm and the smallest hair diameter 
measurement record was 38.49 μm (subject P12, before treatment with 
vehicle); all other hair diameter measurements were above the 40 μm 
threshold, proposed by Rushton (Rushton et al, 1991). 
 
Anagen hair pigmentation measurements  
The Xiantene group showed slightly increased mean hair pigmentation after 
treatment, 175.5 ± 13.8 units compared to pre-treatment 167.2 ± 13.5 units, 
(p = 0.01). This contrasted with the control group where there was no 
significant change in mean hair pigmentation between pre-treatment 175.9 ± 
11.5 and post-treatment 165.9 ± 13.5, p = 0.09, see Figures 2.14. B. and 
2.15. Some staining of the scalp was reported by 2 people from the Xiantene 
group. 
 
Photographic record 
A photographic record was made of each subject’s crown area at the 
beginning and end of the trial to allow a cosmetic assessment to be made of 
hair growth.   
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Figure 2.14  
Comparision of the mean anagen hair diameter measurements and the 
mean anagen hair pigmentation measurements in the treated and 
control groups before and after treatment.  
Results are the mean ± SEM for men treated with vehicle (n=6) or Xiantene 
(n=6) for 3 months. Men with androgenetic alopecia used topical Xiantene (1 
ml) or a vehicle daily. All hairs were plucked from a circle of 50.7 2mm  area 
on the crown before and after 3 months treatment. Values are mean ± SEM 
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Figure 2.15  
Mean pigmentation of anagen hairs before and after treatment in 
subjects using Xiantene or vehicle. 
Men with androgenetic alopecia used topical Xiantene 1ml (n=6) or a vehicle 
(n=6) daily. All hairs were plucked from a circle of 50.7 mm2 area on the 
crown before and after 3 months treatment. Pigment was assessed using a 
digitalised scale, 0 = white, 250 = black. 
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The ultimate test for any hair loss treatment should be the eventual 
improvement to the cosmetic appearance of the scalp hair in the treated 
area.  The Xiantene group subjects did not show any dramatic improvement 
overall, although three of the subjects did appear to show possible 
improvement after treatment (see Figure 2.16). The vehicle group subjects 
did not show any changes (see Figure 2.17). Neither group showed any 
visible deterioration, probably due to the short 3 months period of the study. 
 
2.5 Discussion  
2.5.1 Methodology 
Methods of evaluating hair growth have been reviewed extensively (Rushton 
& James, 1986; Rushton et al, 1993; Van Neste, 2002; Van Neste, 2003; 
Chamberlain & Dawber, 2003) and may be divided into 3 main groups. 
“Invasive” using scalp biopsies sectioned vertically and horizontally to 
assemble a “follicugram” to provide follicle length and anagen:telogen ratios 
(Whiting, 1993). “Semi-invasive” methods, principally the unit area 
trichogram where the hairs are epilated from a small area of the scalp and 
examined to give the required hair parameters (Barman et al, 1965; Rushton 
et al, 1983).  
This has been further developed into the phototrichogram (PTG) method in 
which magnified sequential photographs of the shaved scalp area, possibly 
dyed are examined over a period of days to determine anagen and telogen 
hair numbers, the analysis of which has been enhanced by computer 
assisted imaging (Van Neste & Trűeb, 2006).  
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Figure 2.16  
Photographs of subject before and after treatment with Xiantene. 
Men with androgenetic alopecia used topical Xiantene 1 ml daily for a 3 
month trial. 
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Figure 2.17  
Photographs of subject before and after treatment with vehicle. 
Men with androgenetic alopecia used topical vehicle 1 ml daily for a 3 month 
trail. 
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Thirdly there are “non-invasive” techniques based on questionnaires for 
subject and researcher assisted by macro photography of the scalp and a 
scoring system which is constructed from this data.  
The unit area trichogram was used in this experiment to provide samples 
which could be repeatedly measured and assessed for parameters which 
can be accurately measured (validation see Appendix II) and does not allow 
overestimation of the number of hairs. The method has the draw back of 
being quite painful and possibly unacceptable for the subject and the 
technique is time consuming; however it is well suited to the relatively small 
subject numbers in this experiment. Large scale hair growth studies now 
favour the phototrichogram (PTG) method of assessment which has been 
shown to be of high accuracy and reliability (Van Neste et al, 2006), but care 
must be taken not to underestimate the total hair density due to the difficulty 
of identifying vellus, unpigmented hairs which may remain undetected (Van 
Neste, 2004). The PTG method does not allow assessment of hair 
diameters. 
 
2.5.2 Subjects  
The total of 35 people who commenced the pilot study were reduced to 12 at 
the end of the trial.  This high drop out rate of 65.7% was disappointing, 
probably enhanced by a combination of extremely heavy rain and a central 
London tube strike on the final days. The number of people who completed 
the trial was therefore small, however subject numbers were equal for both 
the Xiantene treated and control groups. No women completed the trial and 
only data relating to male subjects was used in this study. The age 
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distribution (see Figure 2.6) of those starting and those completing the trial 
indicates that the highest drop out rate was amongst the youngest men, 
particularly in the 20-40 years age range where only 32.0 % of subjects 
completed the course. Subjects in the 41-70 years age range, where 66.7 % 
completed the course, were either more conscientious and/or more 
concerned about their hair loss. Interestingly, the major drug hair loss trials 
(Olsen et al, 1985; Kaufman et al, 1998) tend to be based on the younger 
age ranges (18-41 years) for which a greater hair growth recovery might be 
possible. In this study it proved difficult to retain those younger subjects with 
possibly the greater potential to respond to treatments. Subjects with the 
lower Hamilton stages were also less likely to complete the trial.  
Analysis of the Hamilton baldness stages (Hamilton, 1951) of those 
completing and those not completing the study (see Figure 2.7) were 
significantly different (p=0.02) and confirms the loss of 77.77% of Hamilton 
stage 3 group where any hair growth response might have been most easily 
seen. The comparison of mean age of subject for each Hamilton grading 
scale of baldness shows that the Hamilton type 2 group have a higher mean 
age than the Hamilton type 3 group indicating possibly that the trial has 
attracted some older men with a good head of hair. It is not uncommon 
(personal observation) for older men with good heads of hair to be 
particularly interested in hair growth and willing participants in hair growth 
experiments. See also Chapter 5 where the same phenomonon was 
observed. Men with good heads of hair appear to be proud of their natural 
good fortune and want to maintain it.  
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2.5.3 Pre-treatment data 
Before treatment started both groups of men who completed the trial, 
Xiantene and control, shared similar parameters and were well matched. The 
mean ages; Xiantene 34.5 ± 2.3 years; vehicle 35.3 ± 2.4 years (see Figure 
2.6) compared well and were not significantly different, (p = 0.80). Likewise 
the extent of baldness using the Hamilton scale is similar; Xiantene score 3.3 
± 0.2, vehicle 3.4 ± 0.2 (see Figure 2.7), p = 0.71. In normal men not 
suffering from androgenetic alopecia, there is no significant difference in hair 
density between the occipital area, 311 ± 11 hairs per 2cm and the frontal 
area, 312 ± 15 hairs per 2cm (Rushon et al, 1983). Analysis of the pre-
treatment parameters in this trial indicates that the total number of hairs per 
sq cm found here, on the crown 117.8 ± 13.9 Xiantene group and 112.2 ± 
16.2 in the vehicle group, are lower than other published data; Rushton’s 
group (Rushton et at, 1983) reported 175 ± 6 hairs/sq cm on the frontal or 
vertex area of men suffering from androgenetic alopecia, although this group 
were younger, with a lower mean age of 24 years. Other researchers (Olsen 
et al, 1985) found a lower comparable hair count of 58.6 hairs/sq cm for the 
frontal/vertex area in men with androgenetic alopecia, although this later 
photographic counting technique may not have evaluated the total vellus hair 
count (James & Rusthon, 1986). The mean number of anagen hairs per sq 
cm (83.8 ± 10.9, 71.1% of the total) in the Xiantene group and (78.0 ± 9.4, 
69.5% of the total) in the vehicle group recorded is as expected lower than 
published data of 85.4 ± 1.5% for the androgen insensitive occipital area 
(Rushton et al, 1983) but higher than the figure for the androgen sensitive 
frontal area which was found to be 57.3 ± 5.5% (Rushton et al, 1983). It has 
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been proposed based on histological observations that more than 80% of the 
hairs in the anagen phase is normal: more than 20% of the hairs in the 
telogen phase, i.e. an anagen:telogen ratio of less than 4:1 is consistent with 
androgenetic alopecia (Bergfeld, 1989). The lower percentage of hairs in the 
anagen phase in this experiment indicates a more advanced stage of 
patterned hair loss and confirms androgenetic alopecia with a 
correspondingly reduced total number of hairs. The mean hair diameters 
before treatment of 78.3 ± 6.4 μm for the Xiantene treated group and 73.8 ± 
4.3 μm (see Figure 2.14.A) for the vehicle group compare well and are in 
good agreement with 69 ± 3 μm recorded by Rushton’s group for hair from 
the occipital area of balding men (Rushton et al, 1983) but higher that the 54 
± 3 μm found for the frontal/vertex area. Overall the pre-treatment 
measurements confirmed that the subjects were showing the characteristics 
of androgenetic alopecia i.e. they were suitable for study. 
 
2.5.4 Comparision of pre-treatment and post-treatment data 
The Xiantene and vehicle groups completing the trial were well matched. The 
mean ages compare well and are not significantly different; Xiantene group 
37.2 ± 4.9 years, vehicle group 40.8 ± 6.0 years (see Figure 2.6), (p = 0.65). 
Similarly the extent of baldness for the two groups does not differ 
significantly, (p = 0.72) (Xiantene group Hamilton type 3.8 ± 0.3, vehicle 
group Hamilton type 3.7 ± 0.3, see Figure 2.7). The equal subject numbers 
and the non-significant differences in the key parameters allow valid 
comparison between the Xiantene treated group and the vehicle control 
group completing the 3 month study (see Figures 2.9, 2.10.A and 2.10.B).  
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Examination of the vehicle group shows that there were no significant 
changes in the key parameters: number of hairs, number of anagen hairs, 
hair shaft diameter and hair shaft pigmentation when pre and post treatment 
values were compared (see Figures 2.10.A, 2.10.B 2.14.A and 2.14.B). 
Possible changes could have been expected in a balding population over 
time (Rushton et al, 1991; Kaufman et al, 2008); additionally seasonal 
changes could also have been expected (Randall & Ebling, 1991). The lack 
of significant change in any of the four hair growth parameters in the vehicle 
treated group probably reflects the short duration of the study as it was 
carried out only for 3 months. It is now generally accepted that any hair 
growth study should be conducted for a minimum of 12 months to allow for 
seasonal variations (Randall, 2008). 
Treatment with the herbal mixture Xiantene affected several hair follicle 
parameters. The total number of hairs per unit area in the Xiantene treated 
group was increased significantly (p = 0.045) by 47.38% (see Figure 2.10.A). 
This increase could be a reflection of the stimulation of vellus hairs to 
terminal hairs with a consequent increase in the number of “meaningful” 
hairs (Rushton et al, 1983) i.e. the number of hairs that can be seen and 
plucked. “Meaningful” hairs have been defined as those with a diameter of 40 
μm or more (Rushton et al, 1983) i.e. hairs below 40 μm diameter did not 
contribute to the aesthetic appearance of the scalp. Other treatments e.g. 
minoxidil (Olsen, 1985), finasteride (Kaufman et al, 1998) and dutasteride 
(Olsen et al, 2006) have also been shown to increase the numbers of 
meaningful hairs per unit area. It is unlikely that Xiantene treatment would 
actually increase the number of hairs by any other mechanism, particularly in 
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the short time involved. The human scalp is believed to have its full 
complement of hair follicles soon after birth (Dry, 1926) with loss but not 
increase in hair follicles reported in later life (Hamilton, 1951; Whiting, 2001). 
Xiantene would appear to have increased the number of meaningful hairs 
during the 3 month study by stimulating vellus hair follicles into making larger 
hairs, or in view of short time scale, more likely stimulating anagen in “empty” 
follicles where the hair has been shed due to exogen (Stenn et al, 1996; Van 
Neste et al, 2007) while the follicle was resting. The 3 month period of the 
study is unlikely to be long enough for the follicle to go through all the 
processes of replacing a hair. 
The increase in the number of anagen hairs of the Xiantene group was very 
highly significant p = 0.00033, (Figure 2.10.B) with a mean increase in 
anagen hairs for the Xiantene group of 23.70%. There was no corresponding 
increase in the vehicle group p = 0.84, (Figure 2.10.B). The mean number of 
telogen hairs showed no significant difference in either group after treatment; 
(Xiantene p = 0.81, vehicle p = 0.36). The increased numbers of anagen 
hairs, while the number of telogen hairs remains unchanged suggests that 
the increase in overall numbers of hairs is due to increased numbers of 
visible hairs in the anagen phase. This may suggest that Xiantene treatment 
is stimulating vellus follicles, as vellus follicles spend much less time in 
anagen (Chase, 1954) than terminal hairs. A reduction of the number of hairs 
in the anagen phase, along with miniaturisation of the follicles is one of the 
characteristics of androgenetic alopecia (Bergfeld, 1989; Whiting, 2001). 
Histological observations (Bergfeld, 1989), indicate that androgenetic 
alopecia is characterised by: a decrease in the anagen: telogen ratio 
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(normally 80:20), a decrease in the number of hair follicles, miniaturisation 
and involution of the hair follicle; and compacting of the dermal connective 
tissue resembling scar formation. It is proposed that miniaturisation of the 
hair follicle is the key feature of androgenetic alopecia and further that the 
process may not proceed in a gradual progression, but as a series of large 
step processes (Whiting, 2001). It was found (Whiting, 2001) that in cases of 
androgenetic alopecia, the anagen phase may eventually be reduced from 2 
or 3 years to 1 month, but the telogen phase remained constant at 
approximately 3 months, causing a reversed anagen:telogen ratio and further 
that there may be a time lag after the shedding exogen phase (Van Neste, 
2007) of up to 6 months before the appearance of the new anagen hair. The 
rate of hair growth was found to be reduced in androgenetic alopecia 
(Whiting, 2001) corresponding to a reduced dermal papilla size which could 
be seen histologically.  
Finasteride was found to partially reverse miniaturisation of the hair follicle in 
subjects with androgenetic alopecia (Kaufman et al, 1998, Van Neste, 2006) 
although the beneficial effect was gradually lost within 12 months if the 
treatment was discontinued (Kaufman et al, 1998). Minoxidil similarly 
promoted the entry of follicles into, and prolonged the length of anagen, in 
cases of androgenetic alopecia (Olsen et al, 1985, Olsen, 1989), something 
also observed in this 3 month study of treatment with Xiantene. It is possible 
Xiantene has increased the length of the anagen phase in subjects with 
androgenetic alopecia. The increase in the total number of hairs (see Figure 
2.10.A) suggests that new hair has been added i.e. an increase in the 
number of meaningful hairs (Rushton et al, 1983). This reversal and increase 
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in the number of hairs in the anagen phase (see Figure 2.10.B) of the hair 
cycle is significant in any evaluation of herbal mixture Xiantene and suggests 
that further investigations are warranted.  
 
2.5.5 Hair diameter measurements  
The mean anagen hair diameters recorded before treatment (Xiantene group 
78.3 ± 6.4 μm, vehicle group 73.8 ± 4.3 μm, see Figure 2.14.A) compare well 
with earlier work. Subjects with androgenetic alopecia were found to have a 
mean hair diameter of 69 ± 3 μm in the occipital region for men and 66 ± 4 
μm for women (Rushton et al, 1983). Young women not suffering from hair 
loss were found to have a larger hair diameter, 73.69 ± 11.71 μm than 
mature women, 68.63 ± 5.41 μm and post menopausal women, 59.01 ± 
10.08 μm who complained of hair loss (Van Neste, 2004). There was no 
significant alteration in this experiment in mean hair diameter in either group 
after 3 months of treatment. It is the gradual miniaturisation of the hair shaft 
and eventual atrophy of the hair follicle which characterises androgenetic 
alopecia (Bergfeld, 1989; Whiting, 2001), therefore stopping the decrease 
might be expected. It is equally possible that any change in hair diameter 
may not be detectable in the short duration of this pilot trial. An increase in 
the number of hairs less than 40μm diameter in subjects with androgenetic 
alopecia was found to be of diagnostic significance (Rushton et al, 1983). If a 
number of smaller hairs have been increased to “meaningful” hairs (Rushton 
et al, 1983) there would be an increase in the number of hairs with small 
diameters and the mean hair diameter therefore would actually decrease. 
Rushton studied hair diameters in subjects with androgenetic alopecia 
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(Rushton et al, 1983) and found that earlier work on the diameters of human 
scalp hair (Barman et al, 1965; Jackson et al, 1972) may not have 
differentiated between the major and minor axes. Hair shaft diameter 
measurements may also be complicated by swelling due to humidity and 
also variation in diameter along the length of the hair shaft (White & Stam, 
1949), possible variation of diameter of individual hair fibres was also 
observed by other researchers (Rushton et al, 1983). The cross sections of 
hair shafts will depend on genetic background (see section 1.1.3) although 
all subjects in this study were Caucasians and in this experiment no 
distinction was made between major and minor axes. Interestingly it has also 
been observed (Rushton et al, 1983) that in the progression of androgenetic 
alopecia a large percentage of hairs were found of normal diameter but of 
restricted growth (less than 3 cm) i.e. the hairs were shorter indicating a 
shorter anagen (growth) phase. 
 
2.5.6 Anagen shaft pigmentation  
The increase in anagen hair pigmentation of the Xiantene group compared 
with those of the control was significant, (p = 0.012) (see Figure 2.14.B). Hair 
pigmentation is known to decrease with age as tyrosinase activity in the hair 
bulb melanocytes reduces following accumulating reactive oxygen species 
(ROS) damage (Van Neste & Tobin, 2004). Increased melanogenesis of the 
anagen hair shaft might be expected if a partial cessation or reversal of 
androgenetic alopecia had been achieved. The increased pigmentation level 
is therefore consistent with an extended anagen phase and with increased 
mitosis and melanogenesis and this phenomenon of increased pigmentation 
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post treatment has been reported by other researchers (Olsen et al, 1985; 
Rushton et al, 1989). However, it is also possible that the increased 
pigmentation recorded may be due to staining of the hair shaft by the test 
material; a third of the subjects using Xiantene had reported some staining of 
the scalp. Further, Xiantene contains Isatidis indigotica fort (see Chapter 4) 
which is a pre-cursor for the dye indigo. On the other hand the herb 
Polygonum multiflorum also present in Xiantene and used internally as a 
decoction (hot aqueous herbal extract) has been claimed to darken grey hair 
(Reid, 1995), see Chapter 4. The Chinese name for this herb “Ho Shou Wu” 
derives from the ancient king (Ho) whose head (Shou) of white hair turned 
black (Wu) when he used the herb, hence the name “Ho Shou Wu” (Reid, 
1995). However it is not possible to determine the cause of the pigmentation 
and this observation of increased pigmentation using Xiantene is interesting 
but cannot be relied upon.  
 
2.6 Conclusion 
These results showed that topical lotion Xiantene might possibly increase the 
total number of hairs and may increase the percentage of anagen hairs in a 
small group of men with androgenetic alopecia in a 3 month period, 
compared with controls, where no significant increases were observed. This 
could indicate that Xiantene may promote a cessation or partial reversion in 
the progression of androgenetic alopecia. Therefore, Xiantene treatment for 
androgenetic alopecia merits further investigation. An extended study over a 
longer period with a larger subject number is necessary to strengthen these 
observations.   
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3. Investigation into the effects of 12 months application of herbal 
mixture Xiantene on hair growth in men with androgenetic alopecia 
 
3.1 Aim 
The purpose of this study was to extend the results from the earlier 3 months 
preliminary investigation (see Chapter 2), by investigating whether naturally 
occurring hair growth factors in the herbal mixture Xiantene would have any 
effects on hair growth in cases of androgenetic alopecia when applied 
topically for a period of 12 months.  
 
3.2 Experimental design  
The effects of topical application of the herbal mixture Xiantene in cases of 
androgenetic alopecia were studied in a larger group of men over a period of 
12 months to prevent any possibility of seasonal changes affecting the 
results (Orentreich, 1969; Randall & Ebling, 1991; Courtois et al, 1996). The 
trial, similar in design to the shorter 3 month trial (see chapter 2), was 
conducted on a double blind basis, half the participants being treated with 
Xiantene whilst the remainder used a vehicle. The parameters measured 
included the total number of hairs, the number of anagen hairs and the 
anagen:telogen ratio in a specific area of the crown. Hair samples for each 
group were collected using the unit area trichogram method (Rushton et al, 
1983). The changes in parameters over the 12 month period were then 
compared for the two groups, Xiantene and vehicle. Validation of the 
methodology, see Appendix II.  
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3.3 Materials and methods 
3.3.1 Subjects 
A total of 48 male subjects were recruited using local advertising for a 12 
month trial of herbal mixture Xiantene in the treatment of androgenetic 
alopecia. Advertisements were placed in the Brabant House Clinic of Natural 
Medecine in Thames Ditton, Surrey for 6 weeks asking for male volunteers 
for a one year trial of a topical herbal mixture in the treatment of common 
baldness, part of a research programme supervised by the University of 
Bradford. No payment was offered to trial participants, but the study was ‘end 
loaded’ with the offer of a magnum of champagne for all subjects completing 
the 12 month trial, in an effort to reduce the high drop out rate experienced in 
the earlier 3 month trial (see chapter 2). Subject ages ranged from 24 years 
to 85 years. All subjects were examined by a qualified trichologist (the 
author) at the beginning and end of the trial to confirm androgenetic alopecia 
and to eliminate any other underlying hair or scalp condition. Subjects were 
asked to sign a consent form confirming informed consent and confirming 
that they were in good health although it was not possible to check their 
health status. They also signed a disclaimer form and were given a 
standardised washing procedure (see Appendix I). No subject had used any 
treatment for balding in the 12 months prior to the study. Ethical permission 
was obtained from the University of Bradford Ethical Committee. 
 
3.3.2 Application of Xiantene 
Fifty per cent of the subjects were given herbal lotion Xiantene (Xiantene II, 
see chapter 4) and the remainder given a vehicle (see Section 2.3.2 chapter 
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2), and asked to use 1 ml of solution daily on the crown area. Neither 
subjects nor researcher were able to distinguish between the two lotions, 
which were identified by code number only.  The results were de-coded after 
analysis of the data.  
 
3.3.3 Assessment of hair growth 
The assessment of hair growth followed the same procedure as the initial 
investigation, see chapter 2 section 2.3.3.  
 
3.3.4 Hair measurements  
The hair measurements followed the same procedure as the initial 
investigation, see Section 2.3.4, chapter 2, except that two people (author 
and Ms Helena Holicova) independently verified the number of hairs and the 
morphological identification. All hairs were counted and broken hairs were 
classified as telogen. Classification was repeated if necessary until 
concurrence was achieved. Hair diameters and hair pigmentation were not 
measured for the 12 month trial subjects as hair diameters had shown no 
change in the 3 month trial and hair pigmentation measurements were not 
considered meaningful due to the colour of the vehicle. All data are 
expressed as mean value ± S.E.M. (Standard Error Mean). The normality of 
the distribution was determined by producing both histograms and normal 
plots and examining the distribution values; paired Student’s t-tests were 
used for comparision within groups before and after treatment. Results 
where p<0.05 were taken as significantly different. The association between 
variables was examined using Pearson correlation on a correlation 
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coefficient scale between -1 (a strong negative correlation) and +1 (a strong 
positive correlation). 
 
3.4 Results 
3.4.1. Pre treatment data, 3 month (chapter 2) and 12 month (chapter 3) 
trial 
The pre-treatment data for the men with androgenetic alopecia from both the 
3 month (chapter 2) and 12 month (chapter 3) experiments were combined 
for analysis. The parameters: total number of hairs per circle (50.7 mm²), the 
number of anagen hairs per circle (50.7 mm²) and the anagen:telogen ratio 
were related to both age (Figures 3.1, 3.2 and 3.3) and extent of baldness 
measured by the Hamilton stage (Figures 3.4, 3.5, 3.6 & 3.7), using Pearson 
correlation. For this data the Xiantene groups and the vehicle groups have 
been combined. This analysis was therefore carried out on 41 men aged 
between 22 years and 85 years (mean 44.7 ± 2.1 years) with androgenetic 
alopecia ranging from Hamilton stage 2 to 7 (mean 4.2 ± 0.2). The data for 
the 3 month study (n=12) was collected in June, July and August and it was 
not possible to allow for possible seasonal changes in the numbers of 
growing hairs. The data for the larger study was conducted over the full 12 
month period (n=29) and would not be subject to seasonal variation.  
 
3.4.1.1. Relationship of hair parameters to age 
The total number of hairs per template area (50.7 mm²) on the vertex 
decreased with age from a mean of 61.0 ± 6.4 at age 21-30 years to 22.2 ± 
5.3 age over 60 years (Figure 3.1.a).  
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Figure 3.1 
The relationship between age in years and the total number of hairs in 
50.7 mm² area on the crown in men with androgenetic alopecia. 
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments.  
(a) Mean values (± SEM) for each decade 
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(b) Correlation of individual values with age. Pearson coefficient - 0.37, 
p=0.02 
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Figure 3.2 
The relationship between age in years and the number of anagen hairs 
in 50.7 mm² area on the crown in men with androgenetic alopecia.  
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments. 
(a) Mean values (± SEM) for each decade 
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(b) Correlation of individual values with age. Pearson coefficient - 0.30, 
p=0.06 
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Figure 3.3 
The relationship between age in years and the anagen:telogen ratio on 
the crown in men with androgenetic alopecia. 
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiment.  
(a) Mean values (± SEM) for each decade 
Number of men aged 21-30=5, 31-40=13, 41-50=10, 51-60=7, 60+ =6 
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(b) Correlation of individual values with age. Pearson coefficient 0.11, p=0.51 
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Figure 3.4 
The relationship between age in years and the extent of baldness 
(Hamilton stage) in 50.7 mm² area on the crown in men with 
androgenetic alopecia.  
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments.  
(a) Mean values (± SEM) for each decade 
Number of men aged 21-30=5, 31-40=13, 41-50=10, 51-60=7, 60+ =6 
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(b) Correlation of individual values with age. Pearson coefficient 0.35, p=0.03 
 
0 
1 
2 
3 
4 
5 
6 
7 
0 10 20 30 40 50 60 70 80 90
Age 
Hamilton score 
 
 122
Figure 3.5 
The relationship between extent of balding (Hamilton stage) and the 
total number of hairs in 50.7 mm² area on the crown in men with 
androgenetic alopecia.  
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments.  
(a) Mean values (± SEM) for each Hamilton stage 
Number of men aged 21-30=5, 31-40=13, 41-50=10, 51-60=7, 60+ =6 
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(b) Correlation of individual values with age. Pearson coefficient -0.56, 
p<0.001 
 
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6 7
Hamilton scale
Total number of
hairs 
 
 123
Figure 3.6 
The relationship between extent of balding (Hamilton stage) and the 
number of anagen hairs in 50.7 mm² area on the crown in men with 
androgenetic alopecia.  
 This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments.  
(a) Mean values (± SEM) for each Hamilton stage 
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(b) Correlation of individual values with Hamilton stage. Pearson coefficient -
0.60, p<0.001 
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Figure 3.7 
The relationship between extent of balding (Hamilton stage) and the 
anagen:telogen ratio. 
This includes pre-treatment data from 41 men who completed either the 3 
month or 12 month experiments.  
(a) Mean values (± SEM) for each Hamilton stage 
Number of men aged 21-30=5, 31-40=13, 41-50=10, 51-60=7, 60+ =6 
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(b) Correlation of individual values with Hamilton stage. Pearson coefficient -
0.09, p=0.60 
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The relationship between subject age and total number of hairs is also 
shown in Figure 3.1b, correlation coefficient = -0.37 confirming a strong 
significant negative correlation (p=0.02) i.e. the total number of hairs per unit 
area decreased with age. The number of anagen hairs per template area 
(50.7 mm²) on the vertex also decreased with age from a mean of 40.0 ± 5.4 
at age 21-30 years, to 18.3 ± 4.2 over age 60. This correlation analysis is 
shown in Figures 3.2.a & 3.2.b and indicates a negative correlation, 
correlation coefficient =-0.30, although this result was not quite statistically 
significant (p=0.06). The change in number of telogen hairs with age was 
also examined. Subjects aged 21-30 years had a mean telogen hair count of 
20.6 ± 1.4 and the men aged over 60 years had a mean telogen hair count of 
3.8 ± 1.5; correlation coefficient -0.35, p=0.03. The number of telogen hairs 
showed a significant negative correlation with age. 
Figures 3.3.a & 3.3.b show the absence of a relationship between age and 
anagen:telogen ratio. Although the mean anagen:telogen ratio was 2.0 ± 0.2 
between 21-30 years and 4.6 ± 1.2 over age 60 years, there was no strong 
correlation between age and anagen:telogen ratio, correlation coefficient = -
0.11, p=0.51. The overall mean anagen:telogen ratio was 3.4 ± 0.5. 
When the extent of balding as measured by the Hamilton stage was related 
to age there was a significant relationship (Figure 3.4). Men aged 21-30 
years (Xiantene treated + control group) had a mean Hamilton stage 3.2 ± 
0.4, whilst that for men aged over 60 years (Xiantene treated + control group) 
was 4.7 ± 0.7 (see Figure 3.4.a). There was a significant positive correlation 
between age and Hamilton score, correlation coefficient = +0.35 (Figure 
3.4.b) and p = 0.03, indicating that balding increased with age. 
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3.4.1.2. Relationship between hair parameters and extent of balding 
The relationship between the extent of balding as measured by the Hamilton 
stage and the total number of hairs (Figures 3.5.a & 3.5.b), the number of 
anagen hairs (Figure 3.6.a & 3.6.b) and the anagen:telogen ratio (Figures 
3.7.a & 3.7.b) was also investigated. The total number of hairs per circle 
(50.7 mm²) decreased from a mean of 55.3 ± 10.8 at Hamilton stage 2 to a 
mean of 19.3 ± 5.4 at Hamilton stage 6 with one individual at stage 7 having 
only 6 hairs (Figure 3.5.a) and was significantly negatively correlated, 
correlation coefficient -0.56 (p<0.001) (Figure 3.5.b). Similarly the number of 
anagen hairs per circle decreased from a mean of 41.0 ± 10.4 at Hamilton 
stage 2 to a mean of 12.1 ± 2.6 at Hamilton stage 6 with the one individual at 
stage 7 having only 5 anagen hairs (Figure 3.6.a). Again there was a strong 
negative correlation with Hamilton stage, correlation coefficient -0.60 
(p<0.001, Figure 3.6.b). 
In contrast, the anagen:telogen ratio did not change significantly from a 
mean of 3.2 ± 1.0 at Hamilton stage 2 to a mean of 3.1 ± 1.0 at Hamilton 
stage 6 (Figure 3.7.a) and there was no significant correlation, coefficient -
0.09 (p=0.60, Figure 3.7.b). 
Therefore, the extent of balding (Hamilton stage) showed a significant 
negative correlation with the total number of hairs, a significant negative 
correlation with the number of anagen hairs and an insignificant weak 
negative correlation with the anagen:telogen ratio in this group of men with 
androgenetic alopecia. The strong negative correlation between extent of 
balding and both total number of hairs and the number of anagen hairs 
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indicates that as the Hamilton stage increases, the number of visible hairs 
decreases on the crown/vertex. 
 
3.4.1.3 Comparision of pre-treatment data between the control and 
Xiantene treated men who completed the 12 month trial  
The distribution of the initial ages of the men (n=29) who completed the 12 
month trial, in each of the two groups, Xiantene and vehicle, are shown in 
Figure 3.8. The mean ages for the two groups: 47.3 ± 3.7 years for the 
Xiantene treated men (n=17); 46.8 ± 3.3 years for those receiving the vehicle 
(n=12) did not vary significantly (p=0.93) confirming the validity of the 
comparison between groups. The mean age of all subjects completing was 
47.1 ± 2.5 years.  
The distribution of the initial extent of baldness as determined by the 
Hamilton stage of the two groups, Xiantene and vehicle, are shown in Figure 
3.9. The initial mean Hamilton stages for the Xiantene and control groups 
who completed the experiment, pre-treatment were 4.7 ± 0.3 for the Xiantene 
group and 4.0 ± 0.5 for the control. These do not vary significantly (p=0.21) 
confirming the validity of comparing the two groups. The mean Hamilton 
stage of all subjects completing the trial before treatment was 4.4 ± 0.3. 
The mean total hair density on the crown at the beginning of the trial was 
61.4 ± 9.4 hairs/cm² in the Xiantene group and 82.7 ± 13.7 hairs/cm² in the 
control group before the experiment (see Figure 3.10). Although the mean 
total number of hairs/cm² in the Xiantene group pre-treatment were lower 
than the control group, this is not significantly different (p=0.20). 
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Figure 3.8 
Age distribution at initial assessment of male subjects enrolled and 
completing the 12 month study investigating Xiantene treatment in 
androgenetic alopecia.  
Men with androgenetic alopecia (n=48) were invited to enter a 12 month trial 
of Xiantene in the treatment of androgenetic alopecia. Half of the subjects in 
the control group used the vehicle (a) and the remainder of the subjects used 
Xiantene solution (b).  
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Figure 3.9 
The initial extent of balding as indicated by the Hamilton stage of 
subjects enrolled and completing the 12 month study investigating 
Xiantene treatment in androgenetic alopecia. 
Men with androgenetic alopecia (n = 48) were invited to enter a 12 month 
trial of Xiantene in the treatment of androgenetic alopecia. Half of the 
subjects in the control group used the vehicle (a) and the reminder of the 
subjects used Xiantene solution (b).  
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Figure 3.10 
A comparison of the total number of hairs/circle in the Xiantene treated 
men and those using the vehicle before, and after, treatment.  
Men with androgenetic alopecia used topical Xiantene (1ml) or the vehicle 
daily. All hairs were plucked from circles of 50.7 mm² area on the crown 
before, and after, 12 months treatment. Results are the mean ± SEM of 
measurements for each subject before and after treatment involving 12 
subjects for the vehicle and 17 subjects for the Xiantene treatment. 
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The mean number of anagen hairs pre-treatment in the specimen circle (50.7 
mm²) in the two groups were significantly different with Xiantene treated men 
having 35.6 ± 4.5 cm² and control men 68.0 ± 11.1 cm², p=0.005 (Figure 
3.11). Although the subjects were recruited and divided into groups on a 
random basis, the Xiantene group had a lower mean number of anagen hairs 
initially. However, the number of telogen hairs/circle before treatment was 
not found to be significantly different between groups with a mean for the 
Xiantene group of 13.2 ± 2.8 and the control group of 7.4 ± 1.8 (p=0.13). 
There was a significant difference in the anagen:telogen ratio between the 
two groups at baseline; Xiantene 2.2 ± 0.5, control 5.5 ± 1.0, p=0.002. 
Overall key mean parameters, age and Hamilton score, were not significantly 
different between the Xiantene treated and vehicle groups, confirming the 
validity of the comparison. 
 
3.4.1.4 Comparision of control and Xiantene treated groups after 12 
months treatment  
The forty eight subjects who commenced the trial were equally divided into 
treatment and vehicle groups. A total of 29 men were successfully re-
examined, and samples collected from them at the end of the 12 month 
period. This included 17 men using Xiantene and 12 using the vehicle.   
The drop out rate of 39.58% remained high, but was less in the Xiantene 
group, 29.2%, than the 50% of the control group. 
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Figure 3.11 
Mean number of anagen hairs/circle in Xiantene treated men and those 
using the vehicle before, and after, treatment. 
Men with androgenetic alopecia used topical Xiantene (1ml) or vehicle daily. 
All hairs were plucked from circles of 50.7 mm² area on the crown before and 
after 12 months treatment. Results are the mean ± SEM of measurements 
for each subject before and after treatment involving 12 subjects for vehicle 
and 17 subjects for the Xiantene treatment. 
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Subject opinions 
All subjects expressed satisfaction with the treatment at the end of trial 
discussion regardless of whether they were using Xiantene or the vehicle, 
and 4 subjects (3 using Xiantene, 1 vehicle), 13.79% of the total number 
(17.6% of Xiantene group and 8.3% of the vehicle group) spontaneously 
asked to continue treatment beyond the end of the experiment. These 
subjects specifically requested to continue the experiment even though no 
prior offer of continuation had been made. However (see Table 3.1), 3 
subjects using Xiantene (10.35%) reported a slight reaction to the treatment, 
a mild erythema on the crown, and 2 subjects using Xiantene (6.90%) 
complained of the adverse smell of the treatment, and in one of the subjects 
where an adverse reaction was recorded, the reaction was severe enough 
for the subject to stop.  
 
Age and extent of baldness  
To see if age or extent of baldness influenced whether subjects enrolled in 
the study continued to the end, the age and Hamilton stages were compared 
between subjects who completed the 12 month trial (total 29) and the 
subjects who did not complete the trial (total 19) (Figure 3.8). In the control 
group treated with the vehicle alone the subjects that completed the 
experiment were significantly older (46.8 ± 3.3 years) than those who did not 
complete (35.6 ± 2.9 years), p=0.02. In the Xiantene group there was no 
significant difference in age, with the completing group mean age being 47.0 
± 3.7 years, while for those not completing it was 47.6 ± 6.0 years, p=0.94. 
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Table 3.1 
Analysis of subjects dropping out of 12 month study 
In a 12 month study investigating 48 subjects using Xiantene or vehicle 
treatment in androgenetic alopecia, 19 subjects (39.57%) out of a total of 48 
subjects commencing failed to complete the trial. 
 
 
Reason Number of subjects % of Total Drop 
outs 
 Total Xiantene vehicle  
Abandoned, adverse 
erythema reaction 
problem(uncorroborated)
 
1 
 
1 
 
x  
 
2.08 
Dissappeared and could 
not contact 
1 x  1 2.08 
Unrelated medical 
condition diagnosed 
2 1 1 4.16 
Unrelated disagreement 3 x  3 6.25 
Voluntarily stopped after 
2 to 3 months (“Just sort 
of stopped”) 
 
12 
 
5 
 
7 
 
25.00 
 19 Subjects 39.57% 
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There was also no strong evidence of a difference in extent of baldness 
between those completing and those not completing the trial in either the 
Xiantene treated group and the control group (Figure 3.9). People in the 
control group completing the experiment had an initial mean Hamilton stage 
of 4.0 ± 0.3, and those not completing of 3.4 ± 0.3, (p=0.27), while the 
Xiantene group completing had a mean of 4.8 ± 0.3 and those not 
completing of 3.7 ± 0.5, (p=0.08). However, when both groups were 
combined together (i.e. Xiantene treated and control) there was a significant 
difference in extent of baldness with those completing having a higher mean 
Hamilton score of 4.5 ± 0.3, whilst that for those not completing was 3.5 ± 
0.3, (p=0.02), i.e. those who chose not to complete the 12 month trial were 
significantly less bald initially regardless of treatment given to them. 
 
Total number of hairs per measured area 
The mean total number of hairs per area measured (50.7 mm²) before 
treatment 31.1 ± 4.8, increased significantly after treatment to 49.2 ± 3.8 for 
the Xiantene group (p=0.003) which would suggest that Xiantene had 
increased the number of visible hairs in the 12 month period. The control 
group also showed an increase in the total number of hairs from 41.9 ± 7.0 
before the study and 53.1 ± 3.9 after, but this was markedly less than the 
Xiantene group (see Figure 3.10) and was not significant (p=0.06). 
 
Number of anagen hairs 
The number of anagen hairs in the template area (50.7 mm²) for both groups 
are shown in Figure 3.11. The mean number of anagen hairs for the group 
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using Xiantene increased very significantly after treatment from a mean of 
18.1 ± 2.2 to 37.3 ± 3.3 (p<0.001). The value for the control group increased 
slightly but this was not significant being 34.5 ± 5.6 before treatment and 
42.4 ± 2.6 after treatment (p=0.17). Treatment with Xiantene had significantly 
increased the number of anagen hairs unlike the vehicle treatment. 
 
Number of telogen hairs 
The number of telogen hairs in the template area (50.7 mm²) was also 
measured; in the Xiantene group there was a mean of 13.2 ± 2.8 telogen 
hairs before treatment, falling insignificantly to 11.9 ± 0.9 afterwards 
(p=0.61). The number of telogen hairs increased slightly, but insignificantly, 
for the control group after 12 months treatment from 7.4 ± 1.8 before to 10.7 
± 2.7 after (p=0.10). There was no significant change in the number of 
telogen hairs for the Xiantene treated or the control group.  
 
Anagen:telogen ratio 
Treatment with Xiantene had increased the total number of hairs in the 
template area (50.7 mm²) and the number of anagen hairs, but it had no 
effect on the number of telogen hairs. Conversely, treatment with the vehicle 
had not significantly increased the total number of hairs in the template area 
(50.7 mm²), nor had it significantly increased the number of anagen hairs, 
and the number of telogen hairs had not significantly altered.  
Therefore, the mean anagen:telogen ratio also increased significantly by 
over 50% for the Xiantene group from 2.2 ± 0.5 to 3.4 ± 0.4 (p=0.005). In 
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contrast, the anagen:telogen ratio for the vehicle group showed a small, but 
insignificant decrease from 5.5 ± 1.0 to 5.0 ± 1.0 (p=0.68) (see Figure 3.12). 
 
Photographic assessment 
A subjective assessment of hair growth was made with head shot 
photographs, before and after treatment (Table 3.2) using a standardised 
procedure (See chapter 2).  
Three independent assessors, excluding the author, viewed before and after 
head shot photographs and scored each pair of photographs as either; 
increased hair growth, no change in hair growth or reduced hair growth. 
Scores between the three assessors were recorded and then discussed 
before a consensus was reached. The final photographic assessments are 
shown in Table 3.1. Unfortunately the photographic record was not complete 
due to loss of a roll of film and it was only possible to compare 14 subjects, 6 
using Xiantene and 8 using vehicle. Using 3 independent assessors 
evaluating on a blind basis, the paired photographs were scored as follows: 
increased, no change or decreased (Table 3.2). 
In the Xiantene group 3 subjects (50%) were scored as having increased 
growth and 3 subjects (50%) as showing no change, whereas in the vehicle 
group 3 subjects (37.5%) scored as showing increased growth and 5 
subjects (62.5%) no change.  
Reproduceability of this scoring system was not tested and it is not possible 
to confirm the reliability of these results. Sample photographs are shown in 
Figure 3.13 (Xiantene, improvement) and Figure 3.14 (vehicle, no change).  
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Figure 3.12 
Mean anagen:telogen ratio, in Xiantene treated men and those using 
the vehicle, before and after treatment.  
Men with androgenetic alopecia used topical Xiantene (1ml) or vehicle daily. 
All hairs were plucked from a circle of 50.7 mm² area on the crown before 
and after 12 months treatment. Results are the mean ± SEM of 
measurements for each subject before and after treatment involving 12 
subjects for the vehicle and 17 subjects for the Xiantene treatment. 
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Table 3.2 
Hair growth assessment score of head shot photographs, before and 
after 12 month treatment. 
Men with androgenetic alopecia used topical Xiantene (1ml) or vehicle daily.  
 
 
 
 
 
Increased hair 
coverage 
No change Decreased 
hair coverage 
 
 
Xiantene 
 
Number        % 
      3             50 
 
Number        % 
       3           50 
 
Number       % 
     0              0 
 
Vehicle 
 
 
      3           37.5 
 
       5          62.5 
 
     0              0 
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Figure 3.13 
Increased hair growth over a 12 month period for a subject using 
Xiantene treatment. 
Subject with androgenetic alopecia used Xiantene (1ml) daily for 12 months 
(scored, increased hair coverage). 
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Figure 3.14 
Absence of hair growth over a 12 month period for a subject using 
vehicle treatment. 
Subject with androgenetic alopecia used vehicle (1ml) daily for 12 months 
(scored, no change). 
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3.4.1.5 Results addendum 
It has subsequently been suggested (Dr. D.H. Rushton, personal 
communication) that the results of this trial may be open to a different 
statistical interpretation (see Appendix V) and that there was no significant 
increase in the total number of hairs of the Xiantene treated group compared 
with controls. Clearly further investigation is required and the conclusions 
drawn therefore represent this uncertainly. 
 
3.5 Discussion  
3.5.1 Analysis of pre treatment data in men with androgenetic alopecia 
The pre-treatment data for 41 volunteer men suffering from androgenetic 
alopecia in the 3 month (chapter 2) and 12 month (chapter 3) studies were 
combined and then analysed to investigate the relationships between the 
total number of hairs, the number of hairs in anagen and the anagen:telogen 
ratio to both age and extent of baldness as indicated by the Hamilton stage. 
This data related to 41 men with a mean age of 44.7 ± 2.1 years, all suffering 
from androgenetic alopecia, with Hamilton stages ranging from 2-7, mean 
4.2 ± 0.2. There was a significant negative correlation between age and the 
total number of hairs per specimen circle on the crown (p=0.02) (Figure 3.1), 
with the mean total number of hairs/ circle for men aged 21-30 years, being 
much higher at 61.0 ± 6.4 than the 22.2 ± 5.3 for men aged over 60 years. 
This decrease with age in men with androgenetic alopecia confirms earlier 
work (Hamilton, 1951; Rushton et al, 1983; Kaufman et al, 2008).  
The number of anagen hairs/circle on the crown also declined with age with 
men aged 21-30 years having a mean of 40.4 ± 5.4 per circle area falling to 
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18.3 ± 4.2 in men aged over 60 years, although this negative correlation 
(correlation coefficient = -0.30) was not quite statistically significant (p=0.06) 
(Figure 3.2). The decrease in the total number of hairs and the number of 
anagen hairs with age confirms earlier research for men with androgenetic 
alopecia (Hamilton, 1951; Rushton et al, 1983; Bergfeld, 1989; Kaufman et 
al, 2008) and confirms that baldness increases with age in susceptible 
individuals. There was also a positive correlation (p=0.03) between age and 
extent of baldness, as indicated by the Hamilton stage, correlation coefficient 
+0.35 (see Figure 3.4); men aged 21-30 years had a lower mean Hamilton 
stage of 3.2 ± 0.4 than men over 60 years who had a mean Hamilton  stage 
of 4.7 ± 0.7. Therefore the extent of baldness was shown to increase with 
age, while the total number of hairs and the number of anagen hairs 
decreased with age. This confirms earlier work (Hamilton, 1951; Rushton et 
al, 1983; Kaufman et al, 2008) and the age related nature of the condition. 
There was no evidence of an association between age and anagen:telogen 
ratio (Figure 3.3) which  might have been expected as it has been reported 
earlier (Bergfeld, 1989). The inability to show a relationship between the 
anagen:telogen ratio and age in men with androgenetic alopecia suggests a 
more advanced stage of balding at the start of the experiment, than in those 
reported by Bergfeld (1989) who found that less than 20% of hair follicles in 
telogen was normal, i.e. the anagen:telogen is above 4:1 in a normal scalp 
not affected by androgenetic alopecia. This has also been reported in studies 
of percentage anagen on normal male scalp throughout the year (Randall & 
Ebling, 1991). The association between extent of baldness measured by the 
Hamilton stage and the parameters measured was also examined. There 
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was a significant negative correlation between both the total number of 
hairs/unit area, p<0.001 (see Figure 3.5); and the number of anagen hairs 
(p<0.001) (see Figure 3.6) with Hamilton stage. The total number of hairs per 
template area (50.7 mm²) was 55.3 ± 10.8 at Hamilton stage 2 falling to only 
19.3± 5.40 at Hamilton 6, while the number of anagen hairs was 41.0 ± 10.4 
at Hamilton stage 2, decreasing to 12.1 ± 2.6 at Hamilton stage 6. The 
anagen:telogen ratio also showed no strong correlation with Hamilton stage, 
which would have been expected (Bergfeld, 1989). However, the mean 
anagen:telogen ratio for all subjects is low at 3.4 ± 0.5 and below the 
alopecia threshold of 4:1 (Bergfeld, 1989) confirming that the subjects were 
suffering from androgenetic alopecia. The anagen:telogen ratio for a healthy 
young male not suffering from androgenetic alopecia has been suggested to 
be 10:1 (Bergfeld, 1989) though this does not seem theoretically appropriate 
as hair follicles do cycle; others have suggested 9:1 – 8:2 with changes 
throughout the year (Randall & Ebling, 1991). While in cases of advanced 
androgenetic alopecia is stated to be below 4:1 and this ratio may reverse 
(Bergfeld, 1989), i.e. there may be more telogen hairs present than anagen 
hairs. 
 
3.5.2 The effect of herbal mixture Xiantene on hair growth when applied 
topically for 12 months 
The subject drop out rate of 39.58% for this 12 month study was high (see 
Table 3.1), although an improvement on that in the 3 month study (see 
Chapter 2) where the drop out rate was 65.70%. Other researchers have 
found a lower drop out rate of approximately 16% after 12 month period 
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(Rushton et al, 1991) but rising to 64% after 24 months. Interestingly, in the 
12 month study the number of subjects dropping out was not equally divided 
between the two treatment groups. It was only 29.20% in the Xiantene group 
while reaching 50.00% in the control group, which may indicate more 
enthusiasm for the Xiantene group to continue treatment, possibly because 
they were noticing an effect. In the control group, the subjects that completed 
the trial were significantly older (mean age 46.8 ± 3.3 years) that those who 
did not (35.6 ± 2.9 years, p=0.02), but there was no significant difference in 
age for the Xiantene treated group (p=0.94); between those completing (47.0 
± 3.7 years) and not completing (47.6 ± 6.0 years). The people, both 
Xiantene treated and controls who completed the trial were also significantly 
more bald (mean Hamilton stage 4.5 ± 0.3), than those who did not complete 
(3.5 ± 0.3, p=0.02). Interestingly, this confirms the observation from the 
earlier experiment (Chapter 2) that younger men and men with less 
advanced hair loss were more likely not to complete the experiment.  The 
mean initial ages of the two groups completing the trial were similar being 
47.3 ± 3.7 years for the Xiantene group, and 46.8 ± 3.3 years for the control, 
(p=0.93). These are significantly higher than the ages of the subjects 
completing the 3 month initial study where the mean for the Xiantene group 
was 37.0 ± 5.0 years, and for the control group was 40.0 ± 6.0 years (see 
chapter 2). The mean initial Hamilton hair loss stages for both groups were 
also similar, with that for the Xiantene group being 4.70 ± 0.3 with 4.00 ± 0.5 
for the controls (p=0.21). The mean Hamilton scores are higher than the 
earlier 3 month study (see chapter 2) where the mean for the Xiantene group 
was 3.8 ± 0.3 and that for the control group 3.7 ± 0.3 (p=0.65). The absence 
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of any significant differences between age and Hamilton stage in individuals 
completing the study assigned to either the Xiantene or control groups 
confirms the validity of the comparison.  
The random recruiting of volunteers appears to have attracted older men 
with more advanced hair loss. The ideal for testing a hair loss treatment 
product would be a younger and less advanced balding group, where 
subjects were aged no more than 35 years with the extent of baldness no 
more than Hamilton stage III. This is the approach which is used by 
pharmaceutical companies who have the financial resources to carry out 
extensive trials e.g. Merck & Co (Kaufman et al, 1998). The ability to stabilise 
or partially reverse genetic hair loss is probably easier with a younger subject 
group with less advanced hair loss. Possible inflammation and scaring below 
the long term balding follicle has been observed (Jaworsky et al, 1992; 
Whiting, 1993) and the resultant reduced or truncated nerve endings and 
blood supply (Chapter 1) leads eventually to follicular loss. Such 
inflammation etc would potentially prevent an affected follicle regrowing 
deeper into the dermis to produce a larger hair. The unit area trichogram 
method used here and established by Rushton et al (1983) is mechanical 
and precise, the plucked hairs being permanently recorded for repeat 
assessment at a later date. However, the technique suffers from the 
disadvantage of a very small sample area being used in an alopecic area 
(the crown), where the degree of hair loss may not be gradual or linear with 
possible abrupt hair density changes between different areas of the crown; a 
step-change mechanism for androgenetic alopecia has been proposed 
(Whiting, 2001). The measurement of hair density per cm² in this experiment 
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is lower than other reported measurements for men suffering from 
androgenetic alopecia using this technique (Rushton et al, 1983). Mean total 
hair density per cm² at the beginning of the trial was found to be 61.4 ± 9.4 
/cm² in the Xiantene group and 82.7 ± 13.7 /cm² in the controls compared 
with 219 ± 8 /cm² on the occipital area and 175 ± 6 /cm² on the frontal area of 
men with androgenetic alopecia found by Rushton et al (1983) indicating a 
more advanced hair loss stage in this study group; the data reported by 
Rushton’s group also came from a younger group (mean age 25.7 years). 
Men treated with Xiantene demonstrated a highly significant greater total 
number of hairs/unit area (p=0.003) increasing by about 50% after 12 
months, unlike the controls where there was a slight, but insignificant 
increase (p=0.06) (Figure 3.10). The Xiantene group also showed a very 
highly significant increase in the numbers of anagen hairs/circle of 
approximately 100%, (p<0.001), while the control group exhibited only an 
insignificant increase (p=0.17) (Figure 3.11). However, there was no 
significant change in the number of telogen hairs over the year for either 
group. Consequently, the anagen:telogen ratio was very significantly 
increased for the Xiantene group by over 50% from  2.2 ± 0.5 to 3.4 ± 0.4 
(p=0.005), while that for the control group was not significantly altered 
(p=0.68) (Figure 3.12). 
In summary, all 3 parameters measured, the total number of hairs, the 
number of anagen hairs and the anagen:telogen ratio increased significantly 
for the Xiantene treated group, but there was no significant change in any of 
these 3 parameters in the controls. These changes are not due to any 
seasonal changes (Orentreich, 1969; Randall & Ebling, 1991; Courtois et al, 
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1996) as each individual was assessed after 12 months to avoid this. 
Interestingly, the subjects in the control groups appeared to have maintained 
their hair growth on the vertex over the 12 month period, which was 
surprising as all subjects were suffering from androgenetic alopecia, and 
some deterioration might have been expected (Rushton et al, 1991; Van 
Neste, 2003; Kaufman et al, 2008). Unfortunately the photographic 
assessment designed to support the measurements was not successful due 
to the loss of some photographs meaning that the photographic record is not 
complete. However, the apparent unchanged or improved hair growth in both 
the Xiantene and control photographs is encouraging as it parallels the 
measured data, but this photographic data cannot be relied upon. Other 
workers have reported photographic assessment of hair growth has been 
shown not to be necessarily reliable (Van Neste, 2004), though the technique 
is frequently used to assess hair growth treatment. The insignificant increase 
in the total number of hairs/circle of the vehicle treated men may be a 
‘placebo effect’ (Van Neste, 2008). A placebo effect is well documented 
(Koshi & Short, 2007; Postkowska – Nadolska, 2007) to produce a positive 
measurable physiological effect e.g. reduced hair fall, improved hair 
regrowth, although no real treatment has been undertaken, only the 
suggestion of treatment.  The willingness of the subject to believe in the 
treatment, and the real desire to produce a response, can in fact produce a 
response and Kaufman (2008) reported increased hair growth with placebo 
treatment even after 3 years during a 5 years trial. Ironically, a ‘nocebo’ 
effect has been proposed, in which clinically proven drugs failed to work as 
well as planned, or produced unexplained side effects (Olshansky, 2007). In 
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contrast to the placebo effect where the patient’s health improves because 
they believe the treatment is going to work, with the nocebo effect the 
patient’s condition worsens with treatment and the suggestion of sickness 
creates more sickness.  Trials using patients with a history of adverse 
reaction to drugs found that 27% of the subjects experienced an adverse 
reaction with the placebo (Eccles, 2007). A similar trial using finasteride for 
the treatment of benign hyperplasia found a 31% nocebo effect, in increased 
sexual side-effects, compared with a another group who received treatment, 
but were not told about the possible side-effects (Mondaini et al, 2007). It is 
not suggested that androgenetic alopecia, which is androgen dependent and 
genetically influenced (Hamilton, 1942), is a psychosomatic illness, but the 
data suggests a possible placebo effect. Differing rates of the progression of 
androgenetic alopecia in cases of identical male twins has been recorded 
(Roenigk & Kuruvilla, 1987; Stough et al, 2002; Stough, 2007) and a brain – 
hair follicle ‘axis’ has been proposed (Arck et al, 2001) with substance P (SP) 
and nerve growth factor (NGF) as mediators of stress induced hair growth 
inhibition (Peters et al, 2006). Further, loss of proliferative ability of balding 
dermal papilla cells in cases of androgenetic alopecia has been associated 
with oxidative stress and environmental factors (Bahta et al, 2008). The 
validity of the results from the 12 month study are greater than the short 
preliminary investigation (Chapter 2) as the numbers of individuals are 
greater and the 12 months period avoids any difficulties with changes 
occuring through the year due to seasonal variation (Orentreich, 1969; 
Randall & Ebling, 1991; Courtois et al, 1996). Nevertheless, the results of the 
3 month (chapter 2) and 12 month experiments concur. A significant increase 
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in the total number of hairs/unit area and a significant increase in the number 
of anagen hairs/unit area was seen on the vertex in both the 3 month and the 
12 month experiments. There was no corresponding significant increase in 
hair parameters for the control group, in either the 3 month or the 12 month 
experiment. These two studies each used a different set of subjects and 
were not run concurrently. Daily topical application of herbal mixture 
Xiantene significantly increased hair growth in a total of 23 men with 
androgenetic alopecia with no corresponding increase on the 18 men 
applying only the vehicle. There appeared to be no observable difference in 
efficacy between Xiantene I and Xiantene II (see Chapter 4) as both 
produced a measurable hair growth effect compared with control. The 
significant increase in hair number on the vertex in both the 3 month and the 
12 month studies in the Xiantene treated men suggests that Xiantene may 
have stimulated the growth of small vellus hairs to produce larger hairs that 
can be plucked i.e. an increase in the total number of meaningful hairs 
(Rushton et al, 1993) or that it has increased the number of hairs entering 
anagen from follicles in the ‘lag’ phase i.e. with empty follicles where the 
telogen hair has been shed via exogen (Stenn et al, 1996) and the new 
anagen hair not yet started to project above the surface (Whiting, 2001; 
Rebora, 2004). The significantly increased percentage of hairs in the anagen 
phase, whilst the number of telogen hairs was unchanged in both studies, 
concurs with both hypotheses. Other researchers (Van Neste, 2006) have 
found that the reduction in the duration of the lag phase of up to 40% was the 
key mechanism during reversal of male androgenetic alopecia by finasteride. 
They also observed a 23% increase in the length of the anagen phase for 
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thick hairs (>40μm), although not for thinner hairs (<40μm), but there was no 
clear evidence for reversal of miniaturised hair into terminal hair. The 
anagen:telogen ratio for the Xiantene group has increased significantly 
(p=0.005; see Figure 3.12) contrasting  with the control group where there 
was an insignificant decrease and a deterioration would be expected to occur 
over a 12 month period on the scalp of men with androgenetic alopecia (Van 
Neste, 2003; Kaufman et al, 2008). The increase in length of the anagen 
phase is important in assessing a possible treatment in cases of 
androgenetic alopecia which is characterised by a gradual contraction of the 
anagen phase and eventual miniaturisation of the hair follicle (Whiting, 
2001). These observations suggest that Xiantene could promote a cessation 
or partial reversion in the progression of androgenetic alopecia. It has been 
suggested that even a medication capable of maintaining the existing hair 
population in the progression of androgenetic alopecia should be considered 
as effective (Rushton et al. 1991). However, the results with Xiantene 
suggest that these herbal extracts may be effective, in controlled 
experiments, in the short term reversal of androgenetic alopecia, even in 
older men (mean age 47.1 ± 2.5 years) with later stages of hair loss than 
those normally studied (mean Hamilton stage 4.4 ± 0.3). The mode of action 
of the Xiantene mixture is not clear and should be the subject of further 
research. 
3.6 Conclusions 
These results suggest that the combination of plant extracts used in Xiantene 
may or may not be a suitable agent for the topical treatment of androgenetic 
alopecia and that further work will be required. 
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4. Analysis of herbal mixture Xiantene 
 
4.1 Aim 
The aim of this study was to understand the components of Xiantene 
mixtures I & II. In particular to check whether the extracts claimed were 
actually present, determine whether the two formats differed and to confirm 
that Radix Stephaniae Tetrandrae was not present in Xiantene II. Stephania 
tetranda S. Moore and a number of similar alkaloids have been banned from 
use in the UK by the Medecine & Health regulatory authority (MHRA) from 
2004, as a common toxic adulterant Aristolochia (Fang Chi) can not be 
reliably distinguised from Stephania tetranda S. Moore (Fang Ji). The use of 
Aristolochia led to an outbreak of kidney failure at a slimming clinic in 
Belgium (Evans et al, 2004). 
 
4.2 Herbal components of Xiantene 
The herbs used in the preparation of Xiantene are known and are 
summarised in Table 4.1 and shown in Figures 4.1 and 4.2. There is no 
standard nomenclature for herbal products and the systems that are in use 
are often not concise. The nomenclature adopted here is the “Pin Yin” 
system which is in common usage for the TCM products (Dunmu & Jiangbe, 
1995). However even this is not absolutely precise, as the Pin Yin names 
sometimes cover more than one species. The Latin botanical names have 
been included but these differ from the pharmaceutical names, also 
principally in Latin. These are also shown in Table 4.1.  
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Table 4.1 
Active components* of herbal mixtures Xiantene I and II. 
Pin 
Yin 
name 
 
Part used 
Latin scientific name 
 (= botanical scientific 
name) 
Pharmaceutical 
name 
English 
name 
Ce 
Bai 
Ye 
Leaves 
and twigs 
Platycladus orientalis L. 
(synonym is Thuja 
orientalis L.) 
Cacumen 
Platycladi 
 
 
Bai Zi 
Ren 
Seeds  Platycladus orientalis L. 
(synonym is Thuja 
orientalis L.) 
 
Semen Platycladi 
 
 
He 
Shou 
Wu 
Root 
tuber, not 
prepared 
Fallopia multiflora 
(Thunb.) Haralds. 
(synonym = Polygonum 
multiflorum Thunb.) 
 
Radix Polygoni 
Multiflori 
Fleece 
Flower 
root 
Ren 
Shen 
Root Panax ginseng C.A.Mey Radix et Rhizoma 
Ginseng 
Ginseng
San 
Qi 
Root Panax notoginseng 
(Burk.) F.H.Chen 
Radix et Rhizoma 
Notoginseng 
 
Gui 
Zhi 
Twigs Cinnamomum cassia 
Presl 
Ramulus 
Cinnamomi 
Cassia 
twig 
Da 
Qing 
Ye 
Leaves  
Isatis indigotica Fort. 
Folium Isatidis Dyers 
Woad 
leaf 
Fang 
Ji** 
Root  Stephania tetranda S. 
Moore 
Radix Stephaniae 
Tetrandrae 
 
*Clarification of nomenclature by Dr. Chris Leon of Royal Botanical Gardens, 
Kew, is gratefully acknowledged 
** Fang Ji (Stephania) was claimed to be in Xiantene I but was subsequently 
banned for use in EEC countries and was not therefore in the list of 
components for Xiantene II 
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Figure 4.1 
Typical herbs Ce Bai Ye, Bai Zi Ren, He Shou Wu and Ren Shen 
photographed with a 50 pence coin (width 27mm) to show scale 
(photos, author) 
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Figure 4.2 
Typical herbs San Qi, Gui Zhi, Da Qing Ye. photographed with a 50 
pence coin (width 27mm) to show scale (photos, author) and sketch of 
Fang Ji (Dunmu & Jiangbo, 1995). 
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The standardisation of TCM products is complex (Lu et al, 2007) as the 
chemical composition of the extract will depend on the right plant being used 
(most TCM plants are not cultivated but collected in the wild), the plant being 
harvested at the right time of the year, the area in which the plant is grown 
and the right part of the plant being used. 
The parts of the plants used in the preparation of Xiantene varied and 
include; roots, twigs, leaves, bark and seeds and are indicated in Table 4.1 
and photographs are shown in Figures 4.1 and 4.2. 
The standardisation of TCM plants and extracts is being developed at 
several centres including the Institute of Health Research and Policy, London 
Metropolitan University, London and the “Chinese Medicinal Plants 
Authentication and Conservation Centre” (CMPAC) at the Royal Botanical 
Gardens, Kew, Surrey using DNA fingerprinting, chemical analysis and gross 
morphological identification (Dr. Chris Leon, personal communication). 
 
The typical herbs used in Xiantene are shown in Figures 4.1 and 4.2 and 
described in Table 4.1. Descriptions are based on Zhao (2004):- 
Ce Bai Ye 
(Leaves of Thuja orientalis L.) 
Description   Leaves opposite, flat, small scaly, imbricate and closely  
 attached to twigs. 
 Colour: dark green, brownish green to yellowish green.  
 Odour: fresh, fragrant (aromatic/cedar) 
Distribution  Thuja orientalis L. is found in Eastern China, Hong Kong,  
 India and Japan (Zhao, 2004) 
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Components  Thuja orientalis L. leaves contain an essential oil consisting 
of L-borneol, bornyl acetate, α-thujone, camphor, 
sesquiterpene alcohol. The leaves also yield phodozanthin, 
amentoflavone, quercetin, myricetin, carotene, xanthophyl 
and ascorbic acid (Bisset, 1999; Zhao, 2004) 
Bai Zi Ren 
(Seeds or kernel of Thuja orientalis L.) 
Description  Two seeds per scale, ovoid, oblong and highly  
 oleaginous.  
 Tip slightly pointed, orbicular and triangular.  
 Colour: pale yellow, yellowish white or yellowish brown.  
 Odour: mildly aromatic 
Distribution Thuja orientalis L. is found in Eastern China, Hong Kong,  
 India and Japan (Zhao, 2004) 
Components The seeds of Thuja orientalis L. contain as a major  
 constituent an essential oil, mainly cedrol (Zhao, 2004)  
He Shou Wu 
(Root of Polygonum multiflorum Thunb.) 
Description Root tuberous, polyhedral, ligneous and rough surface. 
 Texture: solid and hardly broken. 
 Colour: externally dark brown, reddish brown or black. 
 Odour: none 
Distribution  East and South China, Hong Kong, Japan and Vietnam  
 (Bisset, 1990; Zhao, 2004) 
 158
Components  Rhein, chrysophanic acid, polygonic acid, steroidal saponins 
and rhaponticin (Bisset, 1990; Zhao, 2004) 
 
Note: Polygonum multiflorum Thunb. root may be used “not prepared” as 
used in this study or “prepared” (root is sliced steamed with black bean juice 
and dried) (Zheng, 2000). 
Ren Shen 
(Root of Panax ginseng) 
Description  Root tuberous short and fleshy, producing a branch root  
 from its middle. 
 The surface is wrinkled or furrowed. 
 Colour: greyish-yellow. 
 Odour: characteristic, fragrant 
Distribution  North China, Japan, Korea and Soviet Union (Han, 1989;  
 Zhao, 2004) 
Components  Triterpenoid saponins (Saponins A, B, C, D & F),  
 oleanolic acid, amino acids, leucine, valine, proline  
 oxyproline, histidine, lysine and cysein (Bisset, 1990;  
 Zhao, 2004) 
San Qi 
(Root of Panax notoginseng) 
Description  Main roots tuberous, short, cylindrical and fleshy. 
 Surface wrinkled and furrowed. 
 Colour: pale greyish-yellow or greyish brown 
 Odour: characteristic, sweet 
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Distribution  Mountainous regions of N. E. China, Nepal, India, Tibet  
 and the forested slopes of The Himalayas (Zhao, 2004) 
Components  Major constituents are saponins (saponins A, B, C, D, F,  
 G & H), notoginsenosides, ginsenosides, oleanolic acid  
 and amino acids (Bisset, 1990; Zhao, 2004) 
Gui Zhi 
(Twigs of Cinnamomum cassia presl) 
Description   Long cylindrical twigs with many branches and marked  
 with irregular, fine wrinkles 
 Texture: hard, fragile and easily broken 
 Colour: greyish-brown to reddish-brown 
 Odour: distinctive, aromatic 
Distribution  Southern China, Laos and Vietnam (Zhao, 2004) 
Components  Twigs contain mainly cassia oil, coumarin and  
 cinnamic aldehyde (Bisset, 1990; Zhao, 2004) 
Da Qing Ye 
(Leaves of Isatis indigotica Fort.) 
Description  Leaves are mainly rolled and fragile with upper surface  
 and underneath glabrous slightly undulate, plume shaped  
 and web-like veins. 
 Colour: dark greyish-green or brown 
 Odour: pleasant, mildly aromatic 
Distribution  Central China (Zhao, 2004) 
Components  Main constituents are indigo derivatives, indigotin, isatan  
 B and indirubin (Ferreira, 2004; Zhao, 2004) 
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Fang Ji 
(Root of Stephania tetranda S. Moore) 
Description  Irregularly lump-shaped or semi-cylindrical tuber with  
 transverse channels and “knobbly” at the curved part  
 with a heavy solid texture. 
 Colour: greyish-yellow 
 Odour: slight 
Distribution  Central China (Zhao, 2004) 
Components  Main constituents are alkaloids L-tetrahydro-palmatine,  
 stepharine, roemerine & cycleanine (Bisset, 1990) 
 
4.3 Method of manufacture of Xiantene  
Details of the herbs used in the preparation of Xiantene have been supplied 
by the manufacturer (Table 4.1), but the percentage of each herb and the 
exact manufacturing formula is not known. The manufacturing procedure is 
known in outline (Dr. Z. Xia, personal communication) and is shown in Figure 
4.3. 
The general procedure is as follows: - 
Whole botanical materials (roots, stems, leaves, twigs, seeds) were ground 
to a fine powder (approx. 200μm particle size) and extracted partly with a 
water and glycol mixture (80/20) and partly with ethyl alcohol. The aqueous 
extract underwent a further enzyme extraction process (Wu, 1996) before 
being remixed with the alcoholic extract and the final mixture was chilled, 
filtered and dried. The diluted Xiantene test material was very kindly supplied 
ready for use by Dr. Zhidao Xia of the University of Oxford.  
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Figure 4.3 
Outline manufacturing sequence for Xiantene I 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
           
           
           
            
 
 
 
 
 
Thuja Orientalis + Ethyl alcohol  
       (whole)
Enzyme digestion 
tank 
Dried whole herbs:- 
Polygonum multiflorum 
Thunb 
Panax ginseng 
Panax notoginseng 
Cinnamomum cassia Presl 
Isatis indigotica Fort  
Stephania tetrandra S 
Filter 
Product 
Mixing tank 
Herbal mix 
+ 
Water/glycol 
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The vehicle mixture was prepared using an alcohol/aqueous base (20:80) 
with caramel (Univar Ltd.) to provide a coloured vehicle solution (see chaper 
2). Caramel is not present in the Xiantene herbal mixture. 
Xiantene II differs from Xiantene I and is not physically the same, having 
been produced as an updated and improved version of the original product 
with lighter colour and reduced odour. The manufacturing method for 
Xiantene I (Figure 4.3) was modified for Xiantene II and the details of these 
modifications are not available. An additional solvent (type unknown) was 
introduced obviating the need for a dried extract stage and manufacture 
proceeded directly to a final liquid stage ready for use (Dr. Xia, personal 
communication). Further Xiantene II did not contain Stephania tetranda S. 
Moore since this had been banned from use in the UK by the Medicines and 
Health Regulatory Authority (MHRA). 
The vehicle mixture was the same in both experiments.  
 
4.4 Physical measurements and comparison of Xiantene I, Xiantene II 
and vehicle 
The main physical parameters were measured and are shown in Table 4.2. 
As previously mentioned Xiantene I and II differ substantially in colour and 
odour, although both have a slightly acid pH and both have similar specific 
gravity values, consistent with an approximate water: solvent ratio of 
80:20.The vehicle (pH 8.48), Xiantene I (pH 4.99) and Xiantene II (pH 3.95) 
differ in their pH values which is unfortunate and was not appreciated at the 
time.  
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Table 4.2 
Physical parameters for Xiantene I, Xiantene II and vehicle 
 Xiantene I Xiantene II Vehicle 
Batch no 12241 1603 2711 
Appearance Mobile Liquid Mobile Liquid Mobile Liquid 
Colour Dark Brown Light brown Light brown 
Odour Heavy, aromatic Light, sweet None 
pH at 20 °C 4.99 3.95 8.48 
Specific Gravity 
at 20 °C 
 
0.9409 g/mol 
 
0.9815 g/mol 
 
0.9787 g/mol 
Residue  
on drying 
 
Brown Powder 
 
Viscous Gum 
 
None 
Residue  
on ignition 
43.7 mg/ml 
(0.4% w/w) 
 
Not measured 
 
None 
 
The analytical work was kindly undertaken by Dr. Ian Flockhart of Applied 
Analysis Ltd., Rowley House, Tokenspike Business Park, Hull Road, 
Woodmansey, Hull, HU17 0TB. 
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The subjects would have been unable to detect this, slight difference, 
although the 2 Xiantene mixtures are closer to the normal pH of the skin 
(pH=5) which could conceivably made absorption easier. The difference in 
behaviour on drying between Xiantene I and Xiantene II indicates that a 
different solvent system was used. Dr. Xia has confirmed this (personal 
communication), but the solvent used has not been identified. 
 
4.5 Spectroscopic analysis of Xiantene I, Xiantene II and vehicle 
Infra red spectroscopy (IR) based on the characteristic absorption of infra red 
radiation by functional groups, an obvious choice for “fingerprinting” and 
comparison of broadly similar compounds, could not be used due to the 
presence of water as the main solvent in all three compounds (Xiantene I, 
Xiantene II and vehicle). Water has substantial absorption peaks in the infra 
red region (400 to 4500) which would render any IR spectra unusable. 
Nuclear magnetic resonance spectroscopy (NMR) is a powerful analytical 
technique for the study of bonding in carbon compounds, allowing accurate 
comparison of organic molecules and I am indebted to my colleague Dr. 
Annie Bligh of London Metropolitan University for her assistance with work 
on the NMR spectra of Xiantene I and II and vehicle. Unfortunately it proved 
impossible to obtain a dry extract for Xiantene II either using a steam bath or 
a freeze drying technique. Xiantene I did produce a dry powder extract on 
drying, whereas Xiantene II produced a sticky gum which resisted all 
attempts to produce a dry powder; under the circumstances it was concluded 
that any NMR spectra that might be produced could not be reliably 
interpreted and any comparison would not be valid.  
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Additionally, to confirm the presence of any single component reference 
samples of the herbs would be required and these were not available. 
Reference standards for TCM herbal products are maintained by the CMPAC 
centre at Kew Gardens, but it did not prove possible to access this material.  
 
4.6 Thin layer chromatography (TLC) analysis of Xiantene I, Xiantene II 
and vehicle 
4.6.1 Methods and materials 
Thin layer chromatography allows molecules in mixtures to be separated and 
identified using the different rates at which they move up a TLC plate 
(Pothier, 1999). The solvent moves by capillary action across a suitable base 
or medium carrying the molecules in the mixture with it. The smallest 
molecules move the furthest. This separation based on size gives the 
resultant “chromatograph” (Gumport & Stryer, 2002). Following the 
separation of the mixture, spots are visualised using a stain or spray and the 
distance travelled by the molecules evaluated using retention factors (Rf 
values), i.e. the distance travelled by the component spot relative to the 
solvent front. The discrete spots or stains are identified by UV light or 
chemically reacting with a developing agent once the solvent has dried. Thin 
layer chromatography is a routine and reliable analytical procedure and I am 
indebted to my colleague Mr. S. Al-Adadi of the University of Bradford, for 
the TLC data. Reference herbs were obtained locally (Tian Tian (Sun) Ltd, 
Westside, Manor Road, Barnet, EN5 2LE), pulverised and extracted 
separately using methanol, chloroform and diethyl ether as solvents and the 
subsequent TLC chromatograms used to provide reference or “marker” data 
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using: a polar solvent system (chloroform-methanol-water (6.5:5:1:v/v/v), a 
non-polar solvent system (toluene-ethyl acetate (45:5 v/v) or an acid solvent 
system (chloroform-acetone-formic acid, 37.5:8.25:4.25 v/v/v) to provide 
varying polarity systems for the solvent phase. All solvents were of laboratory 
grade (Fisher Science Ltd., Schwerte, Germany). Stains were identified 
using vanillin-sulphuric acid spray (Pothier, 1996) or potassium hydroxide 
spray (Pothier, 1996). 
 
4.6.2 Results 
The thin layer chromatography analysis of Xiantene I, Xiantene II and vehicle 
are summarised in Table 4.3. 
Polar solvent TLC systems were used to identify anthra-glycosides, a major 
component of Polygonum multiflorum Thunb, and saponins, a major 
component of Panax ginseng root and Panax notoginseng root. Xiantene I 
produced a yellow spot with the same “Rf” value as the reference Polygonum 
multiflorum Thunb. extract whereas Xiantene II did not, or the stain was 
masked by another component; this suggests that Xiantene II may not 
contain Polygonum multiflorum Thunb., or at least only in very small 
amounts. Staining confirmed the presence of anthra-quinone glycosides and 
Polygonum multiflorum Thunb. (not prepared) in Xiantene I but not in 
Xiantene II. Interestingly the TLC chromatograms for Polygonum multiflorum 
Thunb. (not prepared) and Polygonum multiflorum Thunb. (prepared) were 
not the same, indicating that they contain different compounds.  
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Table 4.3 
A comparision of the Chinese medicine plant components detected by 
thin layer chromatography analysis in Xiantene I, Xiantene II and the 
vehicle.  
‘X’ indicates that the component was not detected. 
Component Xiantene I Xiantene II Vehicle 
Thuja orientalis L. 
leaves 
 
X 
 
Positive 
 
X 
Thuja orientalis L. 
seeds 
 
X 
 
X 
 
X 
Polygonum 
multiflorum root 
 
Positive 
 
X 
 
X 
Panax ginseng root  
Positive 
 
X 
 
X 
Panax notoginseng 
root 
 
Positive 
 
X 
 
X 
Cassia 
cinnamomum twigs 
 
Positive 
 
Positive 
  
X 
Isatis indigotica forte  
X 
 
Positive 
 
X 
Stephania* tetranda 
root 
 
X 
 
X 
 
X 
 
* Alkaloid test (Bisset, 1990) 
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Polygonum multiflorum thumb may be used “not prepared” as used in this 
study or “prepared” for which the root is sliced, steamed with black bean 
juice and dried (Zheng, 2000). TLC chromatographs of Panax ginseng root 
and Panax notoginseng root (using diethyl ethyl extracts) were essentially 
the same (Rf values 0.97, 0.88, 0.81, 0.74, 0.72, 0.66) although when a 
methanol extract was used Panax notoginseng contained 2 further 
compounds (Rf 0.42 and 0.23). These compounds present in Panax ginseng 
and Panax notoginseng were not found in methanolic extracts of Xiantene II, 
but were present in the corresponding Xiantene I product. 
A non-polar TLC solvent system (toluene-ethyl acetate 45:5 v/v) was used 
for the identification of essential oils, one of the major components of Thuja 
orientalis L. (leaves), Thuja orientalis L. (seeds) and Cassia cinnamon presl. 
(twigs), the later also containing coumarins. Comparison of Xiantene II and 
Thuja orientalis L. (leaves) showed similar chromatograms with similar Rf 
values (0.73, 0.53, 0.49, 0.25, 0.18, 0.11) suggesting that they contain the 
same compounds. The chromatogram for Xiantene I was not similar with 
several of the Rf values missing. Therefore Xiantene I may not contain Thuja 
orientalis L. (leaves), or they may only be present in very small amounts. 
TLC chromatograms of reference herb Thuja orientalis L. (seeds) did not 
concur with Xiantene I or Xiantene II chromatograms and the presence of 
Thuja orientalis L. (seed) extracts could not be confirmed.  
Acid solvent TLC (chloroform-acetone-formic acid; 37.5:8.25:4.25 v/v/v) was 
used for the identification of compounds, scopoletin, amentoflavone and 
catechin, allowing identification of Thuja orientalis L. leaves, Cinnamomum 
cassia presl. twigs extracts and Polygonum multiflorum Thunb L. Using 
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diethyl ether extracts of the various Chinese plants and the test materials 
(5% w/v each) a yellow spot was separated from the extracts of 
Cinnamomum cassia presl. twigs, Xiantene I and Xiantene II with the same 
Rf value 0.53. However Xiantene II and Cinnamomum cassia presl. twigs 
also exhibited a reddish brown spot with the same Rf value 0.89 which was 
not present in Xiantene I. Also two yellow spots were separated only from the 
extracts of Xiantene I and Polygonum multiflorum Thumb with the same Rf 
value 0.83 confirming the results of the polar solvent TLC chromatographs. 
Further, comparison of Xiantene I and Xiantene II chromatograms showed a 
yellow spot with identical Rf value of 0.52 which was not present in any of the 
reference spectra, and which exhibited a blue flouresence under UV light at 
354nm when sprayed with vanillin-phosphoric acid reagent. This component 
present in Xiantene I and Xiantene II could not be identified.  
Acid solvent TLC was also used to confirm the presence of indigo in 
Xiantene II and leaves of Isatis indigotica Fort (identical spot Rf value 0.25). 
Xiantene I did not exhibit this spot and Xiantene I does not appear to contain 
Isatis indigotica Fort, or only in very small amounts.  
 
4.6.3 Discussion  
The absence of cytotoxicity in applications of Xiantene I had already been 
established by in vitro testing. When the cytotoxicity of Xiantene I on cultured 
human fibroblast cells was assessed using the MTT assay, there was no 
significant difference between Xiantene treated and control groups (Dr. Z. 
Xia, personal communication).  
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Xiantene I and Xiantene II behaved differently under the test conditions and 
do not appear from the TLC results to contain many of the same 
components. Four of the eight specified ingredients, Polygonum multiflorum 
root, Panax ginseng root, Panax notoginseng root and Cassia cinnamomum 
root, were detected in Xiantene I, but Thuja orientalis L seeds, Thuja 
orientalis L leaves and Istatis indigotica forte could not be identified (Table 
4.3). In contrast three out of the seven ingredients, Thuja orientalis L. leaves, 
Isatis indigotica forte and Cassia Cinnamomum twigs were identified in 
Xiantene II, but not Thuja orientalis L. seeds, Polygonum multiflorum root, 
Panax ginseng root and Panax notoginseng root (Table 4.3). Stephania 
tetranda S. Moore root was not deteched in either, although claimed to be 
part of Xiantene I. This is fortuitous as Stephania tetranda S. Moore root has 
been banned from use in EEC countries since 2004. However this raises 
questions about the reliability of the information provided by the suppliers 
since neither Xiantene I or Xiantene II appeared to contain all the ingredients 
listed (see Table 4.1). The vehicle mixture did not contain any of the Chinese 
herbs tested or any additional compounds. This suggests the vehicle would 
be non-toxic and should not contain any hair growth actives.  
This inability to identify all the components claimed to be present in either of 
the Xiantene mixtures could be due to a failure to isolate the components, 
but this seems unlikely since most of the plants components except Thuja 
orientalis L seeds and Stehpania tetranda root were detected in one or other 
of the Xiantene mixtures. Although thin layer chromatography is a widely 
used and convenient method of identification, there are some inherent 
difficulties with the technique. Some components of the mixture may produce 
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spots of stains with identical Rf values, which therefore overlap on the 
chromatograph. This problem might be expected to be particularly acute for 
complex mixtures like Xiantene containing a great number of components, 
some of which cannot be identified. However, similar Rf values would not 
explain the recorded differences and absence of stains in Xiantene I and 
Xiantene II. The thin layer chromatography data for Xiantene I and Xiantene 
II are almost completely different, and only one of the 8 herbs used, Cassia 
cinnamonum presl. twigs, could be positively identified in the two versions of 
Xiantene (see Table 4.3). Further both Xiantene I and Xiantene II exhibited 
other components that could not be identified as any of the eight listed 
ingredients.  
These identifications are somewhat preliminary and have some difficulties. 
The reference herbs used as markers were purchased in the UK and may or 
may not be the same type and species as those used in the manufacture of 
Xiantene in China. Further the reference samples were obtained as dried 
extracts and would have been subjected to some storage and possible 
deterioration since harvesting. Xiantene is prepared directly from the fresh 
herbal components in China (leaves, roots, twigs, seeds or kernels) which 
are treated and prepared locally and may not therefore equate to the 
reference samples used. However, clear spots corresponding to each of the 
reference materials, except Stephania tetrana S. Moore root and Thuja 
orientalis L seeds were detected in at least one of the Xiantene mixtures, so 
this is unlikely to cause the differences found between the two batches.  
However, the methods of manufacture of Xiantene I and Xiantene II were 
markedly different (Dr. Z. Xia, personal communication) with different solvent 
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systems being used for the extraction and no intermediate dried extract 
being produced during preparation of Xiantene II (see section 4.3). This may 
have meant that the efficiency of extraction from each plant component 
varied between the two methods. Certainly both Xiantene I and Xiantene II 
also exhibited components that could not be identified as any of the eight 
listed ingredients. There were noticeable differences in the physical 
parameters of the two Xiantene mixtures, particularly the residue on drying 
(see Table 4.2). Components although present originally may not therefore 
be extracted equally from both Xiantene I and II solutions. Thin layer 
chromatography depends crucially on the solubility of the test material in the 
various solvent systems used (Gumport & Steyr, 2002). Xiantene I and II are 
composed of at least two solvents, water and alcohol [types not disclosed], 
with a possible third solvent glycol [type not disclosed] present; the vehicle 
also contains two solvents, ethanol and water. Differential solubility of the 
different plant components in the TLC solvent and the different solvents 
present in Xiantene I and Xiantene II could have resulted in different 
chromatographic results. However, the same thin layer chromatography 
system and 3 extraction solvents were used for both versions of Xiantene 
and each plant, except Stephania tetranda and Thuja orientalis L seeds was 
identified making differential solubility of herbal components in the TLC 
solvents a possible but unlikely cause of the observed differences between 
Xiantene I and Xiantene II.  
Although the differences detected between Xiantene I and II (Tables 4.2 and 
4.3) may be due to the different solvents used interfering with the extraction 
for thin layer chromatography, it could also indicate that the materials do not 
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contain all the ingredients that are claimed or that the different methods of 
manufacture extracted different components from the correct plants used 
particularly since the extraction solvents for Xiantene I and Xiantene II were 
not identical (Dr. Xia, personal communication) and may have made a 
difference to what was initially extracted.  
The potentially unreliable quality of traditional Chinese medicinal products 
has been identified previously (Yong et al, 2007; Lu et al, 2007). The 
mixtures may or may not contain the herbal extracts claimed or the 
composition may vary from batch to batch or there may be differences in 
composition with herbs from different sources (Xie & Leung, 2008). 
Traditional Chinese medicine mixtures are complex mixtures of many 
bioactive compounds and the identification and subsequent quality control of 
these products limits their full application and development (Liang et al, 
2008). This is currently a key area of research. Although the thin layer 
chromatography results differed, both Xiantene I and Xiantene II stimulated 
hair growth in men with androgenetic alopecia (see Chapters 2 and 3). This 
could suggest that, either the effect is mainly due to the extract of Cassia 
cinnamomum twigs found in both, or that the differences were due to the 
difficulties in extracting the components from the two Xiantene mixtures. How 
the herbal mixture actually works remains intriguing.  
It is possible that Xiantene is acting as a mitotic agent i.e. a direct stimulant 
for hair growth. Some herbal extracts are known to have mitogenic activity 
(Schubert et al, 2002) and recently eucalyptus extract was shown to act as a 
direct hair growth stimulant (Taguchi et al, 2006). Eucalyptus extract was 
shown to promote the gene expression and protein secretion of VEGF in 
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human cultured keratinocytes (Taguchi et al, 2006). VEGF (see Chapter 1, 
section 1.1.5) is a highly specific mitogen produced by the dermal papilla and 
highly expressed during anagen, with decreased expression during catagen 
and telogen (Lachgar et al, 1995). Although eucalyptus extract is not a 
component of Xiantene, herbal extracts clearly have the ability to up regulate 
hair growth promoting factors. 
Some of the extracts used in the preparation of Xiantene are known to be 
enzyme inhibitors (Park et al, 2003). In fact a recent virtual screening 
assessment programme of 240 commonly used Chinese herbs containing 
8264 compounds (Ehrman et al, 2007), found a relatively large number of 
herbs (62%) contained potential inhibitors against 'therapeutically important 
molecular targets’. Additionally, a number of herbs contained inhibitors of the 
same target from different, phytochemical classes, suggesting different 
molecular pathways to target inhibition (Ehrman et al, 2007.  Five of the 
seven herbs used in the preparation of Xiantene were identified in Ehrman’s 
study as potential inhibitors for specific enzymes; cyclic adenosine 3-5-
monophosphatase (cAMP), inducible nitric oxide synthase (iNOS), 
cyclooxygenase (COX), lipoxygenase (LOX), aldose reductase (AR), HIV-I 
integrase, protease and reverse transcriptase (RT). The herbs identified 
were Ce Bai Ye (Thuja orientalis L.), Qing Dai (Isatis indigotica Fort), He 
Shou Wu (Polygonum multiflorm Thunb), San Yi (Panax notoginseng) and 
Ren Shen (Panax ginseng).  
All five herbs were detected in Xiantene by TLC (Table 4.3), although Isatis 
indigiotica forte and Thuja orientalis L seeds were found to be present only in 
Xiantene II and Polygonum multiflorum, Panax ginseng and Panax 
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notoginseng were shown to be present only in Xiantene I. Polygonum 
multiflorum or the ‘Tree of Life’, a component of Xiantene has also been 
suggested to exhibit enzyme inhibition properties by Yim et al, (1998) and Li 
et al, (2003); it is also a significant anti-oxidant (Ryu et al, 2002). Similarly 
considerable bio-activity of Thuja extracts has also been reported (Schuberth 
et al, 2002), with both mitogenic activity and potent enzyme inhibition action 
reported (Gohla, 1989; Offergeld, 1992).  
Cassia cinnamomum, which was present in both forms of Xiantene has been 
shown to have potent inhibitory activity against a range of enzymes including 
aldose reductase (Lee, 2002), tyrosinase (Kong et al, 2008) and 
phosphodiesterase 5 (Dell’Agli et al, 2008). Cassia cinnamomum also 
exhibits excellent antioxidant activity (Lin et al, 2003). Tyrosinase levels 
determine the level of activity of follicular melanocytes (Slominski et al, 2004) 
and therefore hair pigmentation levels (see Section 1.2.2). A reduction in 
tyrosinase levels and thus pigmentation, may lower the level of cytotoxicity of 
some metabolic intermediates associated with melanogenesis, and may 
therefore allow increased follicular cell activity and possibly alter some 
aspects of hair growth. Unpigmented hair is known to grow faster (Van 
Neste, 2006). In traditional Chinese medicine (TCM) Cassia cinnamomum 
has been used for the treatment of dyspepsia, gastritis and inflammatory 
disorders as well as cancer where anti-tumor activity and inhibition of the 
anti-apoptosis regulating gene BCL-2 has been demonstrated (Lee et al, 
2007).  
The conversion of testosterone to the more active androgen 5α-
dihydrotestosterone by the enzyme 5α-reductase plays a crucial role in the 
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development of androgenetic alopecia (see Section 1.4). Controlled clinical 
studies showed a specific inhibitor of 5α-reductase type 2, finasteride 
(Kaufman et al, 1996) and dutasteride which inhibits both 5α-reductase type 
1 and type 2 (Olsen et al, 2006) promoted hair growth in male pattern 
alopecia.  A number of naturally occurring 5α-reductase inhibitors which have 
been extracted from plants are known, for example, ‘Seronoa repens’ (Saw 
Palmetto) which has been used in the treatment of prostatic enlargement 
(Rhodes et al, 1993; Habib et al, 2005) and androgenetic alopecia (Prager et 
al, 2002). Humulus lupulus from hops and eugenyl glucoside from clove 
extract are also claimed to inhibit 5α-reductase activity (Okano et al, 1994; 
Hamada et al, 2001) and other naturally occuring compounds e.g. rose fruit 
extract are known to be 5α-reductase inhibitors (Yamashita et al, 1991).  
 
Recent investigations have shown that ‘Thujae’ extracts (specifically Thuja 
occidentalis) also exhibit 5α-reductase type 2 inhibition in mice (Park et al, 
2003); Thuja orientalis seeds (also a member of the Thujae family) are 
claimed to be present in both herbal mixture Xiantene I and II, although this 
could not be confirmed in the TLC analysis, however the Thuja orientalis L 
leaves extract was detected in Xiantene II which may also have this 5α-
reductase type 2 inhibition ability. Therefore it seems possible that the 
Xiantene mixture may be acting as an enzyme inhibitor in the hair follicle, 
possibly as an apoptosis inhibitor or by interfering with the 5α-reductase 
activity, blocking the 5α-dihydrotestosterone synthesis pathway, and 
modifying androgen conversion. 
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4.7 Conclusions 
The TLC analysis confirmed that 6 out of the 7 claimed herb extracts were 
present in the Xiantene mixtures. Stephania tetranda was not identified in 
either although claimed to be in Xiantene I. This is beneficial as this is no 
longer allowed to be used in the UK due to risks associated with its incorrect 
identification. Physical tests and thin layer chromatography results of 
Xiantene I and Xiantene II indicated that there were differences between the 
two lotions. Only Cassia cinnamomum was detected in both preparations of 
Xiantene. They also confirmed that as expected the vehicle did not contain 
any components detectable by thin layer chromatography. 
Since both Xiantene mixtures (Xiantene I and Xiantene II) stimulated hair 
growth despite their apparent differences, the active ingredients may come 
from the Cassia cinnamomum extracts detected in both. Alternatively the 
effect may come from a range of activities in different extracts as suggested 
by traditional Chinese medicine (TCM) practice. Potential routes include 
stimulating mitogenic activity or enzyme inhibition of apoptosis or possibly of 
the enzyme 5α-reductase preventing the formation of the active androgen 
5α-dihydrotestosterone in the hair follicle. 
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5. Investigation of a possible relationship between male pattern 
alopecia and the early onset of greying 
 
5.1 Introduction 
Loss of hair colour, canities (see chapter 1.2), and male pattern baldness, 
androgenetic alopecia (see chapter 1.4), are two of the key visible markers of 
increasing age (Bulpitt et al, 2001). Both conditions gradually spread across 
the head in a patterned progression. Canities starts in the parietal areas 
spreading gradually to the vertex and the whole scalp, affecting the occipital 
area last (Boas & Michelson, 1932; Straile, 1964; Keogh & Walsh, 1965), 
while male androgenetic alopecia begins with a bi-temporal recession, 
movement of the frontal hair line and thinning of the frontal and crown area 
(Hamilton, 1951; Rushton et al, 1991). These stages of progressive hair loss 
are described as Hamilton I – VII (Hamilton, 1951) modified by Norwood 
(Norwood, 1975).The occipital and parietal areas do not usually exhibit hair 
loss, although complete baldness may occur (see Figure 5.1.). However, 
androgenetic alopecia is predominantly a male, androgen dependent 
condition (Hamilton, 1942; Randall, 2007), whereas loss of hair pigmentation 
occurs in both sexes and is presumed to be androgen-independent. The 
causes of canities are not clear, though early canities is a feature of a 
number of auto-immune diseases including pernicious anaemia (Dawber, 
1970) and hyperthyroidism (Rook & Dawber, 1991). In alopecia areata, also 
an auto-imunne condition, in which grey hair are spared and exhibit disease 
resistance, the initial hair re-growth is often unpigmented (McDonagh & 
Messenger, 1996).  
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Figure 5.1 
Scales used to grade androgenetic alopecia and hair greying 
Hamilton scale (grade 1-7) 
Scale of hair loss in androgenetic alopecia in men devised by Hamilton, 
modified by Norwood (Hamilton, 1951; Norwood, 1975) 
 
 
Grey scale (grade 1-5) 
Scale of hair greyness devised by the author 
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Children under the age of puberty (10-12 years) do not exhibit grey hair apart 
from certain rare syndromes which disrupt normal melanogenesis (Gilkes et 
al, 1974). Skin pigmentation also changes with age; the skin becomes 
thickened, becomes more yellow and wrinked due to changes in the 
connective tissue structure and lentigines, dark spots of hyperpigmentation 
may appear due to a localised increase in the number of epidermal 
melanocytes (Monestier et al, 2006).  
Hairdressers have been known to console men suffering from early greyness 
(under the age of 30 years) with the adage that early greyness will prevent or 
delay baldness (anecdotal evidence) and personal observation suggests that 
men who become prematurely grey may not then proceed to full 
androgenetic hair loss. However, this may be misleading as a full head of 
grey or white hair may simply be more noticeable.  
 
5. 2 Aim 
This study was designed to investigate the hypothesis that the loss of hair 
pigmentation may afford protection from the onset of androgenetic alopecia 
by examining whether the early onset of canities delayed the progression of 
androgenetic alopecia in men. 
 
5. 3 Experimental design 
The hypothesis was investigated by conducting a study of apparently healthy 
men aged 30 or over to determine whether there was any change in the 
incidence or extent of androgenetic alopecia if men exhibited canities before 
age 30. The aim was to consider 700 men overall, and to increase the 
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validity of the data two separate studies were carried out concurrently 
involving men at different geographical locations. In study 1 a group of over 
500 Thai men were interviewed and their stage of greying and androgenetic 
alopecia determined by the author. In study 2, approximately 100 subjects in 
the UK, mainly friends and acquaintances from the London area, were 
invited to take part in the study completing a questionnaire themselves, 
approximately 30% of which were verified by the author, while a further 100 
volunteered to complete a questionnaire on a self-assessed basis, online in 
response to an advertisement in “Chemistry World” (a newletter published by 
the Royal Society of Chemistry). This data for a total of approximately 200 
men in the UK based on self-assessment is therefore less reliable as this 
was self validated.  
The age of each subject was recorded and the extent of androgenetic 
alopecia was assessed using the Hamilton scale (Hamilton, 1951) modified 
by Norwood (Norwood, 1975) (see Figure 5.1). A hair greyness scale (see 
Figure 5.1) was devised and used to record the degree of canities, and the 
age of canities onset was also recorded.  
Subjects in each study were subsequently divided into 2 categories; those 
grey by the age of 30 and those who were not. Relationships between age 
and the stages of androgenetic alopecia and greyness and whether these 
were influenced by the early development of greying were analysed in each 
group and compared. Comparison was also made between the two different 
experimental groups.  
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5.4 Materials and Methods 
5.4.1. Subject group 
Ethical approval for the research was granted by the University of Bradford 
Ethics Committee.  
Thai men 
The first experiment was conducted using Thai men who presented at a 
chain of clinics in Thailand, specialising in the treatment of androgenetic 
alopecia and hair loss. All subjects gave informed consent and were 
assessed by a single examiner (the author) to record the grade of hair loss 
using the Hamilton scale, modified by Norwood, from 1-7 (Hamilton, 1951, 
Norwood, 1975), and the grade of hair greyness on a hair greyness scale 
devised by the author (see Figure 5.1) on a scale of 1-5. The subjects 
underwent a clinical examination, by the author, to eliminate persons with an 
underlying trichological condition e.g. seborrhoeic eczema, alopecia areata.  
 
The scalps and hair shafts at the root end were examined using a 
videomicroscope (Optica Ltd., Bangkok) to also eliminate Thai men who had 
dyed their hair black (a common Thai tradition) and may not have admitted to 
being grey. The age of the subject was recorded as was the age the 
subject’s grey hair first appeared, although it was of course not possible to 
independently verify this last parameter. All subjects were asked to confirm 
that they were in good health and were not aware of any underlying medical 
condition. A total of 502 Thai subjects were successfully examined and used 
for the study. 
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European men 
A further 208 European men were recruited by personal invitation and 
advertising and invited to complete a similar questionnaire (see Appendix VI) 
using a self-assessment technique. The European group was comprised of 
106 men who were personally selected by the author from friends, relatives 
and casual aquaintances and invited to participate in the study, and of these, 
30 were assessed by both the subject and the examiner, whereas the 
remaining 76 subjects, completed their own assessment and no independent 
scoring was made. A further 102 subjects were recruited at random amongst 
scientists by advertising in a scientific journal, and completed the 
questionnaire via the internet. These results could not therefore be 
independently verified. The total number in the European group was 
therefore 208 subjects.  
 
5.4.2. Statistical Analysis  
The data was tabulated using an Excel (Microsoft Ltd.) spreadsheet and the 
subjects split into two groups in each category: those who were first grey at 
age 30 years or earlier, and those who were not. Initially the relationships 
between age and greying, and age and androgenetic alopecia were 
investigated using Pearson’s correlation (Cohen et al, 2003). Secondly, 
mean values were compared using non-paired Student’s t-tests to determine 
whether early greying affected the stage of balding comparing the grey 
before 30 groups with the grey after 30 groups. Results where p<0.05 or = 
0.05 were taken as statistically significant. Thanks are due to Mr. Edward 
Kent of the Universtity of Warwick and Mr. Paul Bassett of Stats Consultancy 
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Ltd., for verifying the statistical analysis. A total of four subject groups were 
therefore used for comparison in this study: Thai men grey at 30 or earlier, 
Thai men not grey by age 30, European men grey at 30 or earlier and 
European men not grey by age 30. Due to the different method of data 
collection between the Thai group (personal interview and assessment) and 
the European group (Internet questionnaire, self validation), the two groups 
were not combined for analysis. 
 
5.5 Results 
5.5.1. Subjects 
The initial data for the subjects assessed is shown in Table 5.1. A total of 
843 subjects were used in the study. This included 626 Thai men and 217 
European men; in the Thai group 52 men were grey by 30, representing 
8.30% of the total Thai group, while 51 European men were grey by 30 i.e. 
23.50% of the European group.  
All the Thai subjects (total 626 men) were assessed by a single examiner, 
the author but only 14.75% of the total European group were independently 
assessed by the author and none of the European internet respondees could 
be checked meaning that 85.25% European men were not checked. In all 
cases where the assements were checked by the author, n=30, the 
agreement for the degree of baldness (1-7) and the degree of greyness (1-5) 
were within 1 unit of the appropriate scale. The mean ages of the two Thai 
groups were 39.3 ± 1.2 (mean ± SEM) years (range 30-63 years) for the grey 
by 30 group and 41.4 ± 0.4 years (range 30-72 years) for those who were not 
(see Table 5.1) and did not differ significantly (p=0.13).  
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Table 5.1 
Summary of the subjects assessed for androgenetic alopecia and hair 
greyness. 
Subjects ages by geographical group and by age grey group are 
summarised 
 
  
Group 
Number of 
Subjects 
Mean age  
± SEM 
(years) 
Age range 
(years) 
 
 
Thai 
Thai men Grey by 
30 
 
45 
39.3 
± 1.2 
 
30-63 
Thai men not 
grey by 30 
 
457 
41.4 
± 0.4 
 
30-72 
 
 
European 
European men 
grey by 30 
 
47 
51.3 
± 2.2 
 
31-86 
European men 
not grey by 30 
 
161 
53.6 
± 1.1 
 
30-95 
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The mean ages of the two European groups were 51.3 ± 2.2 years for  
(range 31-86 years) the grey by 30 group and 53.6 ± 1.1 years for those who 
were not (see Table 5.1) again showing no significant difference (p=0.33) 
(Figure 5.2).However, the mean ages of the Thai groups compared with the 
European groups do vary significantly; Thai men who were grey before 30 
had a significant lower mean age 39.3 ± 1.2 years than  European men who 
were grey before 30, whose mean age was 51.3 ± 2.2 (p<0.001). Similarly 
Thai men who were not grey before age 30 had a mean age of 41.4 ± 0.4, 
significantly lower than that of European men who were not grey before 30 
(mean age 53.6 ± 1.1 years) (p<0.001), and comparison between different 
geographical groups is therefore limited. 
 
5.5.2 Age of onset of greying  
The mean age for the onset of hair greying (all subjects but excluding those 
not yet grey) was 37.9 ± 0.8 (mean ± SEM) years for the Thai group (n=170) 
and 38.7 ± 0.9 years for the European group (n=172). There was no 
significant difference (p=0.49) in the age of onset of greying between the 
Thai men and the European men.  
Interestingly 3 Thai subjects (5.66% of the Thai grey 30 or under group) gave 
the age of 12 years i.e. puberty for the first appearance of grey hair and this 
was in some cases apparently repeated in subsequent generations. It was 
not possible to fully eliminate the presence of thyroid disease from this 
observation, although all subjects had confirmed that they were in good 
health. The percentage of the participants who were exhibiting canities was 
33.9% of the Thai group and 82.7% of the European group.  
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Figure 5.2 
The relationship between the age of men at assessment who went grey 
by, or after, age 30. 
Mean ± SEM of age at assessment date of all men in the study separated 
according to whether they first lost their hair pigmentation by or after age 30 
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The mean age for the onset of canities in the grey before 30 or after 30, of 
both groups, Thai and European are shown in Figure 5.3.  
The mean ages for the onset of greying for those who were grey but not grey 
by 30 were 42.4 ± 0.7 years for the Thai men who weren’t and 43.8 ± 0.8 
years for the European men; these are not significantly different (p=0.12). 
The grey before 30 groups also had no differences in the mean age at which 
greying began at this was; 25.9 ± 0.8 years for Thai men and 25.5 ± 0.6 
years for Europeans (p=0.45). The mean age of greying of the men grey 
before 30 and grey after 30 for each geographical group (Thai and 
European) are of course different as they have been pre selected on this 
basis.  
 
5.5.3. Relationship between age and balding 
The extent of balding as measured by the Hamilton stage (modified by 
Norwood) for the 2 groups, Thai and European, were compared with age, for 
all men in that group and within each group with the men divided into 
subjects who were grey before or after 30 years of age.  
The correlation analysis for all groups confirmed the expected relationship 
that baldness correlated positively with age. In the Thai group (see Figure 
5.4), the men who were grey before 30 (n=45) showed a very highly 
significant correlation between age and balding with a correlation coefficient 
= 0.43 (p=0.003). This was also seen in those who were grey after 30 
(n=457), correlation coefficient = 0.32 (p<0.001).  
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Figure 5.3 
The relationship between the mean age for the onset of canities for 
men who went grey by, or after, age 30. 
Mean age ± SEM for the onset of canities of (a) Thai (n=170), (b) European 
(n=172), men grey by or after age 30, but excluding men not yet grey 
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Figure 5.4 
The relationship between age and extent of male pattern baldness as 
indicated by Hamilton stage in Thai men at assessment who went grey 
by, or after, age 30. 
The extent of hair loss as indicated by the Hamilton stage was related to age 
for 502 Thai men; 45 men were grey by age 30 and 457 men were not grey 
age 30 
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In the European group the correlation between age and balding was weaker 
(Figure 5.5). European men who were grey before 30 (n=47) showed an 
insignificant, correlation coefficient = 0.14 (p=0.33) and this also occurred 
with European men who became grey after 30 (n=161), correlation 
coefficient = 0.08 (p=0.33).  
This experiment confirms that male androgenetic alopecia advances with 
age in all 4 groups used in the experiment. 
 
5.5.4 Relationship between age and hair greyness 
The extent of hair greyness was also found to correlate with age. The grey 
after 30 groups all showed a strong positive correlation. In Thai men who 
were grey after 30 (Figure 5.6) (n=457) the correlation was highly significant; 
correlation coefficient = 0.55 (p<0.001). This also occurred in European men 
who were grey after 30 (n=161) where the correlation was also highly 
significant; correlation coefficient = 0.66, (p<0.001) (Figure 5.7). 
The men who were grey before 30 also showed a strong positive correlation 
between age and extent of greying. Thai men (n=45) the positive correlation 
was very highly significant; correlation coefficient = 0.63 (p<0.001) (Figure 
5.6). This was also true for European men (n=47), correlation coefficient = 
0.75 (p<0.001) (Figure 5.7). In both the Thai subjects and the European 
subjects hair greyness and balding were found to correlate strongly and 
positively with age. However hair greyness had a much stronger correlation 
with age in both the Thai and the European groups than the correlation of 
balding with age. 
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Figure 5.5 
The relationship between age and male pattern baldness as indicated 
by the Hamilton stage in European men at assessment who went grey 
by, or after, age 30. 
The extent of hair loss as indicated by the Hamilton stage was related to age 
for 208 European men; 47 men were grey by age 30 and 161 men were not 
grey age 30 
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Figure 5.6 
The relationship between age and extent of pigment loss in Thai men at 
assessment who went grey by or after age 30. 
The extent of hair greyness was related to age for 502 Thai men; 45 men 
were grey by age 30 and 457 men were not grey age 30 
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Figure 5.7 
The relationship between age and extent of pigment loss in European 
men at assessment who went grey by or after age 30. 
The extent of hair greyness was related to age for 208 European men; 47 
men were grey by age 30 and 161 men were not grey age 30 
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5.5.5. Comparison of the extent of pigmentation loss in men who were 
grey by age 30 and those who were not 
Loss of pigmentation was strongly correlated with age whether the men had 
been grey at an early stage or not (see 5.5.4; Figures 5.6 and 5.7). Both 
groups however when the extent of pigment loss was compared between the 
men who were grey before 30 and those who became grey after 30 (Figure 
5.8), those who became grey early had a very significantly higher mean grey 
score than those who became grey after 30.  
Thai men who were grey before 30 (n=45; grey score 3.06 ± 0.14) were 
significantly more grey than Thai men who became grey after 30 (n=457; 
grey score 1.50 ± 0.04, p<0.001) Figure 5.8; European men who were grey 
before 30 (n=47; grey score 3.85 ± 0.18) were similarly significantly more 
grey than European men who were not grey by 30 (n=161; grey score 2.85 ± 
0.12, p<0.001). All men who were grey before 30 were significantly more 
grey compared with those who were not (Figure 5.8). 
 
5.5.6. Comparison of the extent of androgenetic alopecia in men who 
were grey by age 30 and those who were not 
The extent of androgenetic alopecia also correlated with age (see 5.5.3., 
Figures 5.4 and 5.5) in all groups. However, when the mean Hamilton 
(modified by Norwood) stages (Hamilton, 1951; Norwood, 1975) were 
compared, men who were grey aged 30 and before had significantly lower 
baldness scores than those who were grey after 30, in all subjects (see 
Figure 5.9). 
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Figure 5.8 
The relationship between the extent of pigment loss in men at 
assessment who went grey by, or after, 30 
The extent of hair greyness, mean ± SEM, greyness scale grade (a) Thai, (b) 
European 
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Figure 5.9 
Relationship between the extent of male pattern baldness as indicated 
by the Hamilton stage in men at assessment who went grey by, or after, 
age 30. 
Value are the mean ± SEM Hamilton stage of (a) Thai, (b) European 
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This was more pronounced in the European men p=0.01 with the grey before 
30 group having a mean Hamilton stage of 2.62 ± 0.26 and grey after 30 
group 3.48 ± 0.16.  
If the results from all men were combined this difference was maintained 
p=0.003, grey before 30 group 2.58 ± 0.15, grey after 30 group 3.07 ± 0.06. 
Overall, in all groups, the men who were grey 30 or before were very 
significantly less bald. 
 
5.5.7 Comparison of the extent of androgenetic alopecia in men who 
were grey by age 30 and those who were not, aged over 40 and 
adjusted for age 
The final analyses compared the Hamilton stage between those grey and not 
grey by 30 adjusted for age. The analysis was restricted to those aged 40 or 
over. Linear regression was used for the analysis, and the results were 
performed with and without an adjustment for age. 
The results are summarised in Table 5.2. The figures are the mean 
difference in Hamilton score between those who went grey by 30 and those 
not grey by 30. These are calculated as the values for those who went grey 
by 30 minus the values for those not grey by 30. So a positive difference 
would imply higher values for those who went grey by 30, and a negative 
diference would imply a lower value for those who went grey by 30. 
The results suggested that for this age, aged 40 and over, there was no 
difference in Hamiton stage between those greying by 30 and not greying by 
30 for Thai men (p=0.28), adjusted for age. 
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Table 5.2 
Summary of extent of baldness adjusted for age 
Comparision of extent of androgenetic alopecia calculated as the value for 
those  men over 40 who were grey by 30 minus the value of those men over 
40 who were not. Differences are shown both unadjusted and adjusted for 
age.  
 
 
Nationality Analysis Difference 
Mean (SEM) 
p-value 
Thai Unadjusted -0.35 (0.35) 0.32 
 Age adjusted -0.36 (0.34) 0.28 
European Unadjusted -0.79 (0.41) 0.05 
 Age adjusted -0.80 (0.41) 0.05 
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However, there was evidence that European men grey by 30 had a lower 
Hamilton stage than European men not grey by 30 (p=0.05). 
However if Thai and European men over 40 are combined, the results are 
significant (p=0.01). Men over 40 who were grey by 30 had a statistically 
significant lower stage than men not grey by 30 on an age adjusted basis. 
 
5.6 Discussion 
This investigation looked at the relationship between early greying and 
androgenetic alopecia in two groups of men, 502 from Thailand and 208 from 
Europe. The data obtained from the Thai group of subjects is consistent, 
using a single examiner, the author, to examine the subject’s hair and the 
scalp, assess the extent of their greying and balding, and to verbally verify 
each subject’s health status. This data from the Thai group therefore has a 
good, reliable scientific basis. The data from the European group, using a 
self-assessment technique, is not so reliable. Self-assessment of one’s own 
hair parameters is not completely reliable and subjects tend to underscore 
(personal observation) i.e. a subject’s perception is of less balding and less 
hair greyness than a third party examiner may record. The validity of self-
reported male balding assessments has been discussed (Taylor et al, 2004); 
it was found that self-assesment of stage of balding was significantly less 
accurate than using trained third party examiners with approximately 50% 
agreement between the two methods using the Hamilton stage as modified 
by Norwood (Hamilton, 1942; Norwood, 1975). Older subjects have been 
reported to be better at assessing their balding group, than men under 50 
years of age (Taylor et al, 2004). Although it was possible to check some 
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14.78% of the total European group (n=32), none of the European internet 
respondees could be checked. Therefore the data from this group does not 
have such a firm scientific basis as that from the Thai group. However the 
total number of participants in the European group is smaller (29.30% of the 
total subjects) than the Thai group (70.70%) and the bulk of the data used in 
this study was collated by a single 3rd party examiner (the author). All 
analysis was carried out on the groups separately and then combined. 
The recruiting of subjects for the study was not completely random. The 
subjects attending the hair treatment clinics in Thailand were in effect pre-
selected i.e. these were men who already felt they had a hair loss problem, 
albeit possibly quite mild, especially in the younger age range. The study, 
because of the method of recruitment, therefore used a group with possibly 
an above average degree of hair loss. The European group was also not 
random; the first European section were invited to participate and this was 
therefore not fully randomised. Interestingly, a number of invitees refused to 
take part in the study while some, particularly those with a full head of grey 
hair, willingly volunteered their details (personal observation). Data from the 
internet survey among academics may also not be completely reliable with 
the natural tendency to underscore present, a further difficulty might be the 
inability to understand the grading scales correctly. Since both greying and 
androgenetic alopecia are age related conditions the ages of the participants 
were compared. The mean ages of the two comparison groups on the date 
of analysis i.e. the men who were grey before 30 or grey after 30 within each 
geographical group are comparable and do not vary significantly: Thai 39.3 ± 
1.2 years and 41.4 ± 0.4 years respectively (p=0.13) and European 51.3 ± 
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2.2 years and 53.6 ± 1.1 years respectively (p=0.33) (see Figure 5.2). 
However the two geographical groups, Thai and European, have significantly 
different mean ages with the Thai group being significantly younger; grey 
before 30 groups p<0.001, and grey after 30 groups p<0.001, meaning that 
the data from each area needs to be analysed separately to avoid age-bias. 
The difference in mean age of the two geographical groups probably reflects 
the methods of recruitment; probably younger men with greater hair loss 
concern have been attracted to the hair loss clinics in Thailand. Older men 
have responded to the invitations in the European study. The Thai people 
are of Mongol descent and they have not been subject to mass immigration 
or colonisation (Warren et al, 2002). Consequently, they present a tight 
genetic group with a specific phenotype. The north European people are 
considerably more diverse with a much wider genetic spread and a non-
specific skin and hair colouring (Tobin & Paus, 2001). Unfortunately, the 
differing mean ages of the Thai and European groups means that it is not 
valid to interpret differences between these geographical groups as due only 
to their varying genetic backgrounds.  
The mean age for the onset of hair greying in all subjects, excluding those 
who were not yet grey was found to be 37.9 ± 0.8 years for Thai men 
(n=170) and 38.7 ± 0.9 years for European men (n=172) (see Figure 5.3). 
This compares well with previous published data where the mean reported 
values were 34.2 years for caucasians, 43.9 years for African-Americans and 
30-34 years for Japanese (Keogh & Walsh, 1965; Wasserman, 1974). The 
percentage of subjects exhibiting canities for each group, 33.9% of Thai 
men, 82.7% of European men, is also consistent with earlier work  where it 
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was found that 50% of caucasians were 50% grey by the age of 50 (Keogh & 
Walsh, 1965). The age for early canities has been defined as, 20 years for 
Caucasians and 30 years for people of Afro-American origin (Rook & 
Dawber, 1982). The figure used in this study to define early canities was 30 
years of age. It is known that health status can influence the onset of canities 
(Dawber, 1970) and although all subjects were asked to confirm that they 
were in good health, underlying thyroid disease (Wright, 1986) or pernicious 
anaemia (Dawber, 1970) could not be fully eliminated from distorting the 
data. Re-pigmentation of grey hair which continued into old age has also 
been observed in cases of hypothyroidism (Wright, 1984). Grey hair was 
found to re-darken substantially 6 months prior to overt hypothyroidism, but 
lightened on treatment with thyroid hormone (Wright, 1986).  
When the extent of pigment loss was related to ageing, the data confirmed 
that loss of hair pigment correlates positively with age in a highly significant 
manner in all groups: Thai men grey by 30, p<0.001, Thai men not grey by 
30, p<0.001 (see Figure 5.6), European men grey by 30, p<0.001, European 
men not grey by 30, p<0.001 (see Figure 5.7). This data fits with earlier work 
reporting that grey hair incidence increases with age (Boas & Michelson, 
1932; Keogh & Walsh, 1965; Burch et al, 1971) and means that the men who 
went grey by the age of 30 showed a normal progression of pigment loss 
with age. Comparison of the extent of pigment loss for the men grey before 
or after 30 years (Figure 5.8) showed that the grey before 30 men in all 
groups were significantly more grey; Thai men (p<0.001), European men 
(p<0.001) and all subjects (p<0.001). Early onset of hair greyness had 
allowed the pigment loss to proceed further for those individuals compared to 
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those who did not experience early canities. Loss of hair pigment (see 
chapter 1.2) is thought to be due to incomplete melanocyte stem cell 
maintenance in the hair follicle niche (Nishimura et al, 2005; Steingrimsson 
et al, 2005), affecting both the bulb and the outer root sheath (Como et al, 
2004) and resulting in an inability to synthesise the pigment melanin in the 
hair follicle. The strong correlation of increased greying with age in early 
greyness would fit with loss of this sort.  
Androgenetic alopecia was also found to correlate positively with age in this 
study in a very highly significant way for the Thai group; men who were grey 
before aged 30, p=0.003 (see Figure 5.4), the correlation for European men 
was weaker and was not significant, p=0.33 (see Figure 5.5) which probably 
reflects both the smaller subject number of this group and the not fully 
randomised method of recruitment. This fits with previous reports that the 
extent of androgenetic alopecia correlates with age (Hamilton, 1951; 
Norwood, 1975; Ellis & Harrap, 2001), and confirms the relationship found in 
the earlier 12 month trial of herbal mixture Xiantene (Chapter 3). In subjects 
with the inherited susceptibility, the hair follicles in response to androgens, 
begin to miniaturise and there is an increased lag before the new smaller 
anagen hair is produced, leading eventually to follicular atrophy and 
baldness on pre-determined areas of the scalp. This process, androgenetic 
alopecia, correlates positively with age although in this experiment the 
correlation between hair greyness and age was found to be stronger.  There 
was no difference between the relationship of androgenetic alopecia and age 
in men who were grey either before of after aged 30 in any of the groups. 
However, men who went grey by age 30 differed in the extent of their 
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androgenetic alopecia (see Figure 5.9) and had significantly lower Hamilton 
stages compared with controls i.e. the subjects who were not grey before 30, 
in all groups. Thai men who were grey before aged 30, balding measured by 
Hamilton stage 2.53 ± 0.16, Thai men who were grey after aged 30, Hamilton 
stage 2.93 ± 0.06 (p=0.04) and European men who were grey before aged 
30, extent of balding, Hamilton stage 2.62 ± 0.26 and European men who 
were grey after aged 30, Hamilton stage 3.48 ± 0.16 (p=0.01). Examination 
of the data for all men over 40, with and without an adjustment for age, 
showed that there was no significant difference in the grey before and grey 
after 30 groups for the Thai men in the extent of androgenetic alopecia 
(p=0.28) but there was a significant difference for the European men 
(p=0.05) and if all men were combined, the men grey by 30 were significantly 
less bald (p=0.01) than the men not grey by 30. In both study groups the 
men who went grey age 30 years or before, had significantly less hair loss 
although the difference was greater for the European group than the Thai 
group. The lower Hamilton score in all of the early canities groups opposes 
predictions if both canities and baldness were solely age related. Early 
pigment loss appears inversely related to male pattern alopecia extent.  
Androgens orchestrate the progression of androgenetic alopecia in 
genetically pre-disposed individuals (Hamilton, 1951; Randall, 2007) and 
androgens can also influence hair pigmentation by inhibiting dermal papilla 
SCF production and melanocyte activity (Hibberts et al, 1996; Randall et al, 
2008). In most young blonde north European people, the hair colour does not 
fully develop until late teens (Sunderland, 1956) and vellus hairs are 
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replaced by larger, thicker pigmented terminal hairs in many areas at puberty 
under the influence of androgens (Hamilton, 1946, reviewed Randall, 2007).  
Interestingly, loss of scalp hair pigment and hair greyness occurs initially at 
the margins and in particular the occipital and parietal areas (Keogh & 
Walsh, 1964). These are the androgen insensitive areas where androgenetic 
alopecia does not usually proceed which may indicate that the two 
conditions, androgenetic alopecia and canities, are not completely 
independent of each other. Canities also occurs in women in the same 
pattern as men which does suggest that the greying process is independent 
of androgens unlike androgenetic alopecia which is androgen dependent.  
Although hair greyness (Tobin & Paus, 2001; Van Neste & Tobin, 2004) and 
androgenetic alopecia (Rebora, 2004; Randall, 2007; Otberg et al, 2007) are 
both positive markers of the aging process and are both main areas of hair 
research, a possible link between the two conditions does not appear to have 
been investigated and no reference to this could be found. Early canities has 
however been tentatively linked to other conditions; e.g. low bone mineral 
density (Morton et al, 2007). During active pigmentation of the hair shaft the 
synthesis of melanin by the melanocytes produces considerable oxidative 
stress (Tobin & Paus, 2001; Arck et al, 2006). The free radical theory of 
ageing (Tobin & Paus, 2001) proposes that the normal cell function is 
damaged or compromised by these circulating, highly reactive free radicals 
(Arck et al, 2006) which can lead to diseases such as Alzheimer’s disease 
and to certain cancers (Kim et al, 2007; Kulbacka et al, 2009). Oxidative 
stress is implicated in cellular aging and senescence (Hayflick, 2007) as the 
body’s anti-oxidant system becomes less effective. Cellular sensitivity to 
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peroxidising agents has been shown (Grammatico et al, 1997); cultured 
pigmented hair follicles exposed to external oxidative stress (hydroquinone) 
showed increased apoptosis of melanocyte population in the hair bulb (Arck 
et al, 2006) and H2O2 mediated oxidative stress has been shown to be a key 
element in senile grey graying (Wood et al, 2009). In this study early canities 
appears to delay the onset or progression of androgenetic alopecia and the 
loss of pigment synthesis or the absence of melanin itself possibly, lowers 
these toxic or inhibitory factors, allowing hair growth to proceed faster and 
more fully (Van Neste, 2004; Arck et al, 2006) despite the androgen drive to 
miniaturisation. Unpigmented hairs in the scalp and beard are known to be 
thicker and to grow faster than pigmented hairs (Nagl, 1995; Van Neste, 
2004). This observation has been confirmed using scalp hairs in culture 
(Arck et al, 2006), suggesting that the synthesis of melanin or its presence in 
the hair follicle interferes with or reduces the rate of hair growth. Hair growth 
rate and hair diameter are known to decrease with age and alopecia (Van 
Neste et al, 1991), however the reduced rate of hair growth of terminal hairs 
is limited to the pigmented hairs (Van Neste, 2004) and the white hairs are 
spared from this ageing process. It is possible that grey hair does not suffer 
the full miniaturisation and atrophy characteristic of androgenetic alopecia, 
and loss of pigment may offer protection from genetic hair loss. 
 
5.7. Conclusion 
This study suggests that early canities in men (i.e. before the age of 30 
years), may delay the full onset of androgenetic alopecia.  
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6. Summary and conclusions 
Hair is the distinguishing feature of the mammals, providing insulation and 
protection and the ability to vary coat colour and pattern with season and 
age, via the hair cycle, gives camouflage with social and sexual 
communication. The communication aspects are particularly important for 
human beings whose body hair is sparse remaining abundant essentially 
only on the scalp. Pre-puberty children have abundant and full scalp hair, like 
adults, often not fully pigmented (Sunderland, 1956), but the arrival of 
androgens in both sexes initiates the specific body hair patterns of adulthood 
(Randall, 2007). 
The ageing of human hair is pronounced and highly visible compared with 
skin ageing, and the loss or change to scalp hair, especially when it is 
premature, can cause considerable emotional stress e.g. male pattern hair 
loss (Cash, 1992). Loss of hair pigment, which occurs in both sexes, is 
thought to be caused by a genetically regulated exhaustion of active 
melanocytes in the hair matrix which produce the pigment melanin and 
results in grey or white hair (Peters et al, 2002). As a rule of thumb 
approximately 50% of people are 50% grey by the age of 50 years and all 
hair colour is usually lost by the 7th or 8th decade (Keogh & Walsh, 1965), 
when the melanocytes become inactive and no hair colour is produced. The 
loss of hair pigment and the appearance of grey hair is one of the key 
markers of the ageing process (Bulpitt et al, 2001), although scalp hair may 
be very easily and effectively artificially coloured to disguise this part of the 
ageing process.  
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The second hair ageing phenomenon is the permanent loss of scalp hair in 
the progression of androgenetic alopecia, predominantly in men (Hamilton, 
1951); this loss of hair and indicator of ageing is not as easily disguised as 
the appearance of greyness and in a youth and appearance-orientated 
society loss of scalp hair can be a highly distressing condition. In persons 
with a genetic predisposition androgens, post puberty, orchestrate changes 
to the natural hair growth cycle on pre-determined areas of the scalp. Both 
men and women can develop androgenetic alopecia and although 
androgens are the agents for men (reviewed, Randall, 2007), in women the 
mechanism is not so clear cut (Cusen & Messenger, 2010). Initially the 
anagen phase begins to reduce in length over successive hair cycles, the 
hair becoming shorter and smaller in diameter and the dermal papilla at the 
base of the hair follicle begins to get smaller (Whiting, 1993). Also a lag 
develops between the shedding of the previous telogen hair and the 
appearance of the new hair (Whiting, 2001). Eventually over many hair 
follicle cycles the hair follicle miniaturises, atrophies and is lost; the scalp hair 
produced changes from terminal to vellus before being finally lost and bald 
patches (alopecia) appear on the scalp, in a characteristic pattern (Rushton 
et al, 1991). In men, bi-temporal recession and loss of hair on the crown may 
lead to semi or complete baldness and is graded in severity by the Hamilton 
stage 1-7 (Hamilton, 1951).  
This thesis looked at the two key markers in men of hair ageing, canities or 
hair greyness and androgenetic alopecia or patterned hair loss. In the first 
set of experiments a herbal mixture Xiantene, based on 8 traditional Chinese 
medicine herbs was assessed to see if it would affect hair growth in men with 
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androgenetic alopecia. In the final experiment a possible relationship 
between the two ageing characteristics, hair greying and androgenetic 
alopecia was examined. The hypothesis that men who suffer early hair 
greyness (before 30 years) do not develop the full extent of hair loss in 
androgenetic alopecia, was examined.  
In the studies on herbal mixture Xiantene, men with androgenetic alopecia 
used daily topical applications of Xiantene or a vehicle for either three 
(Chapter 2) or twelve (Chapter 3) months. Hair growth was assessed on the 
crown using the unit area trichogram method of assessment (Rushton et al, 
1983). A total of 35 subjects were recruited, but only 12 managed to 
successfully complete the 3 month experiment, a high drop-out rate of 
65.7%. A total of 48 men commenced the 12 month study and 29 men were 
successfully re-examined at the end of the 12 months. The drop out rate of 
39.6% was high, but better than the 3 month study (65.7%). The pre 
treatment data from men completing either the 3 month trial or 12 month 
experiments (n=41) were combined to examine the relationship between the 
extent of balding, measured by the Hamilton stage, with measured hair 
parameters and with age. The extent of balding showed a significant 
negative correlation with the total number of hairs in an area of 50.7 mm² on 
the crown, correlation coefficient = -0.56 (p=0.001) and with the number of 
anagen hairs in the area, correlation coefficient = -0.60 (p<0.001) and a 
weak negative correlation with the anagen:telogen ratio, correlation 
coefficient = -0.09 which was not significant (p=0.60). This data corresponds 
to the previous data (Hamilton, 1942; Rushton et al, 1983) and confirms that 
as the extent of baldness, measured by the Hamilton stage, increases, the 
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number of visible hairs on the crown decreases. In contrast, when the extent 
of baldness as indicated by the Hamilton stage was related to age there was 
a significant positive correlation, correlation coefficient = +0.35  (p=0.03) 
confirming that balding increased with age (Hamilton, 1942; Rushton et al, 
1983).  
Men (n=6) treated with Xiantene for 3 months showed a significant 15.33% 
increase in the total number of hairs (p=0.045) and a very highly significant 
(p=0.00033) increase of 23.71% in the number of anagen hairs unlike the 
vehicle group where there were no significant changes (Chapter 2). Neither 
the Xiantene treated (p=0.50), or the vehicle treated (p=0.78) groups showed 
any significant difference in the number of telogen hairs, nor changes in 
mean hair diameter measurements. Interestingly only one hair diameter 
measurement was below the 40 μm threshold proposed for meaningful hairs 
(Rushton et al, 1993) meaning that the method of detection used was 
essentially unable to detect vellus hairs. The Xiantene treated group also 
showed a significant increase in pigmentation of anagen hairs (p=0.01) 
unlike those using the vehicle (p=0.09). However, there was some evidence 
that this may have been a staining or dye effect from the Xiantene mixture 
itself meaning that this finding cannot be relied upon, although it would be 
consistent with increased melanogensis in the hair bulb if the treatment with 
Xiantene was showing a positive effect.  
Since this increase in hair growth using herbal mixture Xiantene was 
encouraging, but the subject number small and the results may have been by 
influenced by seasonal variation (Randall & Ebling, 1991), these experiments 
were repeated using a new, larger cohort of men with androgenetic alopecia 
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for a full year. Examination of the data from the 12 month study (Chapter 3) 
also showed a highly significant increase in the total number of hairs for the 
Xiantene treated group (p=0.003) unlike the vehicle treated group where was 
no significant change. The number of anagen hairs also increased very 
significantly again for the Xiantene treated group (p<0.001) with no 
significant change in the vehicle group. In the larger 12 month study the 
anagen:telogen ratio also increased for the Xiantene treated group (p=0.005) 
while there was no significant change for the vehicle group. The 
experimental data in this second study was not affected by seasonal 
variation as it was run for a full 12 month period (Randall & Ebling, 1991) and 
confirms the results of the 3 month experiment, which used different subjects 
and was not run concurrently. These observations suggest that herbal 
mixture Xiantene could promote a cessation or partial reversion in the 
progession of androgenetic alopecia.  
Treatment with Xiantene significantly increased the number of meaningful 
hairs unlike the vehicle treatment. This contrast with the control group and 
also what would be expected on the scalp of men with androgenetic alopecia 
where some deterioration would have been expected (Rushton et al, 1991). 
It is possible that terminal hair follicles have been persuaded to stay in the 
anagen phase for longer and not enter telogen, or more likely that hair 
follicles in the lag period (Whiting, 2001) have been prompted to enter the 
anagen phase, thus increasing the number of anagen hairs while the number 
of telogen hairs remain insignificantly different. A reduction in the duration of 
the lag phase in the reversal of androgenetic alopecia in men by finasteride 
was found to be the key mechanism (Van Neste, 2006). It is unlikely that 
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vellus hair follicles have been converted back to fully developed terminal hair 
follicles in the 12 months of the study, the mechanism of androgenetic 
alopecia is more likely to have been delayed rather than fully reversed by the 
treatment with herbal mixture Xiantene.   
Attempts to analyse and confirm the herbal extracts and their proportions in 
the Xiantene mixture, using thin layer chromatography were only partial 
successful (Chapter 4). The Xiantene mixture used in the 12 month study, 
Xiantene II, was described by the suppliers as an upgraded and improved 
version of the Xiantene mixture used for the 3 month study, Xiantene I. The 
assay results for the two mixtures did differ, although they are claimed by the 
suppliers to each contain the same 8 Chinese herbs. Fortunately the item 
that was subsequently banned for use in the U.K. Stephania tetranda S, 
could not be identified in either mixture. All the other herbs could be identified 
in either Xiantene I or Xiantene II apart from Thuja orientalis L seeds which 
was not in either although the leaves of Thuja orientalis L were identified in 
Xiantene II. Interestingly there was evidence from the thin layer 
chromatography data of components present in both that could be not 
identified and did not match the reference samples. Only Cassia 
cinnamomum twigs could be positively identified in both Xiantene I and 
Xiantene II. There may by a number of reasons for the differences in the 
analytical data from that described by the suppliers. The reference herbs 
used for comparison in the analysis were purchased in the U.K. and may not 
be reliable and no standard reference data were available. There are 
limitations in the thin layer chromatography methods used here for the 
analysis of complex herbal mixtures, even though a multiple solvent system 
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was used. The formulation data from the manufacturers in China may be 
unreliable and the herbs used may vary. Traditional Chinese medicine 
products are notoriously different to identify and quantify with certainty (Lu et 
al, 2007) and more sophisticated techniques than those used here would be 
required together with access to certified reference material data for 
comparison. 
The mode of action of Xiantene mixtures is unclear, however 5 of the 8 herbs 
confirmed as present in at least one Xiantene (Thuja orientalis L, Polygonum 
multiflorum, Panax ginseng, Panax notoginseng, Istatis indigotica fort) are 
known to be enzyme inhibitors (Ehrman et al, 2007). Thuja orientalis L 
extracts have both mitogenic activity and potent enzyme inhibition activity 
(Gohla, 1989; Offergeld, 1992) and Thuje extracts can inhibit the enzyme     
5 α-reductase type II (Park et al, 2003). The conversion of testosterone by 
the enzyme 5α-reductase to the metabolite 5 α-dihydrotestosterone is a key 
step in the progression of common baldness and is the process inhibited by 
finasteride, the most successful androgen–selective treatment for male 
pattern baldness (Kaufman et al, 1998). The enzyme inhibition properties of 
Xiantene mixture are a possible mode of action for the stimulation of hair 
growth in the two studies of herbal mixture Xiantene.  
A second set of experiments investigated the hypothesis that the premature 
loss of hair pigmentation, e.g. before 30 years of age, may afford protection 
from the onset of androgenetic alopecia in men (Chapter 5). When 710 men 
were examined, 502 Thai and 208 European and the extent of their 
pigmentation loss, hair greyness, was related to age there was a highly 
significant positive correlation for all Thai and European groups whether or 
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not they went grey before 30 years (p<0.001). The correlation was stronger 
for the men who went grey by the age of 30; Thai men correlation coefficient 
= 0.47, European men = 0.62. This was consistent with a normal increase in 
pigment loss with age (Keogh & Walsh, 1965). Androgenetic alopecia was 
also found to correlate positively with age for all subjects, Thai and European 
whether or not they were grey before 30 years. However the positive 
correlation of androgenetic alopecia with age was stronger for the Thai men 
(p<0.001) than the European men who showed a weak positive correlation 
(p=not significant). When the grey before and after 30 years group were 
compared there was a stronger correlation between age and baldness for the 
Thai men who were grey after 30 years (p<0.001) than those who were not 
(p=0.003). All subjects, Thai and European, confirmed that androgenetic 
alopecia increased with age (Rushton et al, 1983).  
The mean ages of the grey 30 years before and after groups were not 
significantly different; Thai men (p=0.13), European men (p=0.33) allowing 
valid comparison between groups. However the mean ages comparing the 
Thai men and European men, both grey before and after 30 years were 
significantly different (p<0.001) which did not permit comparison between 
different geographical groups.   
However, when the degree of hair loss, measured by the Hamilton stage 
(Hamilton, 1975) modified by Norwood (Norwood, 1975) was examined, the 
men who went grey by the age of 30 differed in the extent of their baldness 
compared with controls. The men who were grey before 30, had a 
significantly lower mean Hamilton stage in all groups, (Thai p=0.04, 
European p=0.01). This significantly reduced hair loss in men who went grey 
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age 30 or before would not be expected if both canities and baldness were 
solely age related. Therefore, although hair greying before 30 years does not 
prevent hair loss as many of the early greying men showed androgenetic 
alopecia, canities (age 30 years of before) appears to delay the onset or 
progression of androgenetic alopecia, supporting the original hypothesis.  
 
The reactive oxygen species (R.O.S.) theory of ageing (Hayflick, 2007) 
proposes that cell function is gradually damaged or compromised by 
circulating highly reactive free radicals, byproducts of normal metabolic 
activity. Hair pigment production in the hair matrix produces considerable 
oxidative stress (Tobin & Paus, 2001) and apoptosis of the melanocyte 
population due to external oxidative stress has been shown (Arck et al, 2006; 
Wood et al, 2009). In this study loss of pigmentation synthesis or the 
absence of melanin itself possibly lowers these toxic or inhibitory factors 
allowing hair growth to proceed faster or more fully (Arck et al, 2006), despite 
the androgen drive to miniaturisation (Randall, 2007). 
Unpigmented hairs of the beard (Nagl, 1995) and scalp (Van Neste, 2004) 
are known to be thicker and to grow faster and this has been confirmed by in 
vitro studies of scalp hair follicles in organ culture (Arck et al, 2006). In the 
progression of androgenetic alopecia, hairs in the affected areas become 
smaller in diameter and grow more slowly (Van Neste, 1991) however these 
changes appears to be limited to the pigmented hairs only (Van Neste, 2004) 
and the unpigmented or grey hairs appear to grow normally and this study 
suggests that it is possible that the grey or unpigmented hairs do not suffer 
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the full miniaturisation and atrophy characteristic of androgenetic alopecia. 
Hair pigment loss may offer protection from genetic hair loss.  
In this thesis, Xiantene, a mixture of 8 traditional Chinese medecine herbs, 
when applied topically to the scalp has been shown in two separate double 
blind vehicle controlled studies to slow the rate of progression of 
androgenetic alopecia. This warrants further investigation as this may lead to 
a new topical treatment for androgenetic alopecia. It will be important to 
classify which are the active ingredients. The phenomenon of early canities 
in men was also shown to inhibit the progression of androgenetic alopecia. 
Men who experienced the appearance of grey hair before the age of 30 
years were found to be very significantly less bald than men who were grey 
after 30 years. Loss of pigment production appears to reduce the toxic or 
inhibitory factors associated with pigmentation allowing the resultant 
unpigmented hair to grow faster and thicker, counterbalancing at least in part 
the atrophy of androgenetic alopecia.  
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7. Future work 
 
The results with the use of Xiantene herbal mixture in the treatment of 
androgenetic alopecia were interesting, but not conclusive and a further 
investigation would be warranted. Firstly, it would be important to standardise 
the mixture itself, either with a standardised product of precisely known 
composition, which could be verified, from the Chinese manufacturers 
themselves or possibly by re-manufacturing the product from verifiable 
extracts here in the UK, although though this second course might result in 
the loss of some or all of the efficacy of the product. Secondly, the high drop 
out rate in subjects commencing the study would have to be addressed. This 
could be accomplished by using the facilities of a professional hair treatment 
clinic where subjects pay for their treatment having previously been advised 
of the novel nature of the application. The unit area trichogram method is 
precise and reproducible, but it is time consuming and a number of treatment 
operators would be required to perform a larger investigation.  
 
Further analysis using reduced numbers of components in the mixtures 
should clarify whether the effects are due to one component or the 
interactions of several. For example, initially dividing the components into 
two groups and assessing each separately, to see if one, both or neither had 
any effect, would determine whether all components are necessary together 
or not. If there were no effects with any, this would indicate some synergy or 
interactions between the components. If only one had an effect, this could be 
further broken down to eventually establish if the effects were due only to 
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one component. If so, this may lead to a single plant extract and the active 
ingredient similarly established. If so, this could be concentrated or even 
synthesised to remove the variations inherent in Chinese medicine 
medications. 
 
The results of the grey/MPA survey were very interesting, suggesting a 
significantly lower baldness score for men who go grey early. A repeat 
experiment to confirm and extend these findings would be appropriate. The 
single examiner system used here is fast and accurate and a larger trial in 
Thailand could be easily accomplished. Additional questions such as diet, 
lifestyle etc. could possibly be included from which further conclusions might 
be drawn. Also, the very early greying of children at puberty, which was 
recorded here is most interesting and much larger survey might enable this 
area to be investigated. With sufficient extra data it might be possible to 
propose a mechanism by which the hormonal changes at puberty are able to 
“knock out” the pigmentation process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 220
References 
Adams J.M., Cory S. The BCL-2 protein family: arbiter of cell survival. 
Science, (1998), 281, 1322-1326. 
Ahsan M.K., Urano Y., Kato S. Immunohistochemical localisation of thyroid
hormone nuclear receptors in human hair follicles and ‘in vitro’ of 
L-triodothyronine on cultured cells of hair follicles and skin. J. Med. Invest.,
(1998), 44, 179-184. 
Akiyama M., Smith L.T., Shimizu H. Changing patterns of localisation of
putative stem cells in developing human hair follicles. J. Invest. Dermatol., 
(2000), 114, 321-327. 
Alexeev V., Igoucheva O., Domashenko A., Cotsarelis G., Yoon K. Localised
in vivo genotypic and phenotypic correction of the albino mutation in skin by
RNA-DNA oligonucleotide. Nat. Biotechnol., (2000), 18, 43-47. 
Alhaidari Z., Olivry T., Ortonne J.P. Melanocytogenesis and melanogenesis:
genetic regulation and comparitive clinical diseases. Vet. Dermatol., (1999),
10, 3-16. 
Allende M.F. The enigmas of pigmentation. J. Am. Med. Assoc., (1972), 220, 
1443-1447. 
Alonso L.C., Rosenfield R. Molecular genetic and endocrine mechanisms of
hair growth. Horm. Res., (2003), 60, 1-13. 
Anderson K.M., Liao S. selective retention of dihydrotestosterone by prostatic
nuclei. Nature, (1968), 219, 277-279. 
Anderson S., Russell D.W. Structural and biochemical properties of cloned
and expressed human and rat steroid 5α-reductases. Proc. Nat. Acad. Sci. 
U.S.A., (1990), 87, 3640-3644. 
 221
Anderson S., Berman D.M., Jenkins E.P. Deletion of steroid 5α-reductase 2 
gene in male pseudohermaphroditism. Nature, (1991), 354, 159-161. 
Aoki N., Ito K., Ito M.  μ-crystallin, thyroid hormone-binding protein is 
expressed abundantly in the murine inner root sheath cells. J. Invest.
Dermatol., (2000), 115, 402-405. 
Arck P.C., Handjiski B., Hagen E., Joachim R., Klapp B.F., Paus R.
Indications for a brain-hair follicle axis (BHA): inhibition of keratinocyte
proliferation and up-regulation of keratinocyte apoptosis in telogen hair
follicles by stress and substance P. Faseb J., (2001), 15(3), 2536-2538. 
Arck P.C., Overall R., Spatz K., Liezman C., Handjiski B., Klapp B.F.
Towards a “free radial theory of greying”: melanocyte apoptosis in the ageing
human hair follicle is an indicator of oxidative stress induced tissue damage.
Faseb J., (2006), 20, E908-E920. 
Artavanis-Tsakonas S., Matsuno K., Fortini M.E. Notch signalling. Science,
(1995), 268, 225-232. 
Asada Y., Sonoda T., Ojiro M., Kurata S., Sato T., Ezaki T., Takayasu S.
5α-reductase type 2 is constitutively expressed in the dermal papilla and 
connective tissue sheath of the hair follicle in vivo but not during culture in 
vitro. J. Clin. Endocrinol. Metab., (2001), 86, 2875-2880. 
Atkins S., Smith K.G., Loescher A.R., Biossonade F.M., Ferguson M.W.,
Robinson P.P.  The effect of antibodies to TGF-beta 1 and TGF-beta 2 at a 
site of sciatic nerve repair. J. Peripher. Nerv. Syst., (2006), 11(4), 286-293. 
Babu K.G., Rasheshyam D., Lalitha N. Canities–reversal with chemotherapy. 
J. Assoc. Physicians India, (1995), 43(8), 577.  
Bahta A.W., Farjo N., Farjo B., Philpott M.P. Premature senescence of
 222
balding dermal papilla cells in vitro is associated with p16(INK4a) expression.
J. Invest. Dermatol., (2008), 128(5), 1088-1094. 
Balica R.A.M. Rainforest Remedies. Twin Lakes, Lotus Press, London,
(1993). 
Baran R., Dawber R.P.R., Levene G.M. A colour atlas of hair, scalp and
nails. Publ:  Wolfe Publishing, London, 1st Edition, (1991). 
Barch G., Gunn T., He L., Wilson B., Lu X., Gantz I., Watson S.
Neuoroendocrine regulation by the Agouti/Agrp-melanocortin system. 
Endocrinol. Res., (2000), 26(4), 571. 
Barman J.M., Astore I., Pecoraro V. The normal trichogram of the adult.
J. Invest. Dermatol., (1965), 44, 233-236. 
Barsh G., Cotsarelis G. How hair gets its pigment. Cell, (2007), 130 (5), 779-
781. 
Barth J.H., Wilkinson J.D., Dawber R.P.P. Prepurbertal hypertrichosis:
normal or abnormal? Arch. Disease Child., (1988), 63, 666-668. 
Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the concept
of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. Eur. 
Urol., (2000), 37, 367-380. 
Beas F., Vargas L., Spada R.P., Merchak N. Pseudoprecocious puberty in
infants caused by a dermal ointment containing estrogens. J. Pediatr.,
(1969), 75, 127-130. 
Bentley N.J., Eisen T., Goding C.R. Melanocyte specific expression of the 
human tyrosinase promoter: activation by the microphthalmia gene product
and role of the initiator. Mol. Cell. Biol., (1994), 14, 7996-8006. 
Bergfeld W.F. Alopecia: Histologic changes. Adv. Dermatol., (1989), 4,
 223
301-320. 
Bergfeld W.F. Androgenic alopecia, an autosomal dominant disorder. Am. J.
Med., (1995), 98, 955-985. 
Bertazzo A., Biasiolo M., Costa C., Allegri G., Elli G., Seraglia R., Traldi P.
Laser desorption ionisation mass spectrometry in the study of natural and
synthetic melanins II serotonin melanins. Biol. Mass. Spectrom., (1994), 23,
391-398. 
Bertazzo A., Costa C., Biasolo M., Allegri G., Cirricncione G., Presti G.
Determination of copper and zinc levels in human hair: influence of sex, age
and hair pigmentation. Biol. Trace Elem. Res., (1996), 52, 37-53. 
Bickenbach J.R., Chism E. Selection and extended growth of murine
epidermal stem cells in culture. Exp. Cell Res., (1998), 244, 184-195. 
Birch M.P., Messenger A.G. Genetic factors predispose to balding and non-
balding in men. Eur. J. Dermatol., (2001), 11(4), 309-314. 
Birch M.P., Messenger J.F., Messenger A.G. Hair density, hair diameter and
the prevalence of female pattern hair loss. Brit. J. Dermatol., (2001), 144,
297-304. 
Birch N.P., Lalla S.C., Messenger A.G. Female pattern hair loss. Clin. Exp. 
Dermatol., 2002, 27(5), 383-388. 
Birkbeck M.S.C, Mercer E.H. The electron microscopy of the human hair
follicle. J. Biophys. Biochem. Cytol., (1957), 3, 202-233. 
Bisset N. Medical plants in Vietnam. Publ. World Health Organisation: 
Institute of Materia Medica, Manila, (1990). 
Bjornson C.R., Rietze R.L., Reynolds B.A., Magli M.C., Vercovi A.L. Turning
brain into blood: a hematopoietic rate adopted by adult neural stem cells in 
 224
vivo. Science, (1999), 283, 534-537. 
Blanpain C., Lowry W.E., Geoghegan A., Polak L., Fuchs E. Self-renewal, 
multipotency and existence of two cell populations within an epithelial stem
cell niche. Cell, (2004), 118, 635-648.  
Blessing M., Nanney L.B., King L.E., Jones C.M., Hogan B.L.M. Transgenic 
mice as a model to study the role of TGF-β related molecules in the hair 
follicle. Genes Develop., (1993), 7, 204-215. 
Boas F., Michelson N. The greying of hair. Am. J. Phys. Anthropol., (1932),
17, 213-228. 
Bolognia J.L. and Pawalek J.M. Biology of hypopigmentation. J.Am.Acad.
Dermatol., (1988), 19, 217-255. 
Boshoff H., Myers T., Copp B., McNeil M., Wilson M., Barry C. The
transcriptional responses of mycobacterium tuberculosis to inhibitors of 
metabolism. J. Biol. Chem., (2004), 279(38), 40174-40184. 
Botchkarev V.A., Welker O.P., Albers K.M., Botchkareva N.V., Metz M.,
Lewin G.R., Bulfone-Paus S., Peters E.M., Lindner G., Paus R. A new role
for neurotrophin –3: involvement in the regulation of hair follicle regression
(catagen). Am. J. Pathol., (1998), 153, 785-799. 
Botchkarev V.A., Botchkareva N.V., Roth W., Nakamura M., Chen L.H.
Noggin is a mesenchymally derived stimulator of hair-follicle induction. 
Nature Cell Biol., (1999), 1, 157-163. 
Botchkarev V.A., Botchkareva N.V., Albers K.M., Chen L.H., Welker P., 
Paus R. A role for p75 neurotrophin receptor in the control of apoptosis-
driven hair follicle regression. Faseb. J., (2000), 14, 1931-1942. 
Botchkarev V.A., Botchakareva N.V., Huber O., Funa K., Gilchrest B.A.
 225
Modulation of BMP signalling by noggin is required for the induction of 
secondary (non-tylotrich) hair follicles. J. Invest. Dermatol., (2002), 118, 3-10.
Botchkarev V.A., Paus R. Molecular biology of hair morphogenesis:
development and cycling. J. Exp. Zoolog. B. Mol. Dev. Evol., (2003), 298(1), 
164-180. 
Botchkareva N.V., Botchkarev V.A., Chen J.H., Lindner G., Paus R. A role for
p75 neutrotrophin receptor in the control of hair follicle morphogenesis. Dev.
Biol., (1999), 216(1), 135-153. 
Bowden P.E., Hainey S.D., Parker G., Jones P.O. Characterisation and 
chromosomal localisation of human hair-specific keratin genes and 
comparitive expression during the hair growth cycle. J. Invest. Dermatol.,
(1998), 110, 158-164. 
Bradfield R.B., Bailey M.A., Margen S. Morphological changes in human hair 
roots during deprivation of protein. Science, (1967), 157, 438-439. 
Braun-Falco O., Heilgemeir G.P. The trichogram. Semin. Dermatol., (1985),
4, 40-52. 
Bruchovsky N., Wilson J.D. The conversion of testosterone to 5-alpha-
androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 
(1968), 243, 2012-2021. 
Bruckheimer E.M., Kyprianou N. Dihydrotestosterone enhances transforming
growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer 
cells. Endocrinol., (2001), 142, 2419-2426. 
Bulpitt C.J., Markowe H.L., Shipley M.J. Why do some people look older than
they should? Postgrad. Med. J., (2001), 77(911), 578-581. 
Burch P.R., Murray J.J., Jackson D. The age-prevalence of arcus senilis, 
 226
greying of hair, and baldness.Etiological considerations. J. Gerontol., 1971, 
26(3), 364-372. 
Burke B., Cunliffe W.J. Oral spirolactone therapy for female patients with
acne, hirsutism, or androgenic alopecia. Brit. J. Dermatol., (1985), 112, 124-
128. 
Burton J.L., Marshall A. Hypertrichosis due to minoxydil. Br. J. Dermatol., 
(1979), 101, 593-594. 
Canfield D. Photographic documentation of hair growth in androgenetic
alopecia. Dermatol. Clin., (1996), 14, 713-721. 
Cash T.F. The psychological effects of androgenetic alopecia in men. J. Am.
Acad. Dermatol., (1992), 26, 926-931. 
Castanet J., Ortonne J.P. Hair pigmentation. Hair and its disorders; biology
pathology and management, Eds. Camacho F., Randall V., Price V. Publ:
Martin Dunitz, London, (2000), 1st Edition, p 58. 
Chamberlain A.J., Dawber R.P.R. Methods of evaluating hair-growth 
– a review. Aust. J. Dermatol., (2003), 44(1), 10-18.  
Chang H-M., But P.H.P. Pharmacology and applications of Chinese Materia
Medica. Publ:  Singapore World Scientific, Singapore, English Ed., (1986).  
Chase H.B. Growth of hair. Physiol. Rev., (1954), 34, 113-126. 
Chase H.B., Eaton G.J. The growth of hair follicles in waves. Ann. N.Y. Acad.
Sci., (1959), 83, 365-368. 
Chedid M., Rubin J.S., Csaky M.G., Aaronson S.A. Regulation of
keratinocyte growth factor gene expression by interleukin – I. J. Biol. Chem., 
(1994), 269, 10753-10757. 
Chen W., Zouboulis C.C., Orfanos C.E. The 5 alpha-reductase system and 
 227
its inhibitors. Recent development and its perspective in treating androgen –
dependent skin disorders. Dermatol., (1996), 193, 177-184. 
Choudry R., Hodgins M.B., Van Der Kwasi T.H., Brinkmann A.O., Boersma
W.J. Localisation of androgen receptors in human skin by
immunohistochemistry: implications for the hormonal regulation of hair
growth, sebaceous glands and sweat glands. J. Endocrinol., (1992), 133,
467-475. 
Chuong C.M., Noveen A. Phenotypic determination of epithelial appendages:
genes, developmental pathways, and evolution. J. Invest. Dermatol. Symp.
Proc., (1999), 4, 307-311. 
Clem R.J., Duckett C.S. The iap genes: unique arbitrator of cell death.
Trends Cell. Biol., (1997), 7, 337-339. 
Coffey R.J. (Jnr.), Derynck R., Willcox J.N., Bringman T.S., Goustin A.S.,
Moses H.L., Pittelkow M.R. Production and auto-induction of transforming 
growth factor – α in human keratinocytes. Nature, (1987), 328, 817-820. 
Cohen S. The stimulation of epidermal proliferation by a specific protein 
(EGF). Dev. Biol., (1965), 12 (3), 394-407. 
Cohen J., Cohen P., West S.G., Aiken L.S. Applied multiple
regression/correlation analysis for the behavioural sciences. Publ. Lawrence
Erlbaum Associates, Hillsdale N.J., U.S.A., 3rd Edition, 2003. 
Combates N.J., Chuong C.M., Stenn K.S., Prouty S.M. Expression of two Ig
family adhesion molecules in the murine hair cycle DDC in the bulge epithelia 
and NCAM in the follicular papilla. J. Invest. Dermatol., (1997), 109, 672-678.
Comings D.E., Odland G.F. Partial albinism. J. Amer. Med. Assoc., (1966),
195, 519-523. 
 228
Commo S., Bernard B.A. Melanocytes through the hair cycle. Pig. Cell Res.,
(2000), 13, 253-259. 
Commo S., Gaillard O., Bernard B.A. The human hair follicle contains two
distinct K19 positive compartments in the outer root sheath; a unifying
hypothesis for stem cell reservoir. Differentiation, (2000), 66, 157-164. 
Commo S., Gaillard O., Bernard B.A. Human hair greying is linked a to a
specific depletion of hair follicle melanocytes affecting both the bulb and the
outer root sheath. Br. J. Dermatol., (2004), 150, 435-443. 
Conrad F., Ohnemus U., Bodo E., Bettermann A., Paus R. Estrogens and 
human scalp hair growth – still more questions than answers. J. Invest.
Dermatol., (2004), 122, 840-842. 
Conrad F., Paus R. Oestrogens and the hair follicle. J. Germ. Dermatol. Soc.,
(2004), 2, 412-423. 
Conway G.S., Honour J.W., Jacobs H.S. Heterogeneity of the polycystic 
ovary syndrome; clinical, endocrine and ultrasound features in 556 patients.
Clin. Endocrinol., (1989), 30, 459-470. 
Cotsarelis G., Sun T.T., Lavker R.M. Label retaining cells reside in the bulge
area of the pilosebaceous unit. Implications for follicular stem cells, hair cycle 
and skin carcinogenesis. Cell (1990), 61, 1329-1337. 
Cotsarelis G. Hair follicle development, cycling and stem cells. Prog.
Dermatol., (1998), 32, 1-8. 
Cotsarelis G., Kaur P., Dhouailly D., Hengee U., Bichenbach J. Epithelial 
stem cells in the skin, definition, markers, localisation and functions. Exp.
Dermatol., (1999), 8, 80-88. 
Cott H.B. Adaptive colouration in animals. Publ: Methuen, London, (1983).  
 229
Courtois M., Loussouarn G., Howseau S., Grollier J.F. Periodicity in the 
growth and shedding of hair. Br. J. Dermatol., (1996), 134, 47-54. 
Couse J. F., Lindzey J., Grandien K., Gustafsson J.A., Korach K.S. Tissue
distribution and quantitative analysis of oestrogen receptor-α (ER α) and 
oestrogen receptor-β (ER β) messenger ribonucleic acid in the wild-type and 
ER α-knock out mouse. Endocrinol., (1997), 138, 4613-4621. 
Cousen P., Messenger A. Female pattern hair loss in complete androgen
insensitivity syndrome. Br. J. Dermatol., (2010), 162 (5), 1135-1137. 
Craven A.J., Ormandy C.J., Robertson F.G., Wilkins R.J., Kelly P.A., Nixon
A.J., Pearson A.J. Prolactin signalling influences the timing mechanism of the
hair follicle; analysis of hair growth cycles in prolactin receptor knockout
mice. Endocrinol., (2001), 142(6), 2533-2539. 
Credille K.M., Slater M.R., Moriello K.A. The effects of thyroid hormones on
the skin of beagle dogs. J. Vet. Intern. Med., (2001), 15, 539-546. 
Croft N.J., Randall V.A. The antler of the red deer (Cervus Elaphus) an 
androgen target organ. Proceedings of the 9th annual meeting of the 
European Hair Research Society, Brussels. Belgium, 2002 in “Hair Science
and Technology” editor D. Van Neste, publ. Skinterface sprl. Belgium, 2002,
p 63. 
Dalziel K. and Marks R. Hair follicle change over histiocytomas. Am. J. 
Dermatopath., (1986), 8, 426-466. 
Danilenko D.M., Ring B.D., Yangihara D., Benson W., Wiemann B., Starnes
C.O., Pierce G.F. Keratinocyte growth factor is an important endogenous
mediator of hair follicle growth development and differentiation. Ann. J. 
Pathol., (1995), 145, 147-154. 
 230
Davies A., Bandflow C., Heumann R., Korsching S., Rohrer H., Thoenon H.
Timing and site of nerve growth factor synthesis in developing skin in relation
to innervation and expression of the receptor. Nature, (1987), 326, 353-358. 
Davies G.C., Thornton M.J., Jenner T.J., Chen Y., Hansen J.B., Carr R.D.,
Randall V.A. Novel and established potassium channel openers stimulate
hair growth in vitro: implications for their mode of action in hair follicles.
J.  Invest.  Dermatol., (2005), 24, 686-694. 
Davies P.G., Olsen M.T. (Eds) Ailments and conditions of the hair follicle and
scalp. Publ:  Harley Street Centre for Hair Research, London, (1996),
1st Edition, pages 17-23. 
Davies P.G., Randall V.A. The herbal mixture Xiantene had significant effects
on hair growth in a preliminary double-blind vehicle-controlled study in men 
with androgenetic alopecia. J. Germ. Soc. Dermatol., (2004), 6, 548. 
Dawber R.P. Integumentary association of pernicious anaemia. Brit. J. 
Dermatol., (1970), 82(3), 221-223. 
Dawber R.P. Weathering of hair in monilethrix and pili torti. Clin. Expt.
Dermatol., (1977), 2, 271-277.  
De-An G. Mapping the Herbalone. Shanghai Institute of Materia Medica,
Shanghai, China, Press Release, (2008), 13th Feb. 
Dell’Agli M., Galli G.V., Dal Cero E., Belluti F., Matera R., Zironi E., Pagliuca
G., Bosisio E. Potent inhibition of human phosphodiesterase-5 by icariin 
derivatives. J. Nat. Prod., (2008), 71(9), 1513-1517. 
Derynck R. Transforming growth factor alpha. Cell, (1988), 54 (5), 593-595. 
Deweert J., King A., Geerts M.L. Morphological changes in the proximal area
of the rat’s hair follicle during early catagen. Arch. Dermatol. Res., (1982),
 231
272, 79-82. 
D’Ischia M., Napolitano A., Prota G. Peroxidase as an altenative to 
tyrosinase in the oxidative polymerisation of 5,6-dihydroxyindoles to 
melanin(s). Biochem. Biophys., (1991), 1073, 423-430. 
Donatien P.D., Orlow S.J. Interactions of melanosomal proteins with melanin.
Eur. J. Biochem., 1995, 232, 159-164. 
Dry F.W. The coat of the mouse (mus musculus). J. Genet., (1926), 16, 32-
35. 
Du Cross D.L., Isaacs K., Moore G.P. Localisation of epidermal growth factor
immunoreactivity in sheep skin during wool follicle development. J. Invest.
Dermatol., (1992), 98, 109-115. 
Du Cross D. Fibroblast growth factor and epidermal growth factor in hair
development. J. Invest. Dermatol., (1993), 101, 106-113. 
Du Cross D.L., Isaacs K., Moore G.P. Distribution of acidic and basic
fibroblast growth factors in ovine skin during follicle morphogenesis. J. Cell 
Sci., (1993), 105, 667-674. 
Dunmu Y., Jiangbo Z. (Eds). Coloured atlas of Chinese materia medica.
Publ:  Pharmacopoeia Commission, Ministry of Health, People’s Republic of
China, Beijing, China, (1995). 
Ebling F.J., Harvey G.R. The activity of hair follicles in parabiotic rats.
J. Embryol. Exp. Morphol., (1964), 12, 425-438. 
Eccles R. The power of the placebo. Curr. Allergy Asthma Rep., (2007), 7(2),
100-104. 
Eckstein-Ludwig U., Webb R.J., Goethem I.D., East J.M., Lee A.G., Kimura 
M., O’Neill P.M., Bray A.G., Ward S.A., Krishna S. Artemisins target the
 232
SERCA of plasmodium falciparum. Nature, (2003), 424, 957-961. 
Ehrman T.M., Barlow D.J., Hylands P.J. Virtual screening of Chinese herbs
with Random Forest. J. Chem. Inf. Model., (2007), 47, 264-278. 
Eiberg H., Troelsen J., Nielsen M., Mikkelsen A., Mengel-From J., Kjaer 
K.W., Hansen L. Blue eye color in humans may be caused by a perfectly
associated founder mutation in a regulatory element located within the 
HERC2 gene, inhibiting OCA2 expression. Hum. Genet., (2008), 123(2), 177-
187. 
Ekholm E., Sondell B., Standen P., Brattsand M., Egelrud T. Expression of
stratum corneum chymotryptic enzyme in human sebaceous follicles. Acta.
Dermatol. Venereol., (1998), 78, 343-347. 
Elder J.T., Fisher G.J., Lindquist P.B., Bennett G.L., Pittelkow M.R., Coffey
R.J. (Jnr.), Ellingsworth L., Derynk R., Voorhess J.J. Overexpression of
transforming growth factor alpha in psoriatic epidermis. Science, (1989), 243,
811-814. 
Elghblawi E. Idiopathic hirsutism: excessive bodily and facial hair in women.
Br. J. Nurs., (2008), 17(3), 192-197. 
Elliott K., Stephenson T.J., Messenger A.G. Differences in hair follicle dermal
papilla volume are due to extracellular matrix volume and cell number: 
implications for the control of hair follicle size and androgen responses.
J. Invest. Dermatol., (1999), 113, 873-877. 
Ellis J.A., Harrap S.B. The genetics of androgenetic alopecia. Clin. Dermatol.,
(2001), 19, 149-154. 
Ellis J.A., Sinclair R., Harrap S.B. Androgenetic alopecia: pathogenesis and
potential for therapy. Exp. Rev. Mol. Med., (2002), 19, 1-11. 
 233
Enari M., Sakatira H., Yokoyama H., Okawa K., Iwamatsu A., Lagata S.
A caspase – activated DNAse that degrades DNA during apoptosis and its 
inhibitor ICAD. Nature, (1998), 391, 43-50. 
Epstein E. Alopecia areata, topical minoxydil and balanced reviews. J. Invest.
Dermatol., (1991), 96, 695-705. 
Estrach S., Cordes R., Hozumi K., Gossler A., Watt F.M. Role of the Notch
ligand Delta 1 in embryonic and adult mouse epidermis. J. Invest. Dermatol.,
(2008), 128(4), 825-832. 
Evan G., Littlewood T. A matter of life and death. Science, (1998), 281, 1317-
1322. 
Evans W., Trease G., Evans D. Trease and Evans Pharmacognosy. Publ:
W.B. Saunders, Edinburgh (115th ed.), (2004). 
Faloia E., Fillipponi S., Mancini V., Di Marco S., Mantero F. Effect of
finasteride in idiopathic hirsutism. J. Endocrinol. Invest., (1998), 21, 694-698. 
Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunisation via hair follicles by 
topical application of naked DNA to normal skin. Nature Biotech., (1999), 17,
870-872. 
Fang S., Anderson K.M., Liao S. Receptor proteins for androgens on the role
of specific proteins in selective retention of 17- β-hydroxy-5α-androstan-3-
one by rat ventral prostate in vivo and in vitro. J. Biol. Chem., (1969), 244, 
6584-6595. 
Fantl W.J., Johnson D.E., Williams L.T. Signalling by receptor tyrosine 
kinases. Ann. Rev. Biochem., (1993), 62, 453-481. 
Farnsworth N.R., Akerele O., Bingel A.S., Soejarto D.D., Guo Z. Medicinal 
plants in therapy. Bull. World Health Organ., (1985), 63, 965-981. 
 234
Ferning D.G., Gallagher J.T. Fibroblast growth factors and their receptors: an
information network controlling tissue growth, morphogenesis and repair.
Prog. Growth Factor Res., (1994),5 (4), 353-377. 
Ferraris C., Chevalier G., Favier B., Jahoda C.A.B., Dhouailly D. Adult
corneal epithelium basal cells possess the capacity to activate epidermal
pilosebaceous and sweat gland genetic programs in response to embryonic
dermal stimuli. Development, (2000), 127, 5487-5495. 
Ferreira E., Hulme A., McNab H., Quye A. The natural constituents of
historical textiles. Chem. Soc. Revs., (2004), 33, 329-336. 
Ferriman D., Gallwey J.P. Clinical assessment of body hair growth in women.
J. Clin. Endocrinol., (1961), 21, 1440-1447. 
Fielder J.C. Alopecia areata. Arch. Dermatol., (1992), 128, 1519-1529. 
Findlay G. An optical study of human hair colour in normal and abnormal
conditions. Brit. J.  Dermatol., (1982), 107, 517-527. 
Finch P.W., Rubin J.S., Miki T., Ron D., Aaronson S.A. Human KGF is FGF-
related with properties of a paracrine effector of epithelial cell growth.
Science, (1989), 245, 752-755. 
Finch P.W., Cunha G.R., Rubin J.S., Wong J., Ron D. Pattern of keratinocyte 
growth factor and keratinocyte growth factor receptor expression suggest a
role in mediating morphogenetic mesenchymal-epithelial interactions. 
Develop. Dynamics, (1995), 203, 223-240. 
Fisher T.W., Slominski A., Tobin D.J., Paus R. Melatonin and the hair follicle. 
J. Pineal Res., (2008), 44(1), 1-15. 
Flux J. E. C. Colour change of mountain hares (lepus timidus scotius) in 
north east Scotland. Zoology, (1970), 162, 345-358. 
 235
Foitzik K., Paus R., Doetschman T., Dotto G.P. The TGF-beta2 isoform is 
both a required and sufficient inducer of murine hair follicle morphogenesis.
Dev. Biol., (1999), 212, 278-289. 
Foitzik K., Lindner G., Műller-Rőver S., Maurer M., Botchkareva N.M., 
Botchkarev V.A., Handjiski B., Metz M., Hibino T., Soma T., Dott G.P., Paus
R. Control of murine hair follicle regression (catagen) by TFG- βI in vivo. 
Faseb J., (2000), 14(5), 752-760. 
Foitzik K., Krause K., Conrad F., Nakamura M., Funk W., Paus R. Human
hair scalp follicles are both a target and source of prolcatin, which serves as
an autocrine and/or paracrine promoter of apoptosis-driven hair follicle 
regression. Am. J. Pathol., (2006), 168, 748-756. 
Forslind B., Swanbeck G. Keratin formation in the hair follicle, an ultrasound
investigation. Expt. Cell Res., (1966), 43, 191-209. 
Forslind B., Li H.K., Malinquist K.G., Wiegleb D. Elemental content of anagen
hairs in a normal caucasian population studies with proton induced X-ray 
emission (Pixe). Scan. Elect. Micro., (1986), 1, 237-241. 
Forstrom L. The influence of sex hormones on acne. Acta Derm. Venereol., 
(1980), 89, 27-31. 
Friedmann P.S. Alopecia areata and autoimmunity. Brit. J. Dermatol., (1981), 
105, 153-157. 
Fuchs E., Segre J.A. Stem cells; a new lease of life. Cell, (2000), 100, 143-
155. 
Fuchs E., Raghavan S. Getting under the skin of dermal morphogenesis.
Nat. Rev. Genet., (2002), 3, 199-209. 
Fuchs E., Tumbar T., Guasch G. Socialising with the neighbours: stem cells 
 236
and their niche. Cell, (2004), 116, 769-778. 
Fuchs E. Stem cells rising to the surface. J. Cell. Biol., (2008), 180(2), 273-
284. 
Fuller B.B., Spaulding D.T., Smith D.R. Regulation of the catalytic activity of
pre-existing tyrosinase in black and caucasian human melanocyte cell
cultures. Exp. Cell Res., (2001), 262, 197-208. 
Ganss R., Schultz G., Beerman F. The mouse tyrosinase gene; promotes
modulation by positive and negative regulatory elements. J. Biol. Chem.,
(1994), 269, 29808-29816. 
Gebbie F.E., Forsyth I.A., Arendt J. Effects of maintaining solstice light and
temperature on reproductive activity, coat growth, plasma prolactin and
melatonin in goats. J. Reprod. Fertil., (1999), 116, 25-33. 
Gebhart W., Schmidt J.N., Schemper M., Spona J., Kaposa H., Zazgornik J.
Cyclosporin – A induced hair growth in human renal allograft recipients and
alopecia areata. Arch. Dermatol. Res., (1986), 278(3), 238-240. 
Georgala G., Papasotirion V., Stanropoulos P. Serum testosterone and sex 
hormone binding levels in women with androgenic alopecia. ACTA Dermatol
Venereol (Stockh.), (1986), 66, 532-534. 
Gharzi A., Reynolds A.J., Jahoda C.A. Plasticity of hair follicle dermal cells in
wound healing and induction. Exp. Dermatol., (2003), 12, 126-136. 
Ghazizadeh S. Taichman L.B. Multiple classes of stem cells in cutaneous
epithelium: a lineage analysis of adult mouse skin. Embro. J., (2001), 20,
1215-1222. 
Gilkes J.J., Shavrill D.E., Wells R.S. The premature ageing syndromes report
of 8 cases and description of a new entity named metageri. Brit. J. Dermatol.,
 237
(1974), 91, 243-262. 
Girman C.J., Rhodes T., Lilly F.R.W., Guo S.S., Siervogel R.M., Patrick D.L.,
Chumleea W.C. Effects of self-perceived hair loss in a community sample of 
men. Dermatol., (1998), 197, 223-229. 
Glickman S.P., Rosenfield R.L., Bergenstal R.M., Helke J. Multiple 
androgenic abnormalities, including elevated free testosterone, in
hyperprolactinemic women. J. Clin. Endocrinol. Metab., (1982), 55, 251-257.
Gnoske T.P., Celesia G.G., Kerbis Peterhans J.C. Dissociation between
mane development and sexual maturity in lions (panthera leo): solution to the 
Tsavo riddle. J. Zool., (2006), 270(4), 551-560. 
Gohla S.H., Haubeck H.D., Schrum S., Soltau H., Neth R.D. Activation of
CD4-positive T cells by polysaccharide fractions isolated from the
Cupressaceae Thuja occidentalis L. (Arborvitae). Haematol. Blood Transfus., 
(1989), 32, 268-272.   
Goodhart C.B. The evolutionary significance of human hair patterns and skin
colouring. Adv. Sci., (1960), 17, 53-58. 
Granholm N.M., Japs R.A., Kappenman K.E. Differentiation of hair bulb
pigment cell melanosomes in compound agouti and albino locus mouse
mutants. Pigment Cell Res., (1990), 3, 16-27.  
Green M.R., Couchman J.R. Distribution of epidermal growth factor receptors 
in rat tissue during embryonic skin development, hair formation and the adult
hair growth cycle. J. Invest. Dermatol., (1984), 83, 118-123. 
Guarrera M., Rebora A. Anagen hairs may fail to replace telogen hairs in
early androgenic female alopecia. Dermatol., (1996), 192(1), 28-31. 
Gumport R. I., Stryer L. Student companion to accompany biochemistry.
 238
Publ; W.H. Freeman, New York. (5th ed.), (2002), p 77-83. 
Habib F.K., Ross M., Ho C.K., Lyons V., Chapman K. Serenoa repens
(Permixon) inhibits the 5alpha-reductase activity of human prostate cancer 
cell lines without interfering with PSA expression. Int. J. Cancer, (2005),
114(2), 190-194. 
Hamada K., Thornton M.J., Liang I., Messenger A.G., Randall V.A. The
metabolism of testosterone by dermal papilla cells cultured from pubic and
axillary hair follicles concurs with hair growth in 5α-reductase deficiency. 
J. Invest. Dermatol., (1996), 106, 1017-1022. 
Hamada K., Hideyo U., Ikemoto T., Nishio H., Kuwahara H., Watanbe Y.
Eugenyl glucoside as an active ingredient for hair re-growth agent: release of 
eugenol from eugenyl glucoside on human scalp and 5α-reductase inhibitory 
effect. J. Int. Soc. Cosmet. Chem., (2001), 4, 83-87. 
Hamada K., Randall V.A. Inhibitory autocrine factors produced by the 
mesenchyme-derived hair follicle dermal papilla may be a key to male pattern
baldness. Brit. J. Dermatol., (2006), 154, 609-618. 
Hamilton J.B. Male hormone stimulation is a pre-requisite and an incitant in 
common baldness. Am. J. Anat., (1942), 71, 451-480. 
Hamilton J.B. A secondary sexual characteristic that develops in men, but not
in women upon ageing of an organ present in both sexes. Anat. Record,
(1946), 94, 466-467. 
Hamilton J.B. Patterned loss of hair in man: types and incidence. Ann. N.Y. 
Acad.  Sci., (1951), 53, 708-728. 
Hamilton J.B. Effect of castration in adolescent and young adult males upon
further changes in the proportion of bare and hairy scalp. J. Clin. Endocrinol.
 239
Metab., (1960), 20, 1309-1318. 
Han S.T. Medicinal plants in China. Publ: World Health Organisation,
Regional office for the Western Pacific, Manila, (1989). 
Hansen L.A., Alexander N., Hogan M.E., Sundberg J.P., Dlugosz A.,
Threadgill D.W., Magnuson T., Yuspa S.H. Genetically null mice reveal a
central role for epidermal growth factor receptor in the differentiation of the
hair follicle and normal hair development. Am. J. Pathol., (1997), 150, 1959-
1975. 
Hardy M.H. The secret life of the hair follicle. Trends Genet., (1992), 8,
55-61. 
Harris G., Azzolina B., Baginsky W., Cimis G., Rassmusson G. H., Tolman R.
L., Raetz C. R., Ellsworth K. Identification and selective inhibition of an iso
enzyme of steroid 5α-reductase in human scalp. Proc. Nat. Acad. Sci.
U.S.A., (1992), 89, 10787-10791. 
Hasse E., Ito S., Wakamatsu K. Influence of sex, castration and androgens
on the eumelanin and pheomelanin contents of different feathers in wild
mallards. Pig. Cell Res., (1995), 8, 164-170. 
Hayflick L. Biological ageing is no longer an unsolved problem. Ann. N.Y.
Acad. Sci., (2007), 1100, 1-13. 
Headington J.T. Transverse microscopic anatomy of the human scalp, a
basis for a morphometric approach to disorders of the hair follicle. Arch.
Dermatol., (1984), 120, 449-456. 
Hearing V.J., Tsukamoto K. Enzymatic control of pigmentation in mammals. 
Faseb J., (1991), 5, 2902-2909. 
Hearing V.J. Biochemical control of melanogenesis and melanosomal
 240
organisation. J. Invest. Dermatol. Symp. Proc., (1999), 4, 24-28. 
Hébert J. M., Rosenquist T., Gőtz J., Martin G. R. FGF5 as a regulator of hair
growth cycle: evidence from targeted and spontaneous mutations. Cell,
(1994), 78, 1017-1025. 
Hemesath T.J., Price E.R., Takemoto C., Badalian T., Fisher D.E. MAP
kinase links the transcription factor Microphthalmia to c-kit signalling in 
melanocytes. Nature, (1998), 391, 298-301. 
Hibberts N.A., Messenger A.G., Randall V.A. Dermal papilla cells derived
from beard hair follicles secrete more stem cell factor (SCF) in culture than
scalp cells or dermal fibroblasts. Biochem. Biophys. Res. Commun., (1996),
222, 401-405. 
Hibberts N.A., Howell A.E., Randall V.A. Dermal papilla cells from human
balding scalp hair follicles contain higher levels of androgen receptors than
those from non-balding scalp. J. Endocrinol., (1998), 156, 59-65. 
Hibino T., Nishiyama T. Role of the TGF-β 2 in the human hair cycle. 
J. Dermatol. Sci., (2004), 35, 9-18.   
Hillmer A.M., Hanneken S., Ritzmann S., Becker T., Freudenberg J.,
Brockschmidt F.F., Flaquer A., Freudenberg-Hua Y., Jamra R.A., Metzen C., 
Heyn U., Schweiger N., Betz R.C., Blaumaister B., Hampe J., Schreiber S.,
Schulze T.G., Hennies H.C., Schumacher J., Propping P., Ruzicka T., Cichon
S., Wienker T.F., Kruse R., Nothen M.M. Genetic variation in the human
androgen receptor gene is the major determinant of common early-onset 
androgenetic alopecia. Am. J. Hum. Genet., (2005), 77, 140-148. 
Hirobe T. Structure and function of melanocytes: microscopic morphology
and cell biology of mouse melanocytes in the epidermis and hair follicle.
 241
Histol. Histopathol., (1995), 10, 223-237. 
Hirobe T. Hydrocortisone is involved in regulating the proliferation and
differentiation of mouse epidermal melanoblasts in serum-free culture in the 
presence of keratinocytes. Eur. J. Cell Biol., (1996), 71(4), 387-394. 
Hockenberg D.M., Oltvai Z.N., Yin X.M., Milliman C.L., Korsmeyer S.I. BCL-2 
functions in an antioxidant pathway to prevent apoptosis. Cell, (1993), 75,
241-251. 
Hoffman R., Eicheler W., Wenzel E., Happle R. Interleukin – I beta-induced 
inhibition of hair growth in vitro is mediated by cyclic AMP. J. Invest. 
Dermatol., (1997), 108, 40-42. 
Hoffman R. Trichoscan: combining epiluminescence microscopy with digital
image analysis for the measurement of hair growth in vivo. Eur. J. Dermatol., 
(2001), 11, 362-368. 
Hoffman R. Aromatase and oxidative 3α-hydroxysteroid dehydrogenases are 
present in human hair follicles and regulate intrafollicular DHT levels.
Proceedings of the 9th annual meeting of the European Hair Research
Society, Brussels. Belgium, 2002 in “Hair Science and Technology” editor 
D. Van Neste, publ. Skinterface sprl. Belgium, 2002, p 93. 
Hoffman R.M. Gene targeting of hair follicles. Proceedings of the 9th annual 
meeting of the European Hair Research Society, Brussels. Belgium, 2002 in
“Hair Science and Technology” editor D. Van Neste, publ. Skinterface sprl. 
Belgium, 2002, p 363. 
Hoffman R.M. The hair follicle and its stem cells as drug delivery targets.
Expert Opin. Drug Deliv., (2006), 3(3), 437-443. 
Holbrook K.A. The appearance, density and distribution of melanocytes in 
 242
human embryonic and fetal skin revealed by the anti-melanoma (monoclonal) 
antibody HMB-45. Anyst. Embryol., (1989), 180, 443-455. 
Holbrook K.A., Minami S.I. Hair follicle embryogenesis in the human:
characterisation of events in vivo and in vitro. Anals. N.Y. Acad. Sciences, 
(1991), 642, 167-196. 
Hu Z.B., Yang G. S., Li M., Miyamoto N., Minden M.B., McCulloch E.A.
Mechanism of cytosine arabinoside toxicity to the blast cells of acute
leukemia: involvement of free radicals. Leukemia, (1995), 9(5), 789-798. 
Huang W., Zhang J., Moore D. A traditional herbal medicine enhances
bilirubin clearance by activating the nuclear receptor CAR. J. Clin. Invest.,
(2004), 113, 137-143. 
Huelsken J., Vogel R., Erdmann B., Cotsarelis G., Birchmeier W. β-catenin 
controls hair follicle morphogenesis and stem cell differentiation in the skin.
Cell, (2001), 105(4), 533-545. 
Hunt J., Rose J. Effects of prolactin on underhair follicle development in mink
(Mustela vison) during the winter fur growth cycle. Proceedings of the
9th annual meeting of the European Hair Research Society, Brussels.
Belgium, 2002 in “Hair Science and Technology” editor D. Van Neste, publ.
Skinterface sprl. Belgium, 2002, p 37. 
Hutchinson P.E., Thompson J.R. The cross sectional size and shape of
human terminal scalp hair. Br. J. Dermatol., (1997), 136, 159-165. 
Ibrahim L., Wright E.A. A quantitative study of hair growth using mouse and
rat vibrissal follicles. Dermal papilla volume determines hair volume.
J. Embryol. Exp. Morphol., (1982), 72, 209-224. 
Ihm C., Hong S. Hair follicles of anterior scalp are more vulnerable than
 243
posterior scalp in telogen effluvium. Proceedings of the 9th annual meeting of 
the European Hair Research Society, Brussels. Belgium, 2002 in “Hair
Science and Technology” editor D. Van Neste, publ. Skinterface sprl.
Belgium, 2002, p 203.  
Imperato-McGinley J., Guerrero L., Gautier T., Peterson P.E. Steroid 5α-
reductase deficiency in man: an inherited form of male
pseudohermaproditism. Science, (1974), 186, 1213-1215. 
Ingle D.J., Baker B.L. The inhibition of hair growth by estrogens as related to
adrenal cortical function in the male rat. Endocrinol., (1951), 48, 764-771. 
Inui S., Fukuzato Y., Nakajima T., Yoshikawa K., Itami S. Androgen-inducible 
TGF- β1 from balding dermal papilla cells inhibits epithelial cell growth: a clue
to understanding paradoxical effects of androgen on human hair growth.
FASEB J., (2002), 16, 1967-1969. 
Inui S., Fukuzato Y., Nakajima T., Yoshikawa K., Itami S. Identification of
androgen inducible TGF-beta 1 derived from dermal papilla cells as a key
mediator of androgenetic alopecia. J. Invest. Dermatol. Symp. Proc., (2003),
8, 69-71. 
Iozumi K., Hoganson C.E., Penella R., Everett M.A., Fuller B.B. Role of
tyrosinase as the determinant of pigmentation on cultured human 
melanocytes. J. Dermatol., (1993), 100, 806-811. 
Ishiguro K., Oku H., Kato T. Testosterone 5alpha-reductase inhibitor 
bisnapthoquinone derivative from Impatiens balsamina. Phytother. Res., 
(2000), 14, 544-546. 
Ishino A., Uzuka M., Tsuji Y., Nakanishi J., Hanzawa N., Imamura S.
Progressive decrease in hair diameter in Japanese with male pattern
 244
baldness. J. Dermatol., (1997), 24, 758-764. 
Itami S., Kurata S., Takayasu S. 5 α-reductase activity in cultured human 
dermal papilla cells from beard compared with reticular dermal fibroblasts.
J. Invest. Dermatol., (1990), 94, 150-152. 
Itami S., Kurata S., Takayasu S. Androgen induction of follicular epithelial cell 
growth is mediated via IGF-I from dermal papilla cells. 
Bio.Chem.Bio.Phys.Res. Commun., (1995), 212, 988-994. 
Itami S., Inui S. Role of androgen in mesenchymal epithelial interactions in
human hair follicle. J. Invest. Dermatol., (2005), 10, 209-211. 
Ito M., Sato Y. Dynamic ultrastructural changes of the connective tissue
sheath of human hair follicles during hair cycle. Arch. Dermatol. Res., (1990),
282, 434-441. 
Ito M., Yang Z., Andl T., Cui C., Kim N., Millar S. E., Cotsarelis G. Wnt –
dependent de novo hair follicle regeneration in adult mouse skin after
wounding. Nature, (2007), 447(7142), 316-320. 
Jablonski N.G., Chaplin G. The evolution of human skin coloration. J. Human
Evol., (2000), 39, 57-106. 
Jackson D., Church R.E., Ebling F.J. Hair diameter in female baldness. Brit. 
J. Dermatol., (1972), 87, 361-367. 
Jackson I.J. Molecular and developmental genetics of mouse coat colour.
Ann. Rev. Genet., (1994), 28, 189-217. 
Jahoda C.A.B., Horne K.A. and Oliver R.F. Induction of hair growth by 
implantation of cultured dermal papilla cells. Nature, (1984), 311, 560-562. 
Jahoda C.A.B. Induction of follicle formation and hair growth by vibrissa
dermal papilla implanted into rat ear wounds: vibrissa type fibres are
 245
specified. Development, (1992), 115, 1103-1109. 
Jahoda C.A.B., Reynolds A.J. Hair follicle dermal sheath cells: unsung
participants in wound healing. Lancet, (2001), 358, 1445-1448. 
Jahoda C.A.B. All hair growth controlled by dermal papilla. J. Cell Science,
(2002), 115, 3967-3974. 
Jarrett A. (Ed.) The hair follicle, Publ: Academic Press, London, (1977). 
Jaworsky C., Kligman A.M., Murphy G.F. Characterisation of inflammatory
infiltrates in male pattern alopecia; implications for pathogenesis.
J. Dermatol., (1992), 127, 239-246. 
Jeanmaire C., Danoux L., Gillon V., Moser P., Pauly G. Glycation during
human dermal intrinsic and actinic ageing an in vivo and in vitro model study. 
Br. J. Dermatol., (2001), 145(1), 8-10. 
Jenkins J.S., Ash S. The metabolism of testosterone by human skin in 
disorders of hair growth. J. Endocrinol, (1973), 59(2), 345-51. 
Jih D., Lyle S., Elenitas R., Elder D., Cotsarelis G. Cytokeratin 15 expression
in trichoepitheliomas and a subset of basal cell carcinomas suggest they
originate from hair follicle stem cells. J. Cutan. Pathol., (1999), 244, 618-622.
Jimbow K., Alena F., Dixon W., Hara H. Regulation factors of pheo and
eumelanogenic compartments. Pigment Cell Res., (1992), 2, 36-42. 
Jindo T., Tsuboi R., Imai R., Takamori K., Rubin J. S., Ogawa H. Hepatocyte 
growth factor / scatter factor stimulates hair growth of mouse vibrassae in
organ culture. J. Invest. Dermatol., (1994), 103, 306-309. 
Johnson D.J., Sikorski J. Proceedings of the 3rd International Wool Textile 
Research Conference, Paris, (1965), 53. 
Johnson R., Jackson I.J. Light is a dominant mouse mutation resulting in
 246
premature cell death. Nat. Genet., (1992), 1, 226-229. 
Jones C.M., Lyons K.M., Hogan B.L.M. Involvement of bone morphogenis
protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the 
mouse. Development, (1991), 111(2), 531-542. 
Kahari U.M., Saarialho-Kere U. Matrix metallioproteinases in skin. Exp.
Dermatol., (1997), 6, 199-213. 
Kamimura J., Lee D., Baden H.P., Brissette J., Dotto G.P. Primary mouse
keratinocyte cultures contain hair follicle progenitor cells with multiple
differentiation potential. J. Invest. Dermatol., (1997), 109, 534-540. 
Kamimura A., Takahashi T. Procyanidin B-2 extracted from apples promotes 
hair growth: A laboratory study. Brit. J. Dermatol., (2002), 146, 41-51. 
Kappor L.D. CRC handbook of ayurvedic medicinal plants, Publ: CRC Press,
Boca Raton, (1990). 
Karlsson L., Bondjers C., Betsholtz C. Roles for PDGF-A and sonic 
hedgehog in development of mesenchymal, components of the hair follicle.
Development, (1999), 126, 2611-2621.  
Katsuoka K., Schell K., Wessel B., Homstein O.P. Effects of epidermal
growth factor, fibroblast growth factor minoxydil and hydrocortisone on
growth kinetics in human hair bulb papilla cells and root sheath fibroblasts
cultured in vitro. Arch. Dermatol. Res., (1987), 279 (4), 247-250. 
Kaufman K.D. Androgen metabolism as it affects hair growth in androgenetic
alopecia. Dermatol. Clin., (1996), 14(4), 697-711. 
Kaufman K. D. 5 alpha – reductase inhibitors. Dermatologic therapy, (1998), 
8, 42-48. 
Kaufman K.D., Olsen E.A., Whiting D., Savin R., DeVillez R., Bergfeld W.,
 247
Price V.H., Van Neste D., Roberts J.L., Hordinsky M., Shapiro J., Binkowitz
B., Gormley G.J. Finasteride in the treatment of men with androgenetic
alopecia. Finasteride Male Pattern Hair Loss Study Group. J. Am. Acad.
Dermatol., (1998), 39, 578-589. 
Kaufman K.D. Long term (5 years) multinational experience with finasteride
1 mg in the treatment of men with androgenetic alopecia. Eur. J. Dermatol.,
(2002), 12, 38-49. 
Kaufman K.D., Girman C.J., Round E.M., Johnson-Levonas A.O., Shah A.K., 
Rotonda J. Progression of hair loss in men with androgenetic alopecia (male
pattern hair loss): long-term (5 years) controlled observational data in
placebo-treated patients. Eur. J. Dermatol., (2008), 18(4), 407-411. 
Keogh E.V., Walsh R.J. Rate of greying of human hairs. Nature, (1965), 207,
877-878. 
Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N.
Inhibition of vascular endothelial growth factor – induced angiogenesis 
suppresses tumor growth in vivo. Nature, (1993), 362, 841-844. 
Kim Y.A., Xiao D., Xiao H., Powolny A.A., Lew K.L., Reilly M.L., Zeng Y.,
Wang Z., Singh S.V. Mitochondria-mediated apoptosis by diallyl trisulfide in 
human prostate cancer cells is associated with generation of reactive oxygen
species and regulated by Bax/Bak. Mol. Cancer Ther., (2007), 6(5), 1599-
1609.  
Kimble J., Simpson P. The LIN-12 / Notch signalling pathway and its 
regulation. Ann. Rev. Cell Dev. Biol., (1997), 13, 333-361. 
Kirschner M.A. Hirsutism & virilism in women. Spec. Top. Endocrinol. Metab.,
(1984), 6, 55-93. 
 248
Klagsbrun M., Edelman E. Biological and biochemical properties of fibroblast
growth factors. Implications for the pathogenesis of arteriosclerosis.
Arteriosclerosis, (1989), 9 (3), 269-278. 
Klemp P., Peters K., Hansted B. Subcutaneous blood flow in early male
pattern baldness. J. Invest. Dermatol., (1989), 92(5), 725-726. 
Kligman A.M. The human hair cycle. J. Invest. Dermatol., (1959), 33, 307-
316. 
Kligman A.M. Pathologic dynamics of human hair loss. I. telogen effluvium.
Arch. Dermatol., (1961), 83, 175-198. 
Kligman A.M. The comparative histopathology of male-pattern baldness and 
senescent baldness. Clin. Dermatol., (1988), 6, 108-118. 
Kobayashi K., Rochat A., Barrandon Y. Segregation of keratinocyte colony-
forming cells in the bulge of the rat vibrissa. Proc. Natl. Acad. Sci. U.S.A.,
(1993), 90(15), 7391-7395. 
Koch P.J., Mahoney M.G., Cotsarelis G., Rothenberger K., Lauker R.M.
Desmoglein 3 anchors telogen hair in the follicle. J. Cell Sci., (1998), 111,
2529-2537.  
Koloda T.M., Garlick J.A., Taickman L.B. Evidence for keratinocyte stem cells
in vitro: long-term engraftment and persistence of transgene expression from
retrovirus – transduced keratinocytes. Proc. Nat. Acad. Sci., (1998), 95,
4356-4361. 
Kondo S., Hozumi Y., Aso K. Organ culture of human scalp hair follicles:
effect of testosterone and oestrogen on hair growth. Arch. Dermatol. Res.,
(1990), 828, 442-445. 
Kong Y.H., Jo Y.O., Cho C.W., Son D., Park S., Rho J., Choi S.Y. Inhibitory
 249
effects of cinnamic acid on melanin biosynthesis in skin. Biol. Pharm. Bull.,
(2008), 31(5), 946-948. 
Kopan R., Weintraub H. Mouse notch: expression in hair follicles correlates
with cell fate determination. J. Cell Biol., (1993), 121, 631-641. 
Korner A., Pawalek J. Activation of melanoma tyrosinase by a cyclic amp-
dependent protein kinase in a cell-free system. Nature, (1977), 267, 444-447.
Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell 
death. Cancer Res., (1999), 59 (7), 1693-1700. 
Koshi E.B., Short C.A. Placebo theory and its implications for research and
clinical practice: a review of the recent literature. Pain Pract., (2007), 7 (1),
4-20. 
Kukita A., Fitzpatrick T.B. The demonstration of tyrosinase in melanocytes of
the human hair matrix by autoradiography. Science, (1955), 121, 893-894. 
Kulbacka J., Saczko J., Chwilkowska A. Oxidative stress in cells damage
processes. Pol. Merkur Lekarski, (2009), 27 (157), 44-47. 
Kűster W., Happle R. The inheritance of common baldness: Two B or not two
B? J. Am. Acad. Dermatol., (1984), 11, 921-926. 
Kuttenn F., Mowszowicz I., Wright F., Baudot N., Jaffiol C., Robin M.,
Mauvais-Jarvis P. Male pseudohermaphroditism: a comparative study of one 
patient with 5∝-reductase deficiency and three patients with complete form of
testicular feminisation. J. Clin. Endocrinol.  Metab., (1979), 49, 861-865. 
Lachgar S., Charveron M., Ceruti I.  Distribution of VEGF mRNA in different
hair follicle stages by fluorescence in situ hybridisation combined with 
confocal laser microscopy. Eur. J. Dermatol., (1995), 5, 436. 
Lachgar S., Moukadiri H., Jonca F., Charveron M., Bouhaddioui N., Gall Y.,
 250
Bonafe J.L., Plouet J. Vascular endothelial growth factor is an autocrine 
growth factor for hair dermal papilla cells. J. Invest. Dermatol., (1996), 106,
17-23. 
Lahav R., Dupin E., Lecoin L., Glavieux C., Champeval D., Ziller C., Le
Douarin N.M. Endothelin selectively promotes survival and proliferation of
neural crest-derived glial and melanocytic precursors in vitro. Proc. Natl. 
Acad. Sci. U.S.A., (1998), 95, 14214-14219. 
Lambert J., Westbroek W., Naeyaert J.M. Melanosome dynamics in
epidermal melanocytes: are data applicable to follicular melanocytes?
Proceedings of the 9th annual meeting of the European Hair Research
Society, Brussels. Belgium, 2002 in “Hair Science and Technology” editor
D. Van Neste, publ. Skinterface sprl. Belgium, 2002, p 143. 
Lane E.B., Wilson C.A., Hughes B.R., Leigh I.M. Stem cells in hair follicles. 
Cytoskeletal studies. Ann. N.Y. Acad. Sci., (1991), 642, 197-213. 
Lavker R.M., Risse B., Brown H., Ginsburg D., Pearson J., Baker M.S.,
Jensen P.J. Localisation of plasminogen activator inhibitor type 2 (PAI-2) in 
hair and nails: implications for terminal differentiation. J. Invest. Dermatol., 
(1998), 110, 917-922. 
Leanza S.M., Burk R.D., Rohan T.E. Whole genome amplification of DNA
extracted from hair samples: potential for use in molecular epidemiologic
studies. Cancer Detect. Prev., (2007), 31(6), 480-488. 
LeBrun D.P., Warneke R.A., Cleary M.L. Expression of BCL-2 in fetal tissue 
suggests a role in morphogenesis. Am. J. Pathol., (1993), 142, 743-753. 
Le Douarin N.M., Ziller C., Couly G.F. Patterning of neural crest derivatives in
the avian ambryo: in vivo and in vitro studies. Dev. Biol., (1993), 159(1), 
 251
24-49. 
Lee C.W., Lee S.H., Lee J.W., Ban J.O., Lee S.Y., Yoo H.S., Jung J.K.,
Moon D.C, Oh K.W., Hong J.T. 2-hydroxycinnamaldehyde inhibits SW620 
colon cancer cell growth through AP-1 inactivation. J. Pharmacol. Sci., 
(2007), 104(1), 19-28. 
Lee H.S. Inhibitory activity of Cinnamomum cassia bark-derived component 
against rat lens aldose reductase. J. Pharm. Pharm. Sci., (2002), 5(3),
226-230. 
Leroy T., Van Neste D. Contrast enhanced phototrichogram pinpoints scalp 
hair changes in androgen sensitive areas of male androgenetic alopecia.
Proceedings of the 9th annual meeting of the European Hair Research
Society, Brussels. Belgium, 2002 in “Hair Science and Technology” editor D.
Van Neste, publ. Skinterface sprl. Belgium, 2002, p 243. 
Lemmon M.A., Schlessinger J. Regulation of signal transduction and signal
diversity by receptor oligomerisation. Trends Biochem. Sci., (1994), 19 (11),
459-463. 
Li L.F., Fielder V.C., Kumar R. Induction of hair growth by skin irritants and its 
relation to skin protein kinase C isoforms. Br. J. Dermatol., (1999), 140,
616-623. 
Li R.W., David-Lin G., Myers S.P., Leach D.N. Anti-inflammatory activity of 
Chinese medicinal vine plants. J. Ethnopharmacol, (2003), 85, 61-67. 
Liang T., Pasmussen G.H., Brooks J.R. Biochemical and biological studies
with 4-aza-steroidal 5α reductase inhibitors. J. Steroid Biochem, (1983), 19,
385-390. 
Liang T., Liao S. Inhibition of steroid 5alpha-reductase by specific aliphatic 
 252
unsaturated fatty acids. Biochem. J., (1992), 285, 557-562. 
Liang X., Feng J., Jin Y., Guo Z., Xu Q. Prospects of the development of
quality control technologies for traditional Chinese medicine. Se Pu, (2008),
26(2), 130-135. 
Liao S., Kokontis J. Hiipakka R.A. Androgen receptors: structures, mutations, 
antibodies and cellular dynamics. J. Steroid. Biochem., (1989), 34, 41-51. 
Liao S., Hiipakka R.A. Selective inhibition of steroid 5alpha-reductase 
isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. 
Biochem. Biophys. Res. Commun., (1995), 214, 833-838. 
Lin C.C., Wu S.J., Chang C.H., Ng L.T. Antioxidant activity of cinnamomum 
cassia. Phytother. Res., (2003), 17(7), 726-730. 
Lin M.H., Leimeister C., Gessler M., Kopan R. Activation of notch pathway in
the hair cortex leads to aberrant differentiation of the adjacent hair shaft
layers. Development, (2000), 127, 2421-2432.  
Lincoln G.A., Richardson M. Photo-neuroendocrine control of seasonal cycle 
in body weight, pelage growth and reproduction: lessons from the HPD 
sheep model. Comp. Biochem. Physiol. Part C., (1998), 119, 283-294. 
Lindner G., Botchkarev V.A., Botchkareva N.V., Ling G., Van der Veen C.,
Paus R. Analysis of apoptosis during murine hair follicle regression
(catagen). Am. J. Pathol., (1997), 151, 1601-1617. 
Lindner G., Menrad A., Gharadi E., Mercino G., Welkes P., Handjiski B.,
Roloff B., Paus R. Involvement of hepatocyte growth factor / scatter factor
and MCF receptor signalling in hair follicle morphogenesis and cycling.
Faseb J., (2000), 14, 319-332. 
Link R.E., Paus R., Stenn K.S., Kulinska E., Moellman G. Epithelial growth by
 253
rat vibrissae follicles in vitro requires mesenchymal contact via native 
extracellular matrix. J. Invest. Dermatol., (1990), 95, 202-207. 
Ling J.K. Pelage and moulting in wild mammals with special reference to 
aquatic forms. Q. Rev. Biol., (1970), 45(1), 16-54. 
Liu X., Alexander V., Vijayachandra K., Bhogte E., Diamond I., Glick A.
Conditional epidermal expression of TGF- β1 blocks neonatal lethality, but 
causes a reversible hyperplasia and alopecia. Proc. Natl. Acad. Sci. U.S.A.,
(2001), 98, 9139-9144. 
Lu Q., Chow S.C., Tse S.K. Assessing the consistency of traditional Chinese
medicine with multiple correlative active components. J. Biopharm. Stat.,
(2007), 17(5), 791-808. 
Ludwig E. Classification of the types of androgenic alopecia arising in the
female sex. Br. J. Dermatol., (1977), 97, 249-256. 
Luetteke N.C., Qiu T.H., Peiffer R.L., Oliver P., Smithies O., Lee D.C. TGF –
alpha deficiency results in hair follicle and eye abnormalities in targeted and
waved–1 mice. Cell, (1993), 73, 263-278. 
Lyle S., Christofidou-Slomidou M., Liu Y., Elder D., Albelda S., Cotsarelis G.
The C8/144B monoclonal antibody recognises cytokeratin 15 and defines the
location of human hair follicle stem cells. J. Cell., Sci., (1998), 111, 3179-
3188. 
Lynfield Y.L. The effect of pregnancy on the human hair cycle. J. Invest. 
Dermatol., (1960), 35, 323-327. 
Lyons K.M., Pelton R.W., Hogan B.L.M. Organogenesis and pattern
formation in the mouse: RNA distribution patterns suggest a role for bone
morphogenetic protein-2A (BMP-2A). Development, (1990), 109, 833-844. 
 254
Maguire H.C., Kligman A.M. Common baldness in women. Geriatrics, (1963),
18, 329-334. 
Magerl M., Tobin D., Műller-Rőver S., Lindner G., McKay I., Paus R. Patterns
of proliferation and apoptosis during murine hair follicle morphogenesis.
J. Invest. Dermatol., (2001), 116(6), 947-955. 
Mainwaring W.I. A soluble androgen receptor in the cytoplasm of rat prostate.
J. Endocrinol., (1969), 45, 531-541. 
Majno G., Joris I. Apoptosis oncosis and necrosis an overview of cell death. 
Am. J. Pathol., (1995), 146, 3-15. 
Mak K.K., Chan S.Y. Epidermal growth factor as a biologic switch in hair
growth cycle. J. Biol. Chem., (2003), 278, 26120-26126. 
Mansuy I. M., Van Der Putten H., Schmid P., Meins M., Botteri F. M., Monard
D. Variable and multiple expression of protease nexin-I during mouse 
organogenesis and nervous system development. Development, (1993), 119,
1119-1134. 
Marshall W.A., Tanner J.M. Variations in patterns of pubertal changes in
girls. Arch. Dis. Child, (1969), 44, 291-303. 
Marshall W.A., Tanner J.M. Variations in the pattern of pubertal changes in
boys. Arch. Dis. Child, (1970), 45, 13-23. 
Massagué J. The transforming growth factor beta family. Ann. Rev. Cell Biol.,
(1990), 6, 597-641. 
Massagué J., Chen Y-C. Controlling TGF-beta signalling. Genes Dev., 
(2000), 14, 627-644. 
Maresca V., Roccella M., Roccella F., Camera E., Del Porto G., Passi S.,
Grammatico P., Picadro M. Increased sensitivity to peroxidative agents as a
 255
possible pathogenic factor of melanocyte damage in vitiligo. J. Invest. 
Dermatol., (1997), 109(3), 310-313. 
Matsumoto K., Nakamura T. Hepatocyte growth factor: molecular structure,
roles in liver regeneration and other biological functions. Crit. Rev. Oncog.,
(1992), 3, 27-54. 
Maurer M., Fischer E., Handjiski B., Von Stebut E., Algermissen B., Bavandi 
A., Paus R. Activated skin mast cell are involved in murine hair follicle
regression (catagen). Lab. Invest., (1997), 77, 319-332. 
McDonagh A.J.G., Messenger A.G. The pathogenesis of alopecia areata.
Dermatol. Clin., (1996), 14, 661-670. 
McEwan M., Parsons P.G. Initiation of melanisation in human melanoma
cells by a serotonin uptake inhibitor. J. Invest. Dermatol., (1987), 89, 82-86. 
McPhaul M.J., Young M. Complexities of androgen action. J. Am. Acad.
Dermatol., (2001), 45(3), S87-94. 
Mecklenberg L., Tobin D.J., Cirlan M.V., Cracium C., Paus R. Premature
termination of hair follicle morphogenesis and accelerated hair follicle cycling
in ISAI congenital atrichia (fzica) mice points to fuzzy as a key element of hair 
cycle control. Exp. Dermatol., (2005), 14, 561-570. 
Messenger A.G., Bleehem S.S. Alopecia areata: light and electron
microscopic pathology of the re-growing white hair. Br. J. Dermatol., (1984), 
110, 155-162. 
Messenger A.G., Elliott K., Temple A., Randall V.A. Expression of basement 
membrane proteins and interstitial collagens in dermal papillae of human hair
follicles. J. Invest. Dermatol., (1991), 96(1), 93-97. 
 256
Meyer K.C., Brzoska T., Abels C., Paus R. The alpha-melanocyte stimulating 
hormone-related tripeptide K(D)PT stimulates human hair follicle
pigmentation in situ under proinflammatory conditions. Br. J. Dermatol.,
(2009), 160(2), 433-437.  
Meyer-Ingold W., Eichner W. Platelet – derived growth factor. Cell Biol. Intl., 
(1995), 19 (5), 389-398. 
Michel M., Torok N., Godbout M.J., Lussier M., Gaudreau P., Royal A.,
Germain L. Keratin 19 as a biochemical marker of skin stem cells in vivo and 
in vitro; keratin 19 expressing cells are differentially localised in function of
anatomic sites and their number varies with donor age and culture stage. 
J. Cell Sci., (1996), 109, 1017-1028. 
Migliacio E., Giorgio M., Mele S., Pelicci G., Reboldi P., Pandolfi P.P.,
Lanfrancone L., Pelicci P.G. The p66shc adaptor protein controls oxidative
stress response and life span in mammals. Nature, (1999), 402(6759),
243-245. 
Mikkola M.L. Genetic basis of skin appendage development. Semin. Cell
Dev. Biol., (2007), 18(2), 225-236. 
Mikkola M.L. TNF superfamily in skin appendage develoment. Cytokine.
Growth Factor Rev., (2008), 19(3-4), 219-230. 
Millar S., Miller M.W., Stevens M.E., Barsh G.S. Expression and transgenic
studies of the mouse Agouti gene provide insight into the mechanism by
which mammalian coat colour patterns are generated. Development, (1995),
121, 3223-3232. 
Millar S.E. Molecular mechanisms regulating hair follicle development.
J. Invest. Dermatol., (2002), 118, 216-225. 
 257
Miller S.J., Sun T.T., Lavker R.M. Hair follicles, stem cells and skin cancer.
J. Invest. Dermatol., (1993), 100, 288-294. 
Milner Y., Sudnik J., Filippi M., Kizoulis M., Kashgarian M., Stenn K. Exogen,
shedding phase of the hair growth cycle: characterization of mouse model.
J. Invest. Dermatol., (2002), 119(3), 639-644. 
Miyamoto M., Naruo K.L., Seko C., Matsumoto S., Kondo T., Kurokawa T. 
Molecular cloning of a novel cytokine cDNA encoding the ninth member of
the fibroblast growth factor family which has a unique secretion property. Mol.
Cell Biol., (1993), 13, 4251-4259. 
Mondaini N., Gontero P., Giubilei G., Lombardi G., Cai T., Gavazzi A., 
Bartoletti R. Finasteride 5mg and sexual effects: how many of these are
related to a nocebo phenomenon. J. Sex. Med., (2007), 4(6), 1708-1712. 
Monestier S., Gaudy C., Gouvernet J., Richard M.A., Grob J.J. Multiple senile 
lentigos of the face, a skin ageing pattern resulting from a life excess of
intermittent sun exposure in dark-skinned Caucasians: a case-control study. 
Br. J. Dermatol., (2006), 154 (3), 438-444. 
Montesano R., Matsumoto K., Nakamura T., Orci L. Identification of a 
fibroblast – derived epithelial morphogen as a hepatocyte growth factor. Cell,
(1991), 67 (5), 901-908. 
Moore G.P., Panaretto B., Robertson D. Effects of epidermal growth factor on
hair growth in the mouse. J. Endocrinol., (1981), 88 (2), 293-299. 
Moretti G., Rampini E., Rebora A. Hormone und haarwachstum beim
menschen hautarzt [Hormones and hair growth in man]. (1977), 28, 619-625.
Morris R., Potten C. Highly persistent label – retaining cells in the hair 
follicles of mice and their fate following induction of anagen. J. Invest. 
 258
Dermatol., (1999), 1112, 470-475. 
Morrison S.J., Shah N.M., Anderson D.J. Regulatory mechanisms in stem
cell biology. Cell, (1997), 88, 287-298. 
Morrison S.J. Stem cell potential: can anything make anything? Curr. Biol., 
(2001), 11, R7-R9. 
Morton D.J., Kritz-Silverstein D., Riley D.J., Barrett-Connor E.L., Wingard 
D.L. Premature graying, balding, and low bone mineral density in older
women and men: the Rancho Bernardo study. J. Ageing Health, (2007),
19(2), 275-285. 
Mou C., Jackson B., Schneider P., Overbeek P.A., Headon D.J. Generation
of the primary hair follicle pattern. Proc. Natl. Acad. Sci. U.S.A., (2006),
103(24), 9075-9080. 
Moverare S., Lindberg M.K., Faergemann J. Oestrogen receptor α, but not
receptor β is involved in the regulation of the hair follicle cycling as well as
the thickness of epidermis in male mice. J. Invest. Dermatol., (2002), 119,
1053-1058. 
Műller-Rőver S., Handijski B., Van Der Veen C., Eichmuller S., Foitzik K.,
McKay I., Stenn K.S., Paus R. A comprehensive guide for the accurate
classification of murine hair follicles in distinct hair cycle stages. J. Invest.
Dermatol., (2001), 117(1), 3-15. 
Munro D.D. Hair growth measurement using intradermal sulphur-35 
L-cystine. Arch. Dermatol., (1966), 93, 119-122. 
Muto M., Furumoto H., Ohmura A., Asagami C. Successful treatment of
vitiligo with a sex steroid – thyroid hormone mixture. J. Dermatol., (1995), 22, 
770-772. 
 259
Nagl W. Different growth rates of pigmented and white hair in the beard:
differentiation vs proliferation? Br. J. Dermatol., (1995), 132, 94-97. 
Nakamura M., Tobin D.J., Richard-Smith B., Sundberg J.P, Paus R. Mutant 
laboratory mice with abnormalities in pigmentation: annotated tables.
J. Dermatol. Sci., (2002), 28, 1-33. 
Nakayama K., Negishi I., Kuida K., Sawa H., Loh D.Y. Targeted disruption of
BCL-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease
and lymphocytopenia. Proc. Natl. Acad. Sci. U.S.A., (1994), 91, 3700-3704. 
Nakhla A.M., Ding V.D., Khan M.S., Romas N.A., Rhodes L., Smith R.G.,
Rosner W. 5α-androstan-3-α, 17β-diol is a hormone: stimulation of cAMP 
accumulation in human and dog prostate. J. Clin. Endocrinol. Metab., (1995), 
80, 2259-2262. 
Nanney L., Magin M., Stoscheck C., King L. E. (Jnr.) Comparison of
epidermal growth factor binding and receptor distribution in normal human
epidermis and epidermal appendages. J. Invest. Dermatol., (1984), 83 (5), 
385-393. 
Narisawa Y., Kohda H., Tanaka T. Three dimensional demonstration of
melanocyte distribution of human hair follicles: special reference to the bulge
area. Acta. Derm. Venereol. (Stockh.), (1997), 77, 97-101. 
Newman D.M., Cragg G.M., Snader K.M. The influence of natural products 
upon drug discovery. Nat. Prod. Rep. (2000), 17, 215-234. 
Nishikawa S., Kusakabe M., Yoshinaga K., Ogawa M., Hayashi S.,
Kunishada D., Era T., Sakakura T. In utero manipulation of coat colour 
formation by a monoclonal anti-c-kit antibody. Two distinct waves of c-kit 
dependency during melanocyte development. Embro. J., (1991), 10, 2111-
 260
2118. 
Nishimura E., Jordan S.A., Oshima H., Yoshida H., Osawa M., Moriyama M.,
Jackson I., Barrandon Y., Miyachi Y., Nishikawa S. Dominant role of the 
niche in melanocyte stem-cell fate determination. Nature, (2002), 416,
854-860. 
Nishimura E.K., Granter S.R., Fisher D.E. Mechanisms of hair graying:
incomplete melanocyte stem cell maintenance in the niche. Science, (2005),
307, 720-724. 
Nissimov J. Device for overall diameter measurement of a group of hairs of
fibres (ODMOGH). U.S. Patent, (1994), no. 5, 327, 656. 
Nissimov J., Milner Y., Ofan R., Phillip M. Hair diameter of newly diagnosed
insulin dependent diabetes mellitus (IDDM) patients decreases sharply prior 
to onset of the disease. Proceedings of the 9th annual meeting of the 
European Hair Research Society, Brussels. Belgium, 2002 in “Hair Science
and Technology” editor D. Van Neste, publ. Skinterface sprl. Belgium, 2002,
p 223. 
Nixon A.J., Ford C.A., Wildermoth J. E. Regulation of prolactin receptor
expression in ovine skin in relation to circulating prolactin and wool follicle
growth status. J. Endocrinol., (2002), 176, 605-614. 
Norwood O.T.T. Male pattern baldness.  Classification and incidence. South 
Med. J., (1975), 68, 1351-1370. 
Obana N., Chang C., Uno N. Inhibition of hair growth by testosterone in the
presence of dermal papilla cells from the frontal bald scalp of the
postpubertal stumptailed macaque. Endocrinol., (1997), 138, 356-361. 
Offergeld R., Reinecker C., Gumz E., Schrum S., Treiber R., Neth R.D.,
 261
Gohla S.H. Mitogenetic activity of high molecular polysaccharide fractions
isolated from the cuppressaceae Thuja occidentals L. enhanced cytokine-
production by thyapolysaccharide, g-fraction (TPSg). Leukemia, (1992), 
6 Suppl 3, 189S-191S. 
Ogawa H., Yoshiike T. Keratin, keratinization, and biochemical aspects of
dyskeratosis. Int. J. Dermatol, (1984), 23(8), 507-513. 
Ogoshi M., Le T., Shay J.M., Taylor R.S. In situ hybridisation analysis of the 
expression of human telomerase RNA in normal and pathologic conditions of
the skin. J. Invest. Dermatol., (1998), 110, 818-823. 
Oh H.S., Smart R.C. An estrogen receptor pathway regulates the telogen-
anagen hair follicle transition and influences epidermal cell proliferation. Proc.
Nat. Acad. Sci. U.S.A., (1996), 93, 12525-12530. 
Ohnemus U., Uenalan M., Conrad F., Handjiski B., Meckhenburg L.,
Nakamura M., Inzunza J., Gustafsson J. A., Paus R. Hair cycle control by
estrogens: catagen induction via ER (alpha) is checked by ER (beta)
signalling. Endocrinol., (2005), 145, 1214-1225. 
Ohnemus U., Uenalan M., Inzunza J., Gustafsson J.A., Paus R. The hair
follicle as an estrogen target and source. Endrocrinol. Rev., (2006), 27, 677-
706. 
Okano Y., Rin K., Okamoto N., Yamamura T., Masaki H. Hop extract as new
potent ingredient for hair growth product. Int. Soc. Cosmet. Chem. Cong.,
(1994), 3, 756-761. 
Oliver R.F. Experimental induction of whisker growth in the hooded rat by
implantation of dermal papillae. J. Embryol. Expt. Morphol., (1967), 18,
43-51. 
 262
Oliver R.F., Jahoda C.A.B. The dermal papilla and maintenance of hair
growth. The biology of wood and hair. Eds: Rogers G.E., Reis P.R., Ward
K.A., Marshall R.C., Publ: Chapman & Hall, London, (1989), pp 51-67. 
Olsen E.A., Weiner M.S., Delong E.R., Pinell S. Topical minoxidil in early
male pattern baldness. J. Am. Acad. Dermatol., (1985), 13, 185-192. 
Olsen E.A. Treatment of androgenic alopecia with topical minoxydil. Res.
Staff. Phys., (1989), 35, 53-69. 
Olsen E.A. Current and novel methods for assessing efficacy of hair growth
promoters in pattern hair loss. J. Am. Acad. Dermatol., (2003), 48(2), 253-
262. 
Olsen E.A., Hordinsky M., Whiting D., Stough D., Hobbs S., Ellis M.L., Wilson
T., Rittmaster R.S. The importance of dual 5 alpha-reductase inhibition in the 
treatment of male pattern hair loss: results of a randomized placebo-
controlled study of dutasteride versus finasteride. J. Am. Acad. Dermatol.,
(2006), 55(6), 1014-1023. 
Olshansky B. Placebo and nocebo in cardiovascular health: implications for
healthcare, research, and the doctor-patient relationship. J. Am. Coll. 
Cardiol., (2007), 49(4), 415-421. 
Oro A.E., Scott M.P. Splitting hairs, dissecting roles of signalling systems in
epidermal development. Cell, 1998, 95, 575-578. 
Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Reid I.R.
Premature hair greying and bone mineral density. J. Clin. Endocrinol. Metab.,
(1997), 82, 3580-3585. 
Ortonne J.P., Prota G. Hair melanins and hair colour: ultrastrural and 
biochemical aspects. J. Invest. Dermatol., (1993), 101, 825-895. 
 263
O’Shaughnesy R.F., Christiano A.M., Jahoda C.A. The role of BMP signalling
in the control of ID3 expression in the hair follicle. Exp. Dermatol., (2004),
13(10), 621-629. 
Oshima H., Rochat A., Kedzia C., Kobayashi K., Barrandon Y.
Morphogenesis and renewal of hair follicles from adult multipotent stem cells.
Cell, (2001), 104, 233-245. 
Otberg N., Finner A.M., Shapiro J. Androgenetic alopecia. Endocrinol. Metab.
Clin. North Am., (2007), 36(2), 379-398. 
Oyehaug L., Plathe E., Vage D.I., Omholt S.W. The regulatory basis of
melanogenic switching. J. Theor. Biol., (2002), 215, 449-468. 
Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.,
Gorgun C., Hotamicligil G. Chemical chaperones reduce ER stress and
restore glucose homeostatis in a mouse model of type 2 diabetes. Science,
(2006), 313, 137-140. 
Pan H.J., Uno H., Inui S., Fulmer N.O., Chang C. Roles of testosterone in the
growth of keratinocytes through bald frontal dermal papilla cells. Endocrinol., 
(1999), 11, 321-327. 
Panteleyev A.A., Paus R., Ahmad W., Sundberg J.P., Christiano A.M.
Molecular and functional aspects of the hairless (hr) gene in laboratory
rodents and humans. Exp. Dermatol., (1998), 7, 249-267. 
Panteleyev A.A., Van Der Veen C., Posenbach T., Sokolov V.E., Műller-
Rőver S., Paus R. Towards defining the pathogenesis of the hairless
phenotype. J. Invest. Dermatol., (1998), 110, 902-907. 
Panteleyev A.A., Jahoda C.A.B., Christiano A.M. Hair follicle pre-
determination. J. Cell Sci., (2001), 114, 3419-3431. 
 264
Parakkal P.F., Maltosky A.G. A study of the differentiating products of the
hair follicle cells with the electron microscope. J. Invest. Dermatol., (1964),
42, 23-43. 
Parakkal P.F. Ultrastructural changes of the basal lamina during the hair
growth cycle. J. Cell Biol., (1969), 40(2), 561-564. 
Parakkal P.F. Morphogenesis of the hair follicle during catagen. Zeitschrift fur
Zellforschung, (1970), 107(2), 174-186. 
Park H.Y., Gilchrest B.A. Signalling pathways mediating melanogenesis. Cell
Mol. Biol., (1999), 45, 919-930. 
Park W.S., Lee C.H., Cho W.H., Lee B.G., Chang I.S. The extract of Thujae 
occidentalis semen inhibited 5∝ reductase and andochronogenetic alopecia 
of BGCBAFI/J hybrid mouse. J. Dermatol. Sci., (2003), 31, 91-98. 
Passwater R.A., Cranton E.M. Trace elements, hair analysis and nutrition.
Publ:  Keats Publishing, New Canaan, USA, 1st Edition, (1983), p 105-170. 
Paus R., Krejci-Papa N., Lingna L., Czarnetzki B.M., Hoffman R.M.
Correlation of proteolytic activities of organ cultured intact mouse skin with
defined hair cycle stages. J. Dermatol. Sci., (1994), 7, 202-209. 
Paus R., Lűftl M., Czarnetzki B.M. Nerve growth factor modulates
keratinocyte proliferation in murine skin organ culture. Br. J. Dermatol., 
(1994), 130 (2), 174-180. 
Paus R., Slominski A., Czarnetzki B. Is alopecia areata an auto-immune 
response against melanogenesis-related proteins expressed by abnormal 
MHC class I expression in the anagen hair bulb. Yale J. Biol. Med., (1995), 
66, 541-554. 
Paus R., Foitzik K., Welker P., Bulfone – Paus S., Eichmuller S. 
 265
Transforming growth factor – β type 1 and type 2 expression in murine hair
follicle development and cycling. J. Invest. Dermatol., (1997), 109, 518-526. 
Paus R., Peters E.M.J., Eichmuller S., Botchkarev V.A. Neural mechanisms 
of hair growth control. J. Invest. Dermatol., Symp. Proc., (1997), 2, 61-68. 
Paus R. Műller-Rőver S., Botchkarev V.A. Chronobiology of the hair follicle:
hunting the “hair cycle clock”. J. Invest. Dermatol. Symp. Proc., (1999), 4, 
338-345. 
Paus R., Műller-Rőver S., Van Der Veen C., Maurer M., Eichmuller S., Ling
G., Hoffman U., Foitzik K., Mecklenberg L., Handjiski B. A comprehensive
guide for the recognition and classification of distinct stages of hair follicle
morphogenesis. J. Invest. Dermatol., (1999), 113, 523-532. 
Pawelek J.M. Factors regulating growth and pigmentation of melanoma cells.
J. Invest. Dermatol., (1976), 66, 201-209. 
Pawelek J.M. Evidence suggesting that a cyclic AMP-dependent protein 
kinase is a positive regulator of proliferation on cloudman S91 melanoma
cells. J. Cell. Physiol., (1979), 98, 619-625. 
Pawelek J.M., Korner A.M. The biosynthesis of human melanin. Am. Sci.,
(1982), 70, 136-145. 
Pearton D.J., Yang Y., Dhouailly D. Transdifferentiation of corneal epithelium 
into epidermis occurs by means of a multistep process triggered by dermal
development signals. Proc. Natl. Acad. Sci. U.S.A., (2005), 102, 3714-3719. 
Pera M.F., Reubinoff B., Trounson A. Human embryonic stem cells. J. Cell
Sci., (2000), 113, 5-10. 
Peters E.M., Tobin D.J., Botchkareva N., Maurer M., Paus R. Migration of
melanoblasts into the developing murine hair follicle is accompanied by
 266
transient c-kit expression. J. Histochem. Cytochem., (2002), 50, 751-766.  
Peters E., Botchkarev V., Paus R. Neurotrophins act as regulators of hair
follicle morphogenesis and cycling. Proceedings of the 9th annual meeting of 
the European Hair Research Society, Brussels. Belgium, 2002 in “Hair
Science and Technology” editor D. Van Neste, publ. Skinterface sprl. 
Belgium, 2002, p 23. 
Peters E., Tobin D., Maurer M., Overall R., Arck P., Botchkarev V., Paus R.
The migration of melanoblasts into the developing hair follicle is
accompanied by transient c-Kit-expression in melanocytes as well as 
keratinocytes indicating distinct roles in controls of hair pigmentation and hair
growth. Proceedings of the 9th annual meeting of the European Hair 
Research Society, Brussels. Belgium, 2002 in “Hair Science and Technology”
editor D. Van Neste, publ. Skinterface sprl. Belgium, 2002, p 123. 
Peters E.M., Arck P.C., Paus R. Hair growth inhibition by psychoemotional
stress: a mouse model for neural mechanisms in hair growth control. Exp.
Dermatol., (2006), 15(1), 1-13. 
Peus D., Pittelkow M.R. Growth factors in hair organ development and the 
hair growth cycle. Dermatol. Clin., (1996), 14(4), 559-572. 
Phillipou G., Kirke J. Significance of steroid measurements in male pattern 
alopecia. Clin. Exp. Dermatol., (1981), 6, 53-58. 
Philpott M.P., Green M.R., Kealey T. Human hair growth in vitro. J. Cell Sci., 
(1990), 97, 463-471.  
Philpott M.P., Kealey T. The effects of EGF on the morphology and patterns
of DNA synthesis in isolated human hair follicles. J. Invest. Dermatol., (1994),
102, 186-191. 
 267
Philpott M.P., Sanders D.A., Kealey T. Effects of insulin and insulin-like 
growth factors on cultured human hair follicles: IGF-I at physiologic 
concentrations is an important regulator of hair follicle growth in vitro. 
J. Invest. Dermatol., (1994), 102, 857-861. 
Philpott M.P., Sanders D.A., Kealey T. Cultured human hair follicles and
growth factors. J. Invest. Dermatol., (1995), 104, 445-455. 
Philpott M.P., Sanders D.A., Kealey T. Whole hair follicle culture. Dermatol.
Clin., (1996), 14, 595-607.  
Philpott M., Sanders D.A., Bowen J., Kealey T. Effects of interleukins colony 
stimulating factor and tumour necrosis factor on human hair follicle growth in 
vitro: a possible role for interleukin – 1 and tumour necrosis factor – α in 
alopecia areata. Br. J. Dermatol., (1996), 135, 942-948. 
Picascia D.D., Roenick H.H. Jr. Effects of oral and topical cyclosporine in
male pattern alopecia. Transpl. Proc., (1988), 22 (suppl. 4), 109-111. 
Pierce G.F., Yanagihara D., Klopchin K., Danilenko D.M., Hsu E., Kenney 
W.C., Morris C.F. Stimulation of all epithelial elements during skin 
regeneration by keratinocyte growth factor. J. Exp. Med., (1994), 179 (3),
831-840. 
Pinkus H. Multiple hairs (Flemming-Giovanni report of 2 cases of pili 
multigemini and discussion of some anomalies of the pilary complex).
J. Invest. Dermatol., (1951), 17, 291-301. 
Pinkus H., Iwasaki T., Mishima Y. Outer root sheath keratinisation in anagen
and catagen of the mammalian hair follicle. A seventh distinct type of
keratinisation in the hair follicle: trichilemmal keratinisation. J. Anat., (1981), 
133, 19-35. 
 268
Pittelkow M.R., Coffey R.J., Moses H.L. Keratinocytes produce and are
regulated by transforming growth factors. Endocrine, metabolic and
immunologic functions of keratinocytes. Ann. N.Y. Acad. Sci., (1988), 548,
211-224. 
Pittelkow M.R., Shipley G. Serum-free culture of normal human melanocytes: 
growth kinetics and growth factor requirements. J. Cell Physol., (1989), 140
(3), 565-576. 
Pittelkow M.R. Regulation of the hair cycle and growth factors. J. Cutan.
Ageing Cosmet. Dermatol., (1990), 1, 211. 
Pitts R.L. Serum evaluation of dehydro-epiandposterone sulphate associated 
with male pattern alopecia in young men. J. Am. Acad. Dermatol., (1987), 16,
571-573. 
Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth 
factor is a potential tumor angiogenesis factor in human gliomas in vivo. 
Nature, (1992), 359, 845-848. 
Ponten F., Ren Z., Nister M., Westermark B., Ponten J. Epithelial – stromal 
interactions in basal cell cancer. The PDGF system. J. Invest. Dermatol., 
(1994), 102 (3), 304-309. 
Porras-Reyes B.H., Ksander G., Weeks P.M. Occurrence and localisation of
transforming growth factor – β (TGF – β1, β2) during rabbit skin 
development. Tissue Res., (1993), 29 (3), 203-212. 
Porter P.S., Lobitz W.C. Human hair: A genetic marker. Br. J. Dermatol., 
(1970), 83, 225-241. 
Post P.W., Daniels F., Binford R.T. Cold injury and the evolution of “white”
skin. Hum. Biol., (1975), 47, 65-80. 
 269
Postkowska – Nadolska B. Can the placebo be the cure. Wiad. Lek., (2007),
60 (3-4), 201-204. 
Pothier J. Practical thin-layer chromatography. A multidisciplinary approach.
Publ: CRC Press Publishers, Boca Raton, (1996). 
Potterf S.B., Virador V., Wakamatsu K., Furumura M., Santis C., Ito S.,
Hearing V. J. Cysteine transport in melanosomes from murine melanocytes.
Pigment Cell Res., (1999), 12, 4-12. 
Powell B.C., Passmore E.A., Nesci A., Dunn S.M. The notch signalling
pathway in hair growth. Mech. Dev., (1998), 78, 189-192. 
Prager N., Bickett K., French N., Marcovici G. A randomized, double-blind, 
placebo-controlled trial to determine the effectiveness of botanically derived
inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.
J. Altern. Complement. Med., (2002), 8(2), 143-152. 
Price V.H. Testosterone metabolism in the skin. Arch. Dermatol., (1975), 111, 
1496-1502. 
Price V.H., Roberts J.L., Hordinsky M., Olsen E.A., Savin R., Bergfeld W.,
Fiedler V., Lucky A., Whiting D.A., Pappas F., Culbertson J., Kotey P.,
Meehan A., Waldstreicher J. Lack of efficacy of finasteride in
postmenopausal women with androgenetic alopecia. J. Am. Acad. Dermatol., 
(2000), 43 (5 Pt 1), 768-776. 
Priestley G.C. Histological studies of the skin follicle types of the rat with
special reference to the structure of the Huxley layer. J. Anat., (1967), 101,
491-504. 
Proctor P.H. Hair-raising. The latest news on male-pattern baldness. Adv. 
Nurse Pract., (1999), 83, 39-42.  
 270
Prota G. Progress in the chemistry of melanins and related metabolites. Med.
Res. Rev., (1988), 8(4), 525-526. 
Prota G. The chemistry of melanins and melanogenesis. Fortsch. Chem. 
Organ. Natur., (1995), 64, 93-148. 
Puccinelli V.A., Caputo R., Casinelli T. Electron microscopic stdies of the hair
shaft in normal and alopecic subjects. Biopathology of pattern alopecia, Eds:
Baccaredda-Boy A., Morati G., Harger J.R. Publ: Karger, Basel, (1968). 
Quevedo W.C. Jr, Cairns J.M., Smith J.A., Bock F.G., Burns R.J. Induction of
melanotic tumours in the white (‘partial albino’) Syrian hamster. Nature,
(1961), 189, 936-937. 
Rabinowitz S., Cohen R., Le Roith D. Anxiety and hirsutism. Psychol. Rep., 
(1983), 53, 827-833. 
Ramirez R.D., Wright W.E., Shay J.W., Taylor R.S. Telomerase activity
concentrates mitotically active segments of human hair follicles. J. Invest.
Dermatol., (1997), 108, 113-117. 
Randall V.A., Thornton M.J., Hamada K. Redfern C.P, Nutbrown M., Ebling 
F.J., Messenger A.G. Androgens and the hair follicle.  Cultured dermal
papilla cells as a model system. Ann. N.Y. Acad. Sci., (1991), 642, 355-375. 
Randall V.A., Ebling F.J. Seasonal changes in human hair growth. Br. J. 
Dermatol., (1991), 124, 146-151. 
Randall V.A., Thornton M.J., Messenger A.G. Cultured dermal papilla cells
from androgen dependent human follicles (e.g. beard) contain more
androgen receptors than those from non-balding areas of the scalp. 
J. Endocrinol., (1992), 133, 141-147. 
Randall V.A., Thornton M.J., Messenger A.G. Hormones and hair growth:
 271
variations in androgen receptor content of dermal papilla cells cultured from
human and red deer (cervus elaphus) hair follicles. J. Invest. Dermatol., 
(1993), 101 (Suppl.), 114S-120S. 
Randall V.A., Thornton M.J., Hamada K., Messenger A.G. Androgen action in
cultured dermal papilla cells from human hair follicles. Skin Pharmacol.,
(1994), 7, 20-26. 
Randall V.A. Androgens and human hair growth. Clin. Endocrinol., (1994), 
40, 439-457. 
Randall V.A., Hibberts N.A., Hamada K. A comparison of the culture and
growth of dermal papilla cells, derived from normal and balding (androgenetic
alopecia) scalp.     Br. J. Dermatol., (1996), 134, 437-444. 
Randall V.A. (2000), Hair and its disorders; Biology, Pathology and
Management, Eds. Comacho F., Randall V., Price V. Publ. Martin Dunitz,
London, 1st Edition.  
Randall V.A., Hibberts N.A., Thornton M.J., Merrick A.E., Hamada K., Kato
S., Jenner T. J., De Olivera I., Messenger A.G. Do androgens influence hair
growth by altering the paracrine factors secreted by dermal papilla cells? Eur.
J. Derm., (2001), 11, 315-320. 
Randall V.A., Lanigan S., Hamzavi I., Chamberlain J. New dimensions in
hirsutism. Lasers Med. Sci., (2006), 21(3), 126-133. 
Randall V.A. Hormonal regulation of hair follicles exhibits a biological
paradox. Sem. Cell Dev. Biol., (2007), 18, 274-285. 
Randall V.A. Androgens and hair growth. Dermatol. Ther., (2008), 21, 314-
328. 
Randall V.A., Jenner T.J., Hibberts N.A., De Oliveira I.O., Vafaee T. Stem
 272
cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles.
J. Endocrinol., (2008), 197(1), 11-23. 
Rebora A. Pathogenesis of androgenetic alopecia. J. Am. Acad. Dermatol., 
(2004), 50, 777-779. 
Rees J.L. The melanocortin I receptor (MCRI): more than just red hair.
Pigment Cell Res., (2000), 13, 135-140.  
Reid D. A handbook of Chinese healing herbs. Publ:  Simon & Schuster,
London, 1st Edition, (1995), page 181. 
Rendl M., Lewis L., Fuchs E. Molecular dissection of mesenchymal-epithelial 
interactions in the hair follicle. P.L.oS. Biol., (2005), 3(11), e 331. 
Rennels E.G., Callahan W.P. The hormonal basis for pubertal maturation of
hair in the albino rat. Anat. Rec., (1959), 135, 21-31. 
Reynolds A.J., Jahoda C.A.B. Inductive properties of hair follicle cells. Ann.
N.Y. Acad. Sci., (1991), 642, 226-242. 
Reynolds A.J., Jahoda C.A.B. Hair follicle stem cells. A distinct germinative
epidermal cell population is achieved in vitro by the presence of hair dermal 
papilla cells. Ann. N.Y. Acad. Sci., (1991), 642, 226-242. 
Reynolds A.J., Clifford L., Cserhalmi-Friedman P. B., Christiano A. M., 
Jahoda C. A. B. Trans-gender induction of hair follicles. Nature, (1999), 402,
33-34. 
Reynolds A.J., Jahoda C.A.B. Cultured human and rat tooth papilla cells
induce hair follicle regeneration and fibre growth. Differentiation. (2004),
72(9-10), 566-575. 
Reynolds E.L. The appearance of adult patterns of body hair in man. Ann.
N.Y. Acad. Sci., (1951), 53, 576-584. 
 273
Rhodes L., Primka R.L., Berman C., Vergult G., Gabriel M., Pierre-Malice M., 
Gibelin B. Comparison of finasteride (Proscar), a 5 alpha-reductase inhibitor, 
and various commercial plant extracts in in vitro and in vivo 5 alpha-
reductase inhibition. Prostate, (1993), 22(1), 43-51. 
Rhodes L., Harper J., Uno H. The effect of finasteride on hair growth, hair-
cycle stage and serum testosterone and di-hydrotestosterone in adult male 
and female stump-tailed macaques. J. Clin. Endocrinol. Metab., (1994), 78, 
991-996. 
Roenigk H.H. Jr., Kuruvilla S. Topical minoxidil for male pattern alopecia in
two sets of twins. Cutis., (1987), 39(4), 329. 
Roh C., Tao Q.F., Photopoulos C., Lyle S. In vitro differences between 
keratinocyte stem cells and transient amplifying cells of the human hair 
follicle. J. Invest. Dermatol., (2005), 125, 1099-1105. 
Rosenquist T.A., Martin G.R. FGF signalling in the hair growth cycle.
Expression of the FGF receptor and ligand genes in the murine hair follicle.
Dev. Dyn., (1996), 205, 379-386. 
Rosner W., Hryb D.J., Khan M.S., Nakhla A.M., Romas N.A. Sex hormone
binding globulin. Binding to cell membranes and generation of a second
messenger. J. Androl., (1992), 13, 101-106. 
Rosen C.J., Holick M.F., Millard P.S. Premature greying of hair is a risk 
marker for osteopenia. Clin. Endocrinol. Metab., (1994), 79, 854-857. 
Rushton D.H., James K.C., Mortimer C.H. The unit area trichogram in the
assessment of androgenetic alopecia. Brit. J. Dermatol. (1983), 109, 429-
437. 
Rushton D.H., Norris M.J., James K.C. Amino-acid composition in 
 274
trichorrhexis. Nodosa, (1990), 15, 24-28. 
Rushton D.H., Ramsay I.D., Norris N.J., Gilkes J.J. Natural progression of 
male pattern baldness in young men. Clin. Exper. Dermatol., (1991), 16,
188-192. 
Rushton D.H., de Brouwer B., de Coster W., van Neste, D.J. Comparative
evaluation of scalp hair by phototrichogram and unit area trichogram analysis
within the same subjects. Acta. Derm. Venereol., (1993), 73, 150-153. 
Rushton D. H. Nutritional factors and hair loss. Clin. Exp. Dermatol., (2002), 
27(5), 396-404. 
Russell D.W., Wilson J.D. Steroid 5α-reductase: two genes / two enzymes. 
Ann. Rev. Biochem., (1994), 63, 25-61. 
Ryu G., Ju J.H., Park Y.J., Ryu S.X., Choi B.W., Lee B.H. The radical
scavenging effects of stilbene glucosides from polygonum multiflorum. Arch. 
Pharm. Res., (2002), 25, 636-639. 
Saitoh M. Sakamoto M. Human hair cycle. J. Invest. Dermatol., (1970), 54,
65-81. 
Salamon T. Comparative chemical investigations on hair of various areas of
the capillitium in subjects with normal hair and with alopecia seborrhoeica.
Dermatol. Monatsschr., (1971), 157, 783-788. 
Sandraps E., Leroy T., Demortier Y., Van Neste D. Validation and clinical
relevance of a novel scalp coverage scoring (SCS) method. Proceedings of 
the 9th annual meeting of the European Hair Research Society, Brussels.
Belgium, 2002 in “Hair Science and Technology” editor D. Van Neste, publ.
Skinterface sprl. Belgium, 2002, p 255. 
Sato N., Leopold P.L., Crystal R.G. Induction of the hair growth phase in  
 275
post-natal mice by localised transient expression of Sonic Hedgehog. J. Clin.
Invest., (1999), 104, 855-864.  
Sawaya M.E., Price V.H. Different levels of 5α-reductase type 1 and II, 
aromatase and androgen receptor in hair follicles of women and men with 
androgenetic alopecia. J. Invest. Dermatol., (1997), 109, 296-304. 
Sawaya M.E., Shalita A.R. Androgen receptor polymorphisms (CAG repeat 
lengths) in androgenetic alopecia, hirsutism and acne. J. Cutan. Med. Surg.,
(1998), 3, 9-15. 
Schallreuter K.U., Slominski A., Pawelek J.M., Jimbow K., Gilchrest B.A.
What controls melanogenesis? Exp. Dermatol., (1998), 7(4), 143-150. 
Schallreuter K.U., Wood J.M. The importance of L-phenylalanine transport 
and its autocrine turnover to L-tyrosine for melanogenesis in human 
epidermal melanocytes. Biochem. Biophys. Res. Commun., (1999), 262,
423-428. 
Schallreuter K. The presence of autocrine 6BH4 synthesis in the hair follicle: 
possible implications for pigmentation and differentiation. Proceedings of the
9th annual meeting of the European Hair Research Society, Brussels.
Belgium, 2002 in “Hair Science and Technology” editor D. Van Neste, publ. 
Skinterface sprl. Belgium, 2002, p 133. 
Schirren C.G., Burgdorf W.H.C., Sander C.A., Plewig G. Fetal and adult hair
follicle: an immunohistochemical study of anticytokeratin antibodies in
formalin-fixed and paraffin-embedded tissue. Am. J. Dermatopathol., (1997), 
19, 334-340. 
Schmermer A., Galvin S., Sun T. Differentiation-related expression a major 
G4K corneal keratin in vivo and in culture suggests limbal location of corneal
 276
epithelial stem cells. J. Cell Biol., (1986), 103, 49-62. 
Schouwey K., Beermann F. The Notch pathway: hair graying and pigment
cell homeostasis. Histol. Histopathol., (2008), 23(5), 609-619. 
Schreiber A.B., Winkler M.E., Derynck R. Transforming growth factor alpha: a
more potent angiogenic mediator than epidermal growth factor. Science, 
(1986), 232, 1250-1253. 
Schuberth H.J., Reidel-Caspari G., Leibold W. Flow cytometric testing of
immunological effects of phytomedicinal combination (equimun) and its
compounds on bovine leucocytes. J. Vet. Med. Physiol. Pathol. Clin. Med.,
(2002), 49, 291-298. 
Schweikert H.U., Wilson J.D. Regulation of human hair growth by steroid
hormones: testosterone metabolism in isolated hairs. J. Clin. Endocrinol.
Metab., (1974), 38(6), 1012-1019. 
Seal R., Hyde J., Felix C., Menon I., Prota G. Eumelanins and pheomelanins; 
characterisation by electron spin resonance spectroscopy. Science, (1982),
217, 545-547. 
Seale P., Rudniski M.A. A new look at the origin, function and “stem-cell” 
status of muscle satellite cells. Dev. Biol., (2000), 218, 115-124. 
Seilberg M., Marthinuss J., Stenn K.S. Changes in expression of apoptosis –
associated genes in skin mark early catagen. J. Invest. Dermatol., (1995),
104, 78-82. 
Setty L.R. Hair patterns of the scalp in white and negro males. Am. J. Phys.
Anthrop., (1970), 33, 49-55. 
Shah P.N. Human body hair – a quantitative study. Am. J. Obstet. Gynecol., 
(1957), 73, 1255-1265. 
 277
Sharov A., Tobin D.J., Sharova T.Y., Atoyan R., Botchkarev V.A. Changes in
different melanocyte populations during hair follicle involution (catagen).
J. Invest. Dermatol., (2005), 125(6), 1259-1267. 
Shetty M. Radiation therapy activates melanocytes in hair. Br. Med. J.,
(1995), 311, 1582. 
Shimaoka S., Tsuboi R., Jindo T., Imai R., Takamori K., Rubin J., Ogawa H.
Hepatocyte growth factor / scatter factor expressed in follicular papilla cells, 
stimulate human hair growth in vitro. J. Cell Physiol., (1995), 165, 333-338. 
Shimizu K., Fukuda M., Kondo R., Sakai K. The 5alpha-reductase inhibitory 
components from heartwood of Artocarpus incisus: structure-activity 
investigations, Planta Medica, (2000), 66, 16-19. 
Shipley G.D., Pittelkow M.R., Wille J.J. Jr., Scott R.E., Moses H.L. Reversible
inhibition of normal human prokeratinocyte proliferation by type
β transforming growth factor – growth inhibitor in serum free medium. Cancer
Res., (1986), 46, 2068-2071. 
Shorter K., Farjo N.P., Picksley S.M., Randall V.A. Human hair follicles
contain two forms of ATP-sensitive potassium channels, only one of which is
sensitive to minoxidil. Faseb J., (2008), 22(6), 1725-1736. 
Silvestri U. Studio fisico del capello in causistica de alopecia su base
seborrhoica. Arch. Ital. di Dermatol. Venereol.  Sessuol., (1966), 34, 405-409.
Sims R.T. “Beau’s lines” in hair. Reduction of hair shaft diameter associated 
with illness. Br. J. Dermatol., (1967), 79, 43-49. 
Sinclair R. Genetics of androgenetic alopecia. E.H.R.S. Workshop abstracts,
London, (2006). 
Slominski A., Paus R., Constantino R. Differential expression and activity of
 278
melanogenesis-related proteins during induced hair growth in mice. J. Invest.
Dermatol., (1991), 96, 172-179. 
Slominski A., Paus R. Melanogenesis is coupled to murine anagen: towards
new concepts for the role of melanocytes and the regulation of
melanogenesis in hair growth. J. Invest. Dermatol., (1993), 101, 905-975. 
Slominski A., Paus R., Schadendrorf D. Melanocytes as “sensory” and
regulatory cells in the epidermis. J. Theor. Biol., (1993), 164, 103-120.  
Slominski A., Paus R., Plonka P., Chakraborty A., Maurer M., Pruski D., 
Lukiewicz S. Melanogenesis during the anagen-catagen-telogen 
transformation of the murine hair cycle. J. Invest. Dermatol., (1994), 102,
862-869. 
Slominski A., Pisarcink A., Zbytek B. Tobin D. J., Kauser S., Worstman J.
Functional activity of serotoninergic and melatoninergic systems expressed in
the skin. J. Cell Physiol., (2003), 196, 144-153. 
Slominski A., Tobin D.J., Shibahara S., Wortsman J. Melanin pigmentation in
mammalian skin and its hormonal regulation. Physiol. Review, (2004), 84, 
1228-2004. 
Slominski A., Worstman J., Przemyslaw M., Plonka P., Schallreuter K., Paus
R., Tobin D.J. Hair follicle pigmentation. J. Invest. Dermatol., (2005), 124,
13-21. 
Smart R.C., Oh H.S., Chanda S., Robinette C.L. Effects of 17-beta-oestradiol 
and ICI 182780 on hair growth in various strains of mice. J. Invest. Dermatol.
Symp. Proc., (1999), 4, 285-289. 
Soma T., Tsuji Y., Hibino T. Involvement of transforming growth factor – beta 
2 in catagen induction during the human hair cycle. J. Invest. Dermatol., 
 279
(2002), 118, 993-997.  
Soma T., Dohrmann C.E., Hibino T., Raftery L.A. Profile of transforming
growth factor – beta responses during the murine hair cycle. J. Invest.
Dermatol., (2003), 121, 969-975. 
Sperling L.C. Hair anatomy for the clinician. J. Am. Acad. Dermatol., (1991), 
25, 1-17. 
Spritz R.A. Molecular basis of human piebaldism. J. Invest. Dermatol.,
(1994), 103, 137-140. 
Steel K.P., Davidson D.R., Jackson I.J. TRP2/DT a new early melanocyte
marker shows that steel growth factor (c-Kit ligand) is a survival factor. 
Development, (1992), 115, 111-119. 
Steinert P.M. Structure, function and dynamics of keratin intermediate
filaments. J. Invest. Dermatol., (1993), 100, 729-734. 
Steingrimsson E., Copeland N., Jenkins N.A. Melanocyte stem cell
maintenance and hair greying. Cell, (2005), 121, 9-12. 
Stenn K.S., Prouty S.M., Seiberg M. Molecules of the cycling hair follicle –
a tabulated review. J. Dermatol. Sci., (1994), 7, S109-S124. 
Stenn K.S., Combates N.J., Eilersten K.J., Gordon J.S., Pardinas J.R., 
Parimoo S., Prouty S.M. Hair follicle growth controls. Dermatol. Clin., (1996),
14, 543-558. 
Stenn K.S., Sundberg J.P., Sperling L.C. Hair follicle biology, the sebaceous
gland and scarring alopecias. Arch. Dermatol., (1999), 135, 973-974. 
Stenn K., Nixon A., Jahoda C., McKay I., Paus R. What controls hair follicle
cycling? Exp. Dermatol., (1999), 8, 229-236. 
Stenn K., Paus R. Controls of hair cycling. Physiol. Rev., (2001), 81, 449-
 280
494. 
Stenn K. Exogen is an active, separately controlled phase of the hair growth 
cycle. J. Am. Acad. Deramtol., (2005), 52(2), 374-375.    
Stough D.B., Rao N.A., Kaufman K.D., Mitchell C. Finasteride improves male
pattern hair loss in a randomized study in identical twins. Eur. J. Dermatol.,
(2002), 12(1), 32-37.  
Stough D. Dutasteride improves male pattern hair loss in a randomized study
in identical twins. J. Cosmet. Dermatol., (2007), 6(1), 9-13. 
Straile W.E. A study of the hair follicle and its melanocytes. Dev. Biol.,
(1964), 10, 45-70. 
Su H.Y., Hickford J.G., Bickerstaffe R., Palmer B.R. Insulin-like growth factor 
1 and hair growth. Dermatol. Online J., (1999), 5(2), 1. 
Su H.Y., Hickford J.G., The P.H., Hill A.M., Frampton C.M., Bickerstaffe R.
Increased vibrissa growth in transgenic mice expressing insulin-like growth 
factor-1. J. Invest. Dermatol., (1999), 112, 245-248. 
Sugiyama S., Saga K., Morimoto Y., Takahashi M. Proliferating activity of the
hair follicular melanocytes at the early and anagen III stages in the hair
growth cycle: detection by immunocytochemistry for bromodeoxyuridine 
combined with DOPA reaction cytochemistry. J. Dermatol., (1995), 22(6),
396-402. 
Sunderland E. Hair colour variation in the United Kingdom. Annal. Hum.
Genet., (1956), 20, 312-333. 
Suzuki I. Im S., Tada A. Participation of the melanocortin-I receptor in the 
UV-control of pigmentation. J. Invest. Dermatol. Symp. Proc., (1999), 4,
24-29. 
 281
Suzuki S., Ota Y., Ozawa K., Immura T. Dual mode regulation of hair growth
cycle by two FGF-5 gene products. J. Invest. Dermatol., 2000, 114, 456-463.
Swift J.A. Morphology and histochemistry of human hair. EXS, (1997), 78,
149-75. 
Swingler R., Awala A., Gordon U. Hirsutism in young women. Obstet. &
Gynaecol., (2009), 11, 101-107. 
Taguchi H., Ueda S., Ogawa C., Yoshida H., Monwaki S., Kitahara T. Effects 
of eucalyptus extract on hair properties and their molecular mechanism.
Poster presentation, E.H.R.S., Annual meeting, London, (2006). 
Takahashi T., Kamiya T., Yokoo Y. Proanthocyanidins from grape seeds
promote proliferation of mouse hair follicles in vitro and convert hair cycle in 
vitro. Acta. Derm. Venereol., (1998), 78, 428-432. 
Takahashi T., Kamiya T., Hasegawa A., Yokoo Y. Procyanidin oligomers
selectively and intensively promote proliferation of mouse hair epithelial cells
in vitro and activate hair follicle growth in vivo. J. Invest. Dermatol., (1999), 
112, 310-316. 
Tang L., Bernardo O., Bolduc C., Lui H., Madani S., Shapiro J. The
expression of insulin-like growth factor 1 in follicular dermal papillae
correlates with therapeutic efficiency of finasteride in androgenetic alopecia. 
J. Am. Acad. Dermatol., (2003), 49, 229-233. 
Taylor G., Lehrer M.S., Jensen P.J., Sun T–T., Lauker R.M. Involvement of 
follicular stem cells in forming not only the follicle but also the epidermis. Cell,
(2000), 102, 451-461. 
Taylor S.C. Skin of color: Biology, structure, function and implications for
dermatologic disease. J. Am. Acad. Dermatol., (2002), 46, S 41-62. 
 282
Thigpen A.E., Silver R.I., Guileyarlo J.M., Casey M.L., McConnell J.D.,
Russell D.W. Tissue distribution and ontogeny of steroid 5α-reductase 
isoenzyme expression. J. Clin. Invest., (1993), 92, 903-910. 
Thompson D.L. Jr., Hoffman R., Depew C.L. Prolactin administration to
seasonally anestrous mares: reproductive, metabolic and hair-shedding 
responses. J. Anim. Sci., (1997), 75, 1092-1099. 
Thompson E.B. Special topic: apoptosis. Ann. Rev. Physiol., (1998), 60, 525-
532. 
Thornton M.J., Laing I., Hamada K., Messenger A.G., Randall V.A.
Differences in testosterone metabolism by beard and scalp hair follicle 
dermal papilla cells. Clin. Endocrinol. (Oxford), (1993), 39, 633-639.  
Thornton M.J., Hamada K., Messenger A.G., Randall V.A. Beard but not
scalp dermal papilla cells secrete autocrine growth factors in response to
testosterone in vitro. J. Invest. Dermatol., (1998), 111, 727-732. 
Thornton M.J., Taylor A.H., Mulligan K., Al-Azzawi F., Lyon C.C., O’Driscoll J. 
The distribution of oestrogen receptor beta is distinct to that of oestrogen
receptor alpha and the androgen receptor in human skin and the
pilosebaceous unit. J. Invest. Dermatol. Symp. Proc., (2003), 8, 100-103. 
Thornton J., Nelson L., Taylor A., Mulligan K., Al-Azzawi F., Messenger A. 
Human non-balding scalp dermal papilla cells express estrogen receptor beta
(ERβ) protein in vivo and in vitro. Proceedings of the 9th annual meeting of 
the European Hair Research Society, Brussels. Belgium, 2002 in “Hair
Science and Technology” editor D. Van Neste, publ. Skinterface sprl.
Belgium, 2002, p 105. 
Thornton M.J., Nelson L.D., Taylor A.H., Birch M.P., Laing I., Messenger
 283
A.G. The modulation of aromatase and oestrogen receptor alpha in cultured
human dermal papilla cells by dexamethasone; a novel mechanism for
selective action of oestrogen via oestrogen receptor beta. J. Invest.
Dermatol., (2006), 126, 2010-2018. 
Tobin D.J., Cargnello J.A. Partial reversion of canities in a twenty two year
old Chinese male. Arch. Dermatol., (1992), 129, 789-791. 
Tobin D.J., Colen S.R., Bystryn J.C. Isolation and long-term culture of human 
hair follicle melanocytes. J. Invest. Dermatol., (1995), 104, 86-89. 
Tobin D.J., Bystryn J.C. Different populations of melanocytes are present in
hair follicles and epidermis. Pigment Cell Res., (1996), 9, 304-310. 
Tobin D.J., Hagen E., Botchkarev V.A., Paus R. Do hair bulb melanocytes
undergo apoptosis during hair follicle regression (catagen)? J. Invest.
Dermatol., (1998), 11, 941-947. 
Tobin D.J., Slominski A., Botchkarev V., Paus R. The fate of hair bulb
melanocytes during the hair growth. J. Invest. Dermatol. Symp. Proc., (1999),
4, 323-332. 
Tobin D.J., Paus R. Graying: gerontobiology of the hair follicle pigmentary 
unit. Exp. Gerontol., (2001), 36(1), 29-54, (Erratum exp. Gerontol., (2001), 
36(3), 591-592. 
Tobin D. The aging hair follicle pigmentary unit. Proceedings of the 9th annual 
meeting of the European Hair Research Society, Brussels. Belgium, 2002 in
“Hair Science and Technology” editor D. Van Neste, publ. Skinterface sprl. 
Belgium, 2002, p 155. 
Tumbar T., Guasch G., Greco V., Blanpain C., Lowry W.E., Rendl M.,
Fuchs E. Defining the epithelial stem cell niche in skin. Science, (2004), 303,
 284
359-363. 
Uenalan M., Handjiski B., Paus R. Topical 17 β-estradiol induces premature 
catagen development and accelerates normal hair regrowth after
chemotherapy induced alopecia. Arch. Dermatol. Res., (2000), 292, 146A. 
Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine
kinase. Cell, (1990), 61 (2), 203-212. 
Uno H., Kurata S. Chemical agents and peptides affect hair growth. J. Invest.
Dermatol., (1993), 101, 143-147. 
Vale R.D. The molecular motor toolbox for intracellular transport. Cell,
(2003), 112, 467-480. 
Valverde P., Benedito E., Solano F., Oaknin S., Lozano J.A., Garcia-Borron 
J.C. Melatonin antagonises alpha-melanocyte-stimulating hormone 
enhancement of melanogenesis in mouse melonoma cells by blocking the
hormone-induced accumulation of the C-locus tyrosinase. Nat. Genet., 
(1995), 11, 328-330. 
Van der Donk J., Passchier J., Dutree-Meulenberg R.O., Stolz E., Verhage F. 
Physiologic characteristics of men with alopecia androgenetica and their
modification. Intl. J. Dermatol., (1991), 30(1), 22-28. 
Van der Donk J., Passchier J., Knegt-Junk C., Van der Wegen-Keijser M.H., 
Nieboer C., Stolz E., Vernage F. Psychological characteristics of women with
androgenetic alopecia: a controlled study.  Br. J. Dermatol., (1991), 125(3),
248-252.  
Van Genderen C., Okamura R.M., Farinas I., Quo R.G., Parslow T.G., Bruhn 
L., Grosschedl R. Development of several organs that require inductive
epithelial – mesenchymal interactions is impaired in LEF-I deficient mice. 
 285
Genes Dev., (1994), 8, 2691-2703. 
Van Neste D., De Brouwer B., Dumortier M. Reduced linear hair growth rates 
of vellus and of terminal hairs produced by human balding scalp grafted onto
nude mice. Ann. N.Y. Acad. Sci., (1991), 642, 480-482.  
Van Neste D. Scalp coverage scoring documents natural worsening within
less than 12 months in a majority of men with androgenetic alopecia. 
Proceedings of the 9th annual meeting of the European Hair Research
Society, Brussels. Belgium, 2002 in “Hair Science and Technology” editor
D. Van Neste, publ. Skinterface sprl. Belgium, 2002, p 271. 
Van Neste D., Demortier Y. Detailed monitoring of hair cycle transitions in 
vivo using contrast enhanced phototrichogram. Proceedings of the 9th annual 
meeting of the European Hair Research Society, Brussels. Belgium, 2002 in
“Hair Science and Technology” editor D. Van Neste, publ. Skinterface sprl. 
Belgium, 2002, p 211. 
Van Neste D. Thickness medullation and growth rate of female scalp hairs
are subject to significant variation according to pigmentation and scalp
location during ageing. Eur. J. Dermatol., (2004), 14, 28-32. 
Van Neste D., Tobin D.J. Hair cycle and hair pigmentation: dynamic
interactions and changes associated with aging. Micron., (2004), 35(3), 193-
200. 
Van Neste D. Natural scalp hair progression in preclinical stages of male
androgenetic alopecia and its reversal by finasteride. Skin Pharmacol.
Technol., (2006), 12(2), 83-88. 
Van Neste D., Leroy T., Conil S. Exogen hair characterization in human
scalp. Skin Res. Technol., (2007), 13(4), 436-443. 
 286
Van Neste D. Placebo pills, lotions or potions and the natural progression of 
patterned hair loss in males: another step away from “trichoquackery”? Eur.
J. Dermatol., (2008), 18(4), 373-375. 
Vassar R., Fuchs E. Transgenic mice provide new inights into the role of
TGF-alpha during epidermal development and differentiation. Genes Dev., 
(1991), 5, 714-727. 
Veis D.J., Sorenson C.M., Shutter J.R., Korsmeyer S.J. BCL-2 deficient mice 
demonstrate fluminant lymphoid apoptosis, polycystic kidneys and
hypopigmented hair. Cell, (1993), 75, 229-240. 
Venning V.A., Dawber R. Patterned androgenic alopecia. J. Am. Acad.
Dermatol., (1988), 18, 1073-1078. 
Vexiau P., Chaspoux C., Boudou P., Fiet J., Jouanique C., Hardy N.,
Reygagne P. Effects of minoxydil 2% vs. cyproterone acetate treatment on
female androgenetic alopecia: a controlled, 12 – month randomised trial. 
Br. J. Dermatol., (2002), 146, 992-999. 
Vogt A., Combadiere B., Hadam S., Stieler K., Ladermann J., Schaefer H.,
Autran S., Sterry W., Blume-Peytavi U. 40nm, but not 750 or 1500nm, 
nanoparticles enter epidermal cDia + cells after transcutaneous application 
on human skin. J. Invest. Dermatol., (2006), 126, 1316-1322. 
Walsh P.C., Madden J.D., Harrod M.J., Goldstein J.L., McDonald P.C.,
Wilson J.D. Familial incomplete male pseudohermaphroditism, type 2;
decreased dihydro-testosterone formation in pseudovaginal perineoscrotal
hypospadias. N. Engl. J. Med., (1974), 291, 944-946. 
Wankowitz-Kalinska A., Le Poole C., Van Der Witngaard R., Storkus W.J.,
Das P.K. Melanocyte-specific immune response in melonoma and vitiligo:
 287
two faces of the same coin? Pigment Cell Res., (2003), 16, 254-260. 
Warren R., Wong T.K. Stimulation of human scalp papilla cells by epithelial
cells. Arch. Dermatol. Res., (1994), 286, 1-5. 
Warren W., Stone D., Tettoni L.I. (Eds). Thailand a traveller’s companion. 
Editions Didier Millet pte. Ltd. 121, Telok Ayer St. 03-01, Singapore 068590, 
Second edition, (2002) (ISBN 981 4068829) Archipelago Guides. 
Waters J.M., Richardson G.D., Jahoda C.A. Hair follicle stem cells. Semin.
Cell Dev. Biol., (2007), 18(2), 245-254. 
Weger N., Schlake T. Igf-I signalling controls the hair growth cycle and the
differentiation of hair shafts. J. Invest. Dermatol., (2005), 125, 873-82. 
Weinberg W.C., Brown P.D., Stetler–Stevenson W.G., Yuspa S.H. Growth 
factors specifically alter hair follicle cell proliferation and collagenolytic activity
alone or in combination. Differentiation, (1990), 45, 168-178. 
Weiner L., Han R., Scicchitano B., Li J., Hasegawa K., Grossi M., Lee D.,
Brisette J.L. Dedicated epithelial recipient cells determine pigmentation 
patterns. Cell, (2007), 130, 932-942. 
Weiyi Yang F.M. Diagnosis of traditional Chinese medicine. Publ:  Beijing
Academy Press, Xue Yan, China, 1st Ed., (1998). 
Werner S., Peters K.G., Longaker M.T., Fuller-Pace F., Banda M.J., Williams 
L.T. Large induction of keratinocyte growth factor expression in the dermis
during wound healing. Proc. Nat. Acad. Sci. U.S.A., (1992), 89 (15), 6896-
6900. 
Wessels N.K., Roessner K.D. Non proliferation in dermal condensation of
mouse vibrissae and pelage hairs. Dev. Biol., (1965), 12, 419-433. 
West P.M., Packer C. Sexual selection, temperature and the lion’s mane.
 288
Science, (2002), 297, 1339-1343.  
Westbroek W., Lambert J. Naeyaert J.M. The dilute locus and griscelli
syndrome: gateways towards a better understanding of melanosome 
transport. Pigment Cell Res., (2001), 14, 320-327.  
Westerhof W. A few more grains of melanin. Int. J. Dermatol., (1997), 36(8),
573-4. 
Westerhof W. The discovery of the human melanocyte. Pigment Cell Res.,
(2006), 19(3), 183-193. 
Wheeland R.G. Laser – assisted hair removal. Dermatol. Clin., (1997), 15,
469-477. 
Whiting D.A. The value of horizontal sections of scalp biopsies. J. Cutan.
Ageing. Cosmet. Dermatol., (1990), 1, 165-173.  
Whiting D.A. Diagnostic and predictive value of horizontal sections of scalp 
biopsy specimens in male pattern androgenetic alopecia. J. Am. Acad.
Dermatol., (1993), 28, 755-763. 
Whiting D.A. Possible mechanisms of miniaturisation during androgenetic
alopecia or pattern hair loss. J. Am. Acad. Dermatol., (2001), 45, 3, S81-S86.
Whiting D.A. Advances in the treatment of male androgenetic alopecia:
a brief review of finasteride studies. Eur. J. Dermatol., (2001), 11, 332-334. 
Whiting D.A. The structure of the human hair follicle. Publ: Canfield
Publishing, Fairfield, NJ, First Edition, 2004.  
Wilson C., Cotsarelis G, Wei Z.G. Cells within the bulge region of mouse hair
follicle transiently proliferate during early anagen, heterogeneity and function
differences of various hair cycles. Differentiation, (1994), 55, 127-136. 
Wilson J.D., Griffin J.E., Russell D.W. Steroid 5∝-reductase 2 deficiency. 
 289
Endocrinol. Rev., (1993), 14, 577-593. 
Winkler K. Sebaceous glands, hair and hormones. Dtsch. Zentralbl.
Krankenpfl., (1968), 12(10), 581-582. 
Wong S.T., Winchell L.F., McCune B.K., Earp H.S., Teixido J., Massague J.,
Herman B., Lee D.C. The TGF alpha precursor expressed on the cell surface
binds to the EGF receptor on adjacent cells leading to signal transduction.
Cell, (1989), 56 (3), 495-506. 
Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Withers M.J., Kriz R.W.,
Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular
clones and activities. Science, (1988), 242, 1528-1534. 
Wood J.M., Decker H., Hartman H., Chavan B., Rokos H., Spencer J.D.,
Hasse S., Thornton M.J., Shalbaf M., Paus R., Schallreuter K.U. Senile hair
graying: H2O2-mediated oxidative stress affects human hair color by blunting
methionine sulfoxide repair. Faseb J., (2009), 23(7), 2056-2075. 
Wright C.B. Clinical curio: myxodema and dark hair in old age. Br. Med. J., 
(1984), 288, 1517. 
Wright C.B. hair turning from grey to black in a patient with autoimmune
hypothyroidism. Br. Med. J., (1986), 292, 1430. 
Wu W. Multi-enzyme extraction process. (1996), US Patent#US005595743A. 
Xia T., Wang Q. Hypoglycaemic role of cucurbita ficifolia (cucurbitaceae) fruit 
extract in streptozotocin –induced diabetic rats. J. Sci. Food  Agric., (2007),
87(9), 1753-1757. 
Xie P.S., Leung A.Y. Understanding the traditional aspect of Chinese
medicine in order to achieve meaningful quality control in Chinese materia
medica. J. Chromatogr. A., (2009), 1216, 1933-1940. 
 290
Yamamoto O., Bhawan J. Three modes of melanosome transfers in
caucasian facial skin, hypothesis based on an ultrastructural study. Pigment
Cell Res., (1994), 7, 158-169. 
Yanchi Liu L.D., Zhanwen Liu. Basic theories of traditional Chinese medicine.
publ:   Beijing Academy Press, Xue Yuan, China, (1998), pp 423. 
Yim T.K., Wu W.K., Mak D.H., Ko K.M. Myocardial protection effect of an
anthraquinone containing extract of polygonum multiflorum ex vivo. Planta 
Med., (1998), 64, 607-611. 
Yong E.L., Wong S.P., Shen P., Gong Y.H., Li J., Hong Y. Standardization
and evaluation of botanical mixtures: lessons from a traditional Chinese herb,
Epimedium, with oestrogenic properties. Novartis Found. Symp., (2007), 282,
173-188. 
Young M.C., Jorizzo J.L., Sanchez R.L., Herbert A.A., Thomas D.R., King
C.A. Trichostatis spinulosa. Int. J. Dermatol., (1985), 24(9), 575-580. 
Young R.D. Morphological and ultrastructural aspects of the dermal papilla 
during the growth cycle of the vibrissal follicle in the rat. J. Anat., (1980), 131,
355-365. 
Zhao Z. An illustrated Chinese materia medica in Hong Kong (1st Ed.) publ: 
School of Chinese Medecine, Hong Kong Baptist University, Hong Kong 
(2004). 
Zheng X. Pharmacopoeia of the Peoples Republic of China, publ: Chemical
Industry Press, Beijing, China, (2000). 
Zheng Y., Eilertsen K.J., Ge L., Zhang L., Sundberg J., Prouty S., Stenn K.,
Parimoo S. Scd1 is expressed in sebaceous glands and is disrupted in the 
asebia mouse. Nat. Genet., (1999), 23, 268-270. 
 291
Zhou P., Byrne C., Jacobs J., Fuchs E. Lymphoid enhancer factor I directs
hair follicle patterning and epithelial cell fate. Genes Dev., (1995), 9, 700-713.
Ziller C., Smith J. Migration and differentiation of neural crest cells and their
derivatives: in vivo and in vitro studies on the early development of the avian 
peripheral nervous system. Reprod. Nutr. Dev., (1982), 22, 153-162. 
Zulli F., Suter F. Preparation and properties of small nanoparticles for skin 
and hair care. S. O. F. W.*, (1997), 123(13), 880-885. (* Soap Oils Fats and 
Waxes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 292
Appendices 
Appendix I 
Cosmetic procedure during trial (3 months) 
 
(1) Shampoo hair every day or at least every other day. Do not towel, dry the  
hair vigorously. 
 
(2) Apply test material by single shot spray (1ml) to the crown area EACH 
MORNING. Leave to dry. 
 
(3) Comb hair as required. Comb or brush hair 1 hour before hair sample is 
taken.  
 
(4) Do not use any other treatment on the hair and scalp apart from the 
shampoos and conditioners.  
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Appendix II 
Validation of methodology for unit area trichogram  
A total of 14 circles were drawn on a scalp, using the template (Chapter 2 
and 3) and the areas were calculated. The mean area ± SEM and the 
coefficient of variation (4.94%) are shown below. 
 
Circle No Diameter (mm) Radius (mm) Area (sq mm) 
1 7.67 3.835 46.22271 
2 7.83 3.915 48.17128 
3 8.00 4.000 50.28571 
4 7.67 3.835 46.22271 
5 7.83 3.915 48.17128 
6 7.67 3.835 46.22710 
7 7.50 3.750 44.19643 
8 7.83 3.915 48.17128 
9 7.70 3.850 46.58500 
10 7.80 3.900 47.80286 
11 7.70 3.850 46.58500 
12 7.70 3.850 46.58500 
13 7.20 3.600 40.73143 
14 7.50 3.750 44.19643 
 
Area calculations 
Mean 46.439
Standard Error 0.613
Median 46.585
Mode 46.223
Standard Deviation 2.295
Sample Variance 5.269
Kurtosis 2.160
Skewness -0.991
Range 9.554
Minimum 40.731
Maximum 50.286
Sum 650.150
Count 14
Largest (1) 50.286
Smallest (1) 40.731
CoVar% (SD/Mean%) 4.943
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Appendix III 
Hair shaft parameter measurements for trial subjects using Xiantene, 
before and after treatment 
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Appendix IV 
Hair shaft parameter measurements for trial subjects using vehicle, 
before and after treatment  
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Appendix V 
Chapter 3 alternative statistical analysis (Dr. D.H. Rushton) 
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Appendix VI 
Grey/Androgenetic alopecia survey form 
 
 
 
 
 
